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Abstract 
Psoriasis is a stubborn chronic skin disease affecting 1-3% of the population. 
Although not life threatening, it may be associated with important morbidity and 
disability. Psoriatic Arthritis (PsA), an immunologically mediated disease, is an 
inflammatory form of arthritis usually seronegative for rheumatoid factor, which may 
affect as many as 30% of patients with psoriasis, thus up to 1% of the population 
may have PsA. Whereas the prevalence of inflammatory arthritis in the general 
population is estimated at 2 to 3%, in patients with psoriasis the prevalence of 
inflammatory arthritis varies from 6 to 42%. PsA is highly heritable with the risk ratio 
for siblings of PsA patients estimated at 30.8 times that of the general population. 
PsA is T-cell driven disorder and the pathogenesis derives from multiple processes 
including synovial and entheseal inflammation, angiogenesis, and altered bone 
remodelling. 
Association studies have repeatedly implicated the HLA-Cw*0602 loci of the 
Major Histocompatibility Complex (MHC) in the aetiology of PsA. Numerous other 
genes from several pathways have also been implicated in PsA. Using the unique 
population resource of Newfoundland, and a validation cohort from Toronto, it has been 
observed that there is an association between PsA and the MHC genes TNF-a and 
MICA. For the first time, an association has also been observed between PsA and the 
pro-angiogenic genes VEGF and PPARy. An association was also observed with the 
pleiotropic autoimmune gene PTPN22, and for the first time epistatic gene-gene 
interactions have been observed in PsA via a novel algorithm, adding further evidence 
to the central involvement of /L-23R in PsA. 
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1 
INTRODUCTION 
1.1 -The Phenotype of Psoriatic Arthritis 
Psoriasis and psoriatic arthritis (PsA) are interrelated disorders, as most 
PsA patients have psoriasis (1 ). Psoriasis is a stubborn, chronic, T -cell mediated 
inflammatory skin disease affecting 1-2% of the Caucasian population (2), and 2-
3% of the population worldwide (3). The differing population prevalences of PsA 
are given in Table 1-1 . Although not life threatening, PsA may be associated with 
important morbidity and disability. An association between inflammatory arthritis 
and psoriasis, termed PsA, was formally recognized by the American 
Rheumatology association in 1964 (4 ), but was probably first described by Ali bert 
in 1818 (5). PsA is an inflammatory form of arthritis usually seronegative for 
rheumatoid factor (6), which may affect as many as 30% of patients with 
psoriasis, thus up to 1% of the population may have PsA (7,8). PsA runs a highly 
variable course, from a mild non-destructive disease to a severe rapidly 
progressive erosive arthropathy (9). 
The existence of PsA as a distinct clinical entity remains a topic of debate; 
some authors propose that it is simply the co-occurrence of psoriasis and 
inflammatory arthritis. As recently as July 2007, an editorial by Maxime Dougados 
entitled "Psoriatic Arthritis: Is it for Real?" was published in Joint Bone Spine (1 0). 
A disease entity, if real is likely to have a distinct prevalence differing from the 
expected co-occurrence of psoriasis and inflammatory arthritis and different 
susceptibility factors in addition to those that contribute to psoriasis and 
inflammatory arthritis alone. 
2 
Table 1-1: Prevalence of PsA as reported in studies of different populations 
Study/Year Country Prevalence(%) 
Lomholt, 1963 Faroe Islands 0.04 
Hellgren, 1969 Sweden 0.02 
van Romunde, 1984 Netherlands 0.05 
Shbeeb, 2000 USA 0.1 
Alamanos, 2003 Greece 0.06 
Trontzas, 2005 Greece 0.17 
Madland, 2005 Norway 0.2 
Gelfand, 2005 USA 0.25 
Adapted from ( 11) 
1.2 - Epidemiology of Psoriatic Arthritis 
Psoriasis exists in either an early onset, prior to age 40, typically familial 
form {Type 1), or as a later onset, more sporadic disease {Type II). Psoriasis 
typically precedes the onset of arthritis in roughly 70% of PsA patients, but may 
appear after (20%) or at the same time as ( 1 0%) as the development of arthritis 
{12). Estimates of the prevalence of PsA have been given as roughly 0.1% in 
Rochester Minnesota (13) to 2.5% in Toronto {14 ), to 0.04% to 1.2% in Sweden 
(15-17), while Gelfand et al. reported in 2005 a PsA prevalence of 0.25% (95% 
Cl : 0.18%, 0.31 %) (18). A recent survey by the National Psoriasis Foundation 
suggests prevalence of PsA to be 1.4% of general population in the US and 
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anywhere from 6-42% in psoriasis patients (19), and a recent European study 
that utilized a rheumatologist and dermatologist estimated a prevalence of 
inflammatory arthritis in psoriasis to be 30% (20). The prevalence of PsA in 
psoriasis patients from different populations is given in table 1-2. Given that the 
prevalence of inflammatory arthritis in the general population is estimated at 2 to 
3% (3), the increased prevalence of PsA in psoriasis patients argues for a distinct 
disease entity. As an interesting corollary, it appears that psoriasis occurs more 
often in patients with a background of inflammatory arthritis. Harrison et a/. (21) 
found that 5.3% of patients with early inflammatory polyarthritis had psoriasis on 
examination. Although this prevalence is thought to be higher than the general 
prevalence of psoriasis among Caucasians (roughly 1 - 2% (3,22)), Harrison et 
a!. 's study did not include and internal control group for direct comparison . The 
evidence shows overwhelmingly that psoriasis and PsA are interrelated 
disorders. 
1.3- Clinical Features of Psoriatic Arthritis 
The descriptions of arthritis associated with psoriasis complement the 
argument that it is a distinct entity. Unlike osteoarthritis, PsA is inflammatory in 
nature, and affects both proximal and distal joints. It differs from Rheumatoid 
arthritis (RA) by the lack of gender preference, the frequent involvement of distal 
interphalangeal 
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Table 1-2: Prevalence of PsA as reported in psoriasis patients from 
different populations 
Study Centre Patients with 
Psoriasis 
Leczinsky, 1948 Sweden 534 
Vilanova, 1951 Barcelona 214 
Little, 1975 Toronto 100 
Scarpa, 1984 Naples 180 
Stern, 1985 Boston 1285 
Zaneli, 1992 Winston-Salem, USA 459 
Barisic-Drusko, 1994 Osijek region 553 
Salvarani, 1995 Reggio Emilia 205 
Shbeeb, 2000 Mayo Clinic, USA 1056 
Brockbank, 2001 Toronto 126 
Alenius, 2002 Sweden 276 
National Psoriasis USA 4.4 male 
Foundation, 2002 
Zachariae, 2003 Denmark 5795 
Adapted from (11) 
PsA (%) 
7 
25 
32 
34 
20 
17 
10 
36 
6.25 
31 
48 
23 
30 
(DIP) joints, the tendency of asymmetry, the absence of rheumatoid factor, the 
presence of spondyloarthropathy, as well as associations with HLA-827 and the 
presence of extra-articular features common to the spondyloarthropathies (23). 
No laboratory diagnostic test exists for PsA. The erythrocyte sedimentation rate is 
elevated in 40 to 60% of PsA patients, particularly in those with the polyarticular 
form (8). In the past, the lack of rheumatoid factor activity was considered the 
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most distinctive laboratory feature of PsA. Studies have indicated, however, that 
low titres of rheumatoid factor are detected in 5-16% percent of patients (6) (24) 
(23). 
The majority of PsA patients have the classic form of psoriasis vulgaris, 
although pustular psoriasis and erythroderma have also been reported, and in 
approximately 70% of cases psoriasis precedes the onset of arthritis (25). The 
type of psoriasis itself may play a role in determining the onset of PsA. A study 
examining the onset of PsA determined that patients with Type I psoriasis tend to 
develop skin disease approximately 9 years before joint disease, while those with 
Type II psoriasis tend to display skin and joint manifestations within a year of 
each other (26). There appears to be no clear relationship between the extent of 
psoriasis and severity of inflammatory arthritis (27). Nail lesions are the only 
clinical feature of skin psoriasis that is significantly associated with the 
development of PsA. Indeed, only 35 percent of patients recognize a link 
between the joint and skin disease (8). The onset of arthritis is usually slow and 
begins mildly before progressing, but it can occur acutely (23), and the course of 
PsA is usually characterized by flares and remissions. The first classifications of 
PsA based on arthritic clinical patterns were defined by Moll and Wright (6), and 
broke the disease into 5 patterns: 1) So called 'Classic PsA' confined to DIP 
joints of the hands and feet, affecting approximately 5% of PsA patients; 2} 
Arthritis Mutilans (i .e., bone resorption), otherwise known as destructive arthritis, 
often with sacroiliitis, affecting less than 5% of patients; 3) Symmetric polyarthritis 
indistinguishable from RA, which accounts for roughly 50% of all PsA cases; 4) 
6 
·---------------------------------------------------------
Asymmetric oligoarthritis affecting roughly 35% of patients, and finally; 5) 
Spondyloarthropathy, affecting 20-40% of patients and usually in association with 
peripheral joint involvement. Figure 1-1 (a - g) shows the physical manifestations 
of the different types of PsA in patients. Subsequent reports validated these 
subgroups; however there is considerable overlap and evolution between them, 
and the disease patterns can occur in combination (28). In addition, variability in 
the reporting physician's definition of symmetry, symmetric oligoarthritis, and 
peripheral and axial overlap pattern has led to differences in the reported 
frequency of the subsets of PsA (23). 
Spondylitis is rarely observed at the onset of PsA: it tends to effect men 
and older patients, and it tends to begin later in the course of the disease (29). 
The spondylitis can include sacroiliitis (often asymmetric) and spinal disease 
similar to AS consisting of pain and stiffness of the cervical, thoracic and lumbar 
spine. Other clinical features of PsA include dactylitis and enthesitis (6,30,31 ). 
Dactylitis occurs in more than 30% of patients and is characterized by a diffuse 
swelling of the entire digit along with arthritis of the distal and proximal 
interphalangeal and metacarpophalangeal or metatasrophalangeal joints. 
Magnetic resonance imaging studies have revealed effusions in the affected 
joints and within tendon sheaths (32). Further it is clear that patterns of PsA are 
not permanent; more than 60% change from their initial disease pattern (1 ,33). 
McHugh et a/. (34) observed this phenomenon of changing disease patterns in a 
five year prospective study in which they followed 87 consecutive PsA patients. 
They found that eighteen patients changed subgroup; 11 had an increase 
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Figure 1-1 (a-g): Photographs and X-rays of the various clinical patterns 
of Psoriatic Arthritis 
Fig 1-1 a: Oligoarthritis 
Fig 1-1 b: Distal arthritis 
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Fig 1-1 c: Psoriatic Spondyloarthropathy 
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------------ --------------
Fig 1-1 d: Polyarticular arthritis 
Fig 1-1e: Arthritis Mutilans 
10 
-- -----------------------
1 
Fig 1-1 f: Hand X-ray of severe Psoriatic Arthritis 
II 
Fig 1-1 g: Foot X-ray and photo of severe Psoriatic Arthritis 
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in the number of joints involved, six a decrease, and one changed from an 
oligoarticular pattern to predominant spondylitis. Within the polyarticular group 
37/51 patients had an increase in the number of joints involved. For the whole 
population, there were significant increases in the number of joints involved. 
There were no significant differences in skin and nail scores although nine more 
patients had developed nail disease. 
Despite attempts to optimize medical therapy, a large number of patients 
with PsA go on to develop erosive polyarthritis while some patients develop 
ankylosis. The prevalence of deformity and damage in PsA is similar to that 
reported in RA (23). Over time, there is clinically active arthritis such that by the 
time patients have been followed for more than 1 0 years, 55% have five or more 
deformed joints (29). One study of patients with the early onset form of PsA 
showed that 4 7% presented to the clinic with at least one joint erosion within two 
years of disease onset (35). Thus PsA can be a destructive, inflammatory arthritis 
resulting in a significant health and economic burden (36). 
Likely owing to the debate regarding the acceptance of the existence of 
PsA as a distinct disease entity, until recently it lacked a widely-agreed upon or 
validated case definition (37). While the Moll and Wright classification criteria for 
PsA has been in use for many years, the heterogeneity of clinical features of the 
disease has resulted in several different attempts to further refine the 
classifications for the disease (8,38-42). Recently, the CASPAR study group 
(ClASsification of Psoriatic Arthritis) compared the test performance 
characteristics of these criteria using data retrospectively obtained from case 
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notes and radiographs of patients with PsA or RA, in order to determine more 
accurate and acceptable diagnostic criteria for PsA (25). Data were collected on 
588 PsA cases and 536 controls with RA (n=384 ), ankylosing spondylitis (AS) 
(n=72), undifferentiated arthritis (n=38), connective tissue disorders (n=14 ), and 
other diseases (n=28). The CASPAR diagnostic criteria for PsA consists of 
established inflammatory articular disease Uoint, spine, or entheseal} with at least 
3 points from the following five categories: 1) [A] Current psoriasis (assigned a 
score of 2; all other features were assigned a score of 1 ); [B] A history of 
psoriasis (unless current psoriasis was present); [C] A family history of psoriasis 
in a first or second degree relative. 2) Nail dystrophy; 3) Seronegativity for 
rheumatoid factor; 4) Dactylitis; 5) Radiographic evidence of juxtaarticular new 
bone formation. When applied to PsA patients presenting at rheumatology clinics, 
these criteria were found to be more specific, but slightly less sensitive than the 
various existing diagnostic criteria in use. One major purpose of studies for these 
classification criteria is to enroll appropriate patients into clinical intervention, thus 
criteria with high specificity are more desirable than criteria with high sensitivity. 
The CASPAR criteria have been derived from observed patient data, are more 
specific in a rheumatology clinic setting, and are easier to use than existing 
classification criteria. Thus, the CASPAR criteria (Summarized in Table 1-3) have 
rapidly become the gold standard for PsA diagnosis. 
Even with agreed diagnostic criteria, there remains disagreement as to the 
severity of the disease. While the disease patterns described by Moll & Wright 
and CASPAR may be clearly recognized at disease onset, it has been difficult to 
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Table 1-3: CASPAR Criteria for diagnosis of PsA 
Inflammatory musculoskeletal disease Uoint, spine, or entheseal) 
With 3 or more of the following: 
a. Current psoriasis* Psoriatic skin or scalp disease present 
1. Evidence of today as judged by a dermatologist or 
psoriasis (one rheumatologist 
of a, b, c) 
b. Personal history A history of psoriasis that may be obtained 
of psoriasis from patient, family doctor, dermatologist 
or rheumatologist 
c. Family history of A history of psoriasis in a first or second 
psoriasis degree relative according to patient report 
Typical psoriatic nail dystrophy including 
2. Psoriatic nail dystrophy onycholysis, pitting and hyperkeratosis 
observed on current physical examination 
By any method except latex but preferably 
3. A negative test for rheumatoid by ELISA or nephelometry, according to 
factor the local laboratory reference range 
a. Current Dactylitis Swelling of an entire digit 
4. Dactylitis 
(either a or b) 
b. History of Recorded by a rheumatologist 
Dactylitis 
Ill-defined ossification near joint margins 
5. Radiological evidence of juxta- (but excluding osteophyte formation) on 
articular new bone formation plain x-rays of hand or foot 
Specificity 98. 7%, sensitivity 91.4%. *Current psoriasis scores 2 
Adapted from Taylor W, eta/. 2006 
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ascertain whether these patterns have prognostic implications since there have 
been few prospective longitudinal studies in this disease. Moreover, in the few 
studies that did follow patients over time, the patterns demonstrate change over 
time (1 ,28,33). Earlier studies suggested that PsA was not a severe disease, but 
more recent experience describes a less benign clinical course, with the majority 
of patients (60%) presenting with polyarthritis (8,43), and with evidence of 
progression of deformities over time in a large proportion of patients (8). As 
mentioned previously, psoriasis precedes the onset of arthritis in approximately 
70% of cases. The interval between the onset of psoriasis and arthritis can be 
extremely variable. There is no direct correlation between the severity of skin and 
joint manifestations except perhaps in those patients with simultaneous onset of 
both manifestations (39,44,45). Nail lesions, including pits and onycholysis signal 
the development of PsA (46), but at the same time, the presence of nail lesions 
appears to modify the risk for mortality in this disease (4 7). Nail lesions occur in 
90 percent of patients with PsA and in only 41 percent of those with psoriasis 
uncomplicated by arthritis (46). 
Gladman et a/. introduced the concept of severity in psoriatic arthritis in 
1987 (8), while others have recently confirmed that patients with psoriatic arthritis 
have a severe, progressive disease (34,43,48). Gladman et a/. further 
demonstrated that over a 5 year period there is progression of both clinical and 
radiological damage in PsA, despite medical therapy (49,50), and that the 
radiological changes of patients with PsA are similar to those of patients with RA 
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(51), indicating that while the two diseases are distinct medical conditions, some 
underlying mechanisms in the progression of the diseases may be similar. They 
further demonstrated that progression of clinical damage was related to the 
number of actively inflamed joints at presentation (30). The predictive role of 
polyarthritis in the development of further damage was recently confirmed in 
another cohort of patients with PsA (46), while further studies also demonstrated 
that persistent inflammation leads to further damage (52). Gladman et a/. have 
also demonstrated that disease severity is associated with early mortality in 
patients with PsA (47) (36). On the other hand, there are patients who may have 
milder disease course and experience remission (53). 
With respect to mortality, one study indicated that there was no significant 
increase when comparing PsA patients to the general population (13). Studies 
from hospital environments, however, have indicated that there is an increased 
risk of death for PsA patients, with a standardized mortality ratio of 1.59 (female) 
- 1.65 (male) (36). Disease severity also appears to predispose for increased 
mortal ity (47), however, more recent reports indicate that there has been 
improved survival rates among PsA patients with the advent of newer therapies. 
Follow up data indicates that the mortality risk has dropped, particularly for 
males, to an overall mortality risk of 1.36. Of interest, the numbers of years of life 
lost was calculated at 3 years, similar to the number reported for patients with 
severe psoriasis (54). 
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1.4 Co-morbidities of Psoriatic Arthritis 
Psoriasis and PsA are both T cell driven diseases (55,56) (this will be 
discussed in greater detail in section 1.6). A specific T cell subset known as T 
helper 1 (Th 1) cells are responsible for an increase in antigen presentation and T 
cell activation. Increasing evidence suggests that a Th1 immune response, 
including activated T cells, antigen presenting cells, cytokines, and markers of 
systemic inflammation such as C-reactive protein, are important factors in the 
development of atherosclerotic plaques and ultimately, myocardial infarction (57). 
The observation that other Th1 driven disease such as RA have an increased risk 
of myocardial infarction adds support to the hypothesis that Th1 mediated 
disease may predispose to cardiovascular disease (58,59). The excess risk of 
cardiovascular disease in psoriasis has been demonstrated in a number of 
observational studies (60-64 ). One clinic-based study found that the risk of 
arterial and venous vascular diseases (e.g., myocardial infarction, 
thrombophlebitis, pulmonary embolization, and cerebrovascular accident) was 
2.2 times higher among patients with psoriasis compared with control patients 
with other dermatologic conditions (61 ). In a large European referral cohort of 
patients with psoriasis, obesity, diabetes mellitus, heart failure, and hypertension 
were almost twice as frequent in patients with psoriasis as in control subjects 
(62). One recent study looked at 127,139 mild and 3837 severe psoriasis patients 
and 556,995 control patients and found that - after adjusting for hypertension, 
diabetes, history of myocardial infarction, hyperlipidemia, age, sex, smoking, and 
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body mass index - for a 30-year-old patient with mild or severe psoriasis, the 
adjusted RR of having an Ml is 1.29 (95% Cl, 1.14 - 1.46) and 3.10 {95% Cl, 1.98 
- 4.86), respectively, and concluded that psoriasis likely confers an independent 
risk for myocardial infarction (64 ). 
While obesity and the often accompanying metabolic syndrome are also 
risk factors for Ml, they are serious medical conditions of their own accord often 
requiring medical intervention. Several reports have shown an increased rate of 
obesity in case control studies (65-67). Metabolic syndrome, which comprises a 
cluster of risk factors, including obesity, dyslipidaemia, hypertension and glucose 
intolerance which can lead to diabetes, is a strong predictor of cardiovascular 
disease. Two case-control studies have demonstrated an increased prevalence 
of metabolic syndrome and its contributing components in patients hospitalized 
for severe psoriasis (66,68). 
While psoriasis and PsA are interrelated disorders, there is much less 
literature available regarding the accompanying co-morbidities of PsA. One 
recent review reported on the varying causes of death amongst PsA patients, and 
found that between 25% - 55% of PsA patients die from cardiovascular disease, 
between 10% - 25% from respiratory illnesses, and 11% - 24% die from cancer 
(69). It becomes apparent when examining the co-morbidities that are associated 
with psoriasis and PsA, that several different pathological mechanisms must be 
involved in these disease processes. 
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1.5 - Treatment of Psoriatic Arthritis 
Until very recently, PsA was considered to be a very mild disease, and 
patients were usually treated with non-steroidal anti-inflammatory drugs (NSAIDs) 
(9). In the usual manner of treatment during the early stages of disease, the 
physician typically attempts to treat the most prominent issue for the patient. If 
the major issue is the skin manifestations, then they are treated first, usually by a 
dermatologist, and the joint manifestations are managed with NSAIDs (27). 
NSAIDs, however, are associated with significant adverse events, and it must be 
noted that they do not modify the course of the disease, nor do they prevent 
development or progression of erosions. Thus, if patients respond poorly to 
NSAIDs or if there is already erosive disease, patients should be treated 
aggressively with disease-modifying anti-rheumatic drugs (DMARDs) - although 
ideally patients would be treated with DMARDs before erosive disease is present 
(27). Methotrexate, Cyclosporine, Sulfasalazine and Leflunomide are the most 
commonly used DMARDs for severe psoriasis and PsA in clinical practice (70). It 
has been reported that a higher rate of toxicity has been associated with 
methotrexate use in PsA versus RA, resulting in earlier discontinuation of therapy 
(71 ). It is thought that methotrexate therapy may induce more hepatotoxicity in 
psoriasis and PsA than in RA, although the reason for this is unclear (72). 
Despite this, methotrexate continues to be the DMARD of choice in the treatment 
of PsA as a result of its effects on both arthritis and skin disease (73). Other 
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studies however, have indicated that Cyclosporine is also not tolerated well and 
likewise leads to hepatotoxicity (7 4 ). 
When DMARDs fail to provide sufficient resolution, the next step is the use 
of biologic therapies. As will be described in greater detail in Section 1.5, TNF-a 
is a critical cytokine in the pathogenesis of PsA and thus is an obvious 
therapeutic target. TNF-a antagonists such as etanercept (synthetic TNF-a 
receptor), infliximab (chimeric anti-TNF-a monoclonal antibody), adalimumab 
{humanized anti-TNF-a monoclonal antibody), and golimumab (human anti-TNF-
a monoclonal antibody) have all shown significant improvement in PsA patients 
according to the American College of Rheumatology (ACR) 20 and 50 criteria 
(73). However, it is important to realize that most reports of TNF-a antagonist 
therapy in PsA have focused solely on the treatment of peripheral arthritis while 
not assessing the effect on axial disease, dactylitis, and enthesitis. Although not 
specifically assessed, one trial did report that back pain and stiffness associated 
with PsA responded to infliximab therapy (75). Interestingly, other recent work 
has also suggested that infliximab may have a direct effect on angiogenesis in 
PsA. One study suggests that infliximab was associated with histologic evidence 
of decreased vascularisation in synovial tissue biopsies (76). Further, there 
appeared to be changes in tissue markers suggesting a reduction in 
angiogenesis, including reduction in vascular endothelial growth factor (VEGF). 
An additional study also noted similar findings in that decreased 
neovascularisation was seen in skin and synovial tissue after treatment with 
infliximab (77). Other methods of biological therapy include preventing the 
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activation of T cells, thus disrupting the psoriatic cascade. Medications such as 
Alefacept, and Abatacept block interactions between antigen-presenting cells and 
T cells, thus interfering with activation ofT lymphocytes and migration of cells to 
the site of inflammation (78). 
Newer targets are also being pursued as further advances in the 
understanding of disease pathogenesis are revealed. Ustekinumab, an inhibitor 
of IL-12/23 has shown efficacy in randomized control trials in psoriasis and PsA 
(79)(80), while other agents aimed at reducing bone erosions by inhibiting 
osteoclastogenesis are also being investigated for their efficacy in the treatment 
of PsA (81 ). As newer treatment options in psoriasis and PsA are approved and 
introduced into clinical practice, the mechanisms of the disease are further 
elucidated, enabling a greater understanding of the basis of pathogenesis in PsA. 
1.6 - Pathogenesis of Psoriatic Arthritis 
As with most complex diseases, historically there has been some debate 
as to the exact sequence of events in the development of PsA. This is further 
complicated by the close relationship of PsA to uncomplicated psoriasis. In recent 
years the immunopathogenesis has been greatly debated and reviewed 
extensively (82-85). 
In the mid 1980s, it was discovered that T cells play a role in the 
pathogenesis of psoriasis; the immunosuppressive drug, cyclosporine, cleared 
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psoriasis. Cyclosporine was shown that to have direct antiproliferative effects on 
keratinocytes at therapeutic concentrations, and acts primarily through a 
blockade of the T cells (86). Similar improvements were seen in psoriatic patients 
treated with methotrexate for other disease processes. Further evidence 
supporting the role of T cells in psoriasis was found in the severe combined 
immunodeficiency disease mouse model, where the transplantation of normal 
appearing skin of psoriatic patients, followed by the intradermal injection of 
activated peripheral blood T cells of the same patient, clinically and histologically 
induced the appearance of psoriatic plaques (87). Likewise, psoriasis has been 
triggered or cured by bone marrow transplantation, depending upon whether the 
donor or the host had psoriasis (88,89). 
1.6.1 - Synovial Histopathology 
Skin and synovial biopsies in PsA patients have revealed that T 
lymphocytes are the most common inflammatory cells in the skin and joints 
(31 ,90). CD4+ T cells are the most significant lymphocytes in the tissues, with a 
CD4+/ CD8+ ratio of 2:1; in contrast, this ratio is reversed in the synovial fluid 
compartment and at the enthesis, where CD8+ T cells are more common (91 ,92). 
A dominant CD8+ T cell population in PsA synovial fluid suggests that these cells 
may be driving the immune response in the joint (93).This is strongly supported 
by the long established association of PsA with major histocompatibility complex 
(MHC) class I genes (46). T cell receptor (TCR) repertoire oligoclonality more 
commonly expressed in the CD8+ T cell population has been identified in 
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epidermal cells (94) and in the synovium (95) of patients with PsA. Helper T cells 
have classically been described as two different classes of cells: type 1 (Th1) and 
type 2 (Th2). Th1 cells are thought to mediate cellular immunity and secrete the 
proinflammatory cytokines IL-2, interferon-y (IFN-y) and tumour necrosis factor-a 
(TNF-a). Th2 cells are thought to mediate humoral immunity and secrete anti-
inflammatory cytokines IL-4, IL-5, IL-6, IL-1 0, and IL-13. Studies have shown that 
patients with psoriasis have an increased expression of IFN-y compared with IL-4 
in circulating T cells when compared with healthy volunteers In addition, similar 
studies have found an increased expression of IFN-y over IL-4 in T cells located 
in the epidermal layer. Thus a substantial and growing body of evidence has 
been generated supporting the concept that psoriasis and PsA are mediated by 
activated antigen-specific T cells (96), with a Th1-dominated cytokine profile (97). 
PsA synovial membranes share more common characteristics with other 
forms of spondyloarthritis than with RA (98). Synovial biopsies from patients with 
PsA and other spondyloarthropathies have shown significantly less lining layer 
thickness and greater vascularity than those obtained from RA patients (99), and 
increased vascularity at both the macroscopic and microscopic level in PsA 
membranes have been observed (1 00,101 ). Lining layer hyperplasia is less 
marked in PsA and fewer macrophages are observed trafficking into the 
synovium and out to the lining layer, although the number of T lymphocytes and 
their subsets are similar in frequency to that found in RA (90). Higher neutrophil 
numbers are also observed, which is consistent with the well-described neutrophil 
infiltration seen in psoriatic skin (1 02). When PsA subtypes are compared, 
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however, no significant differences were seen between oligo- and polyarticular 
PsA (99). 
1.6.2 - Enthesitis 
Enthesis are the point at which a tendon, ligament or muscle inserts into 
bone, where the collagen fibres are mineralized and integrated into bone tissue. 
Enthesitis is a common feature in all spondyloarthropathies, and McGonagle, et 
a/ have hypothesized that enthesitis is a primary event in PsA with secondary 
spread of inflammation to the synovium (1 03). Imaging studies suggest that the 
primary site of inflammation is the entheseal insertion of joint capsule and 
extensor tendon, but longitudinal studies are lacking (1 04 ). Jevtic et a/., fi rst 
described the extensive extracapsular inflammation seen on MRI scans in PsA 
(1 05). Half their patients showed extrasynovial inflammation including thickened 
collateral ligaments and periarticular soft tissue, particularly in dactylitic joints. In 
one joint, predominant extracapsular inflammation was seen without significant 
associated synovitis, thus raising the possibility of nonsynovial inflammation in 
PsA (1 05). However, not all patients showed evidence of extracapsular 
inflammation. Thus, in PsA some patients may have a predominantly synovial 
disease as in RA, and some may show a predominantly entheseal disease (as in 
undifferentiated spondyloarthropathy (SpA)). An insertion site per se does not 
appear to be a prerequisite for disease expression, for functional entheses are 
sites of repeated shear and compressive stressing (1 06). 
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While synovial inflammation is a cardinal manifestation of PsA, a link with 
enthesitis was not firmly established until recently (1 07). The recent recognition of 
a synovio-entheseal complex (SEC) may help resolve the relationship between 
synovitis and enthesitis in PsA (32). The SEC model shows how enthesis 
fibrocartilage could derive lubrication and nourishment from adjacent synovium in 
a manner identical to the long appreciated interaction between articular cartilage 
and synovium. Hence, it appears that all sites of disease in PsA can be linked to 
the common denominator of enthesitis. 
1.6.3- Bone Remodelling 
Another of the hallmarks of PsA is an unpredictable pattern of bone 
resorption and concomitant new bone formation. The constantly changing nature 
of the human skeleton is not limited to perpetual bone turnover but can also be 
observed in the interactions between bone and other organ systems. One 
particularly intriguing interaction which has gained much attention in recent years 
is the link between the skeletal and immunological systems. The recent 
understanding of an interplay between adaptive immune cells and cells involved 
in skeletal remodelling led to the development of a field known as 
osteoimmunology (1 08,1 09). This rapidly expanding field has the potential to 
facilitate the translation of basic science knowledge in bone biology into an 
improved understanding of the pathological mechanisms involved in altered 
remodelling in inflammatory arthritis (110). 
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Radiographs of PsA joints reveal significantly altered bone remodelling in 
the form of tuft resorption, large eccentric erosions, and pencil-in-cup deformities 
along with features of new bone formation such as periostitis and bone ankylosis 
(111 ). With respect to bone resorption, biopsies of joints in PsA patients 
demonstrate large multinucleated osteoclasts in deep resorption pits at the bone-
pannus junction (112). Data has indicated that osteoclast formation begins in the 
earliest stages of arthritis (113) 
Until recently, the molecular events that underlie osteoclastogenesis were 
not well understood. Elucidation of the signalling pathway of the receptor 
activator of nuclear factor KB ligand (RANKL) and receptor activator of nuclear 
factor KB (RANK) has clarified some of the crucial first steps required for the 
process of osteoclast formation and activation ( 114 ). To summarize the process 
briefly, Boyle et al observed that RANKL, expressed on the surface of 
osteoblasts, stromal cells in the bone marrow, and infiltrating T lymphocytes and 
synoviocytes in the inflamed joint, binds to RANK, a cell-associated TNF 
receptor-related protein. RANK is expressed on a variety of cell types. including 
osteoclast precursors and osteoclasts. In normal bone. ongoing bone resorption 
mediated by osteoclasts is closely linked to new bone formation by osteoblasts 
(114). High expression of RANKL by synovial fibroblastoid cells coupled with 
diminished expression of osteoprotegerin (OPG). an antagonist of RANKL, has 
been observed by immunohistochemistry in psoriatic synovium (112), and an 
elevated RANKL/OPG ratio favours the differentiation of osteoclasts from 
monocytes and tips the balance towards bone resorption (1 07). The interaction 
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between RANKL and its receptor RANK in the presence of macrophage colony 
stimulating factor is necessary and sufficient for osteoclastogenesis and 
subsequent bone resorption. In addition, osteoprotegerin (OPG), a decoy 
receptor, can bind to RANKL and neutralize bioactivity. OPG inhibits osteolysis, 
and the ratio of RANKL to osteoprotegerin in a particular tissue is the primary 
factor determining the extent of bone resorption. Interestingly, RANKL is also 
expressed by T Cells which infiltrate into the synovial lining of inflamed joints 
(115). Further to this, blocking RANKL has resulted in some protection from 
cartilage destruction in arthritic animal models (116). 
In addition to this, circulating osteoclast precursor cells (OPCs) were 
elevated in PsA patients when compared to healthy controls. Treatment with 
TNF-a inhibiting drugs significantly decreased the level of OCPs in peripheral 
blood thus providing evidence of a central role for TNF-a in the mechanism of 
bone resorption ( 112). TN F-a stimulates osteoclastogenesis via its interaction 
with the p55 subunit of the TN F-a receptor (TNFp55r) (117). Once bound to this 
receptor, TN F-a exerts several effects that foster increased osteoclast formation. 
TNF stimulates RANKL expression in bone marrow stromal cells and also 
activates tt1e p38 mitogen-activated protein kinase (MAPK) cell-signalling 
pathway which leads to increased expression of colony stimulating factor 1 
receptor (c-Fms). Binding of macrophage colony stimulating factor (M-CSF) to c-
Fms stimulates RANK expression in osteoclast precursors. The RANKL 
upregulated by TNF-a in the bone marrow stromal cells binds to RANK on the 
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osteoclast precursors and drives increased cell signalling downstream of RANK 
(110). 
The importance of TNF-a in this process has also been shown in animal 
models of inflammatory erosive arthritis. The TNF-transgenic mouse, for 
example, closely mimics human disease and represents the first predictive 
animal model of arthritis as these animals develop erosive arthritis with focal 
subchondral and joint margin bone erosions (118). On a cellular level, an effect of 
TNF-a in these animals is a four to seven-fold increase in osteoclast precursors 
while treatment of the TNF transgenic mice with anti-TNF-a agents restored the 
number of cells in this population to levels seen in their wild type littermates 
(119). Beyond animal models, one small study of 24 PsA patients and 12 controls 
examined the relationship between elevated TNF and bone-resorbing osteoclasts 
in PsA. The authors observed significantly increased numbers of circulating, 
unstimulated OCPs derived from unstimulated cultured monocytes (i.e. no 
RANKL or M-CSF added to the cultures) in the PsA subjects relative to controls 
(112). Another recent study also demonstrated that OCP frequency dropped 
dramatically following therapy with etanercept in patients with erosive PsA. (120). 
While the mechanisms of bone resorption have recently been elucidated, 
the events responsible for new bone formation are poorly understood (121 ). Only 
a few factors that participate in osteoproliferation and new bone formation have 
been identified . Bone morphogenetic proteins (BMP) are pivotal molecules in 
bony ankylosis as shown in the DBA/1 mouse model (122). Aging DBA/1 male 
mice, when caged together, become extremely aggressive and develop an 
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ankylosing enthesitis, which has features that are similar to the pathology 
observed in psoriatic joints (123). While no studies have yet been performed on 
sites of new bone formation in psoriatic joints, transforming growth factor~ (TGF-
~) is highly expressed in synovial tissues of AS patients (124), and animal models 
indicate that TGF-~ interacts with vascular endothelial growth factor (VEGF) to 
induce bone formation (125). Osteophytes, or the overgrowth of bone tissue more 
commonly called 'bone spurs' have been shown to express VEGF (126). The 
subchondral vascular system has a pivotal role in the regulation of ossification. 
Marginal osteophytes form when capillaries penetrate the subchondral bone and 
deep zone of articular cartilage. VEGF is thus likely to be an important regulator 
of angiogenesis during osteophyte development and thus new bone formation. 
(126). 
1.6.4- Angiogenesis 
Angiogenesis appears to be a first-order event in both psoriasis and PsA 
(127). Abnormalities in the vascular morphology of the nail-folds of psoriasis 
patients without nail disease have been observed (128), as well as an increase in 
the number of synovial membrane blood vessels in PsA joint tissue (90), and as 
described in section 1.5.4, also plays a role in new bone formation. When viewed 
through an arthroscope, the blood vessels in psoriatic arthritis synovia are 
tortuous and dilated, with little or no branching whereas those in rheumatoid 
arthritis membranes have a straight pattern with regular branching, reflecting a 
different pathogenesis and outcome (1 01 ). The existence of these elongated and 
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tortuous vessels in skin and joint suggest dysregulated angiogenesis resulting in 
immature vessels. Angiogenic growth factors such as TGF-~ and VEGF are 
markedly increased in psoriasis, both circulating and within psoriatic plaques 
(129), and VEGF and TGF-~ levels have been observed to be significantly higher 
in the joint fluid in early PsA (130). Further, expression of angiopoietins, co-
localise with VEGF protein and mRNA in PsA synovial membranes in a 
perivascular distribution (131 ). 
Angiogenic targets are also being investigated for their therapeutic value: 
recently, a novel application of the peroxisome proliferator activated receptor-
gamma (PPARG) agonist drug, pioglitazone, originally developed for the 
treatment of diabetes, was reported in the treatment of PsA (132). Activation of 
PPARG by pioglitazone has been shown to significantly reduce inflammatory 
cytokine expression (133) and suppress neoangiogenesis (134) in models of 
inflammatory disease. In this small trial, 60% of enrolled patients saw significant 
improvement from baseline. The benefits of this therapy are further underscored 
by evidence that PPARG plays a role in regulating VEGF expression (135) and 
that polymorph isms in the PPARG gene influence serum OPG levels (136, 137). 
Thus, the evidence for angiogenesis as a common pathogenic pathway in 
psoriatic skin and joints is quite compelling. 
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1.7- Heritability of Psoriatic Arthritis 
Both psoriasis and PsA are highly heritable. One of the most widely 
accepted (and often first attempted) ways to establish the genetic proportion of a 
disease is to examine the concordance rates in monozygotic twins compared to 
dizygotic twins (138). Psoriasis is highly heritable as evidenced by an increased 
rate of concordance - roughly three times higher - in monozygotic versus 
dizygotic twins (35-72% vs. 12- 23% respectively) (139). However, concordance 
is never 100%, and can be as low as 35% which does suggest that 
environmental factors must also play an important role (140). Until early 2008, 
there were no published reports of twin studies in PsA, likely due to its low 
prevalence. The only published article resembling a twin study came from Moll 
and Wright ( 141 ), who reported a triplet consisting of an identical twin and a non-
identical third triplet. The identical twins both developed psoriasis with one having 
spondylitis and the other polyarthritis. The non-identical triplet had no psoriasis or 
arthritis. In January of 2008, Pederson eta/. (142) published the first true twin 
study in Psoriatic Arthritis , using the Danish twin registry. Following responses to 
a survey, 36 pairs of twins were identified with at least one twin positively 
diagnosed with PsA according to both the Moll and Wright (143) and CASPAR 
(25) criteria. According to the Moll & Wright criteria, the proband-wise 
concordance rates were 1/10 (10% (95% Cl: 2%, 40%)) and 1/26 (3.8% (95% Cl: 
0.7%, 19%)) in monozygotic and dizygotic twins respectively (difference 6.3% 
(95% Cl : -11%, 37%), p = 0.49). If the CASPAR criteria was used, the proband-
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wise concordance rates were 1/9 (11% (95%CI: 2%, 44%) and 1/22 (5% (95% 
Cl: 1%, 22%) in monozygotic and dizygotic twins respectively (difference 6.6% 
(95%CI: -13%, 39), p = 0.52). With regard to Ps skin disease in the PsA 
population (defined by the Moll &Wright criteria), the proband-wise concordance 
rates were 6/11 (55%) in monozygotic twins and 6/28 (21 %) in dizygotic twins. 
Thus, based on concordance estimates, they found a significant genetic effect on 
Ps skin disease in PsA twins, and a substantial genetic component for the 
development of PsA. While the data from Pederson et at. 's twin study do 
implicate a genetic component for PsA, the numbers used to calculate remain 
small , again likely due to the disease's low prevalence. 
Following the examination of twin concordances, the magnitude of a 
genetic contribution to a disease is calculated by determining the proportion of 
disease in the siblings (or other degree of relatives) as compared to the 
prevalence of the disease in the general population. This parameter - known as 
the recurrence risk ratio - was originally formulated by Neil Risch, and is denoted 
as P-R. where R represents the degree of relatedness (144) (i.e. , A1 would indicate 
a first degree relative - a full sibling, parent, or child , while As would refer to 
siblings only). Briefly, to calculate the A value for the degree of relatedness being 
studied, the frequency of disease in the (for example, first-degree) relatives is 
divided by the population frequency of the disease. The recurrence risk ratio for 
psoriasis is estimated to be between 4 and 1 0 ( 145 ). 
Re-analysis of publ ished data of psoriasis from the Faeroe Islands (15), 
Sweden (146) and Germany (147) revealed a A1 of 8 for the Faeroe Islands 
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cohort, 4 for the Swedish cohort, and 1 0 for the German cohort, indicating 
substantive familial aggregating of Psoriasis ( 140) ( 148). Risch also developed a 
formula for using risk ratios among relatives of different degrees to obtain 
information about genetic models. When the risk ratio (AR _1) decreases by a 
factor of greater than 2 between the first and second degrees of relatedness, the 
data are consistent with a multilocus model. As this factor was 7 in the Faeroe 
Islands study and 8 in the Swedish study, a multilocus model for psoriasis is 
predicted. 
Due again to the low prevalence of PsA, the number of studies estimating 
the familial aggregation of PsA are quite low in number. Moll and Wright's (141) 
study in 1973 assessed first and second degree relatives of 88 probands with 
PsA. There were a total of 181 first-degree relatives, of which 10 had PsA, 
including 5 siblings indicating that the overall prevalence of PsA among first 
degree relatives is 5.5%. The prevalence of PsA in the UK at the time was 
accepted as being approximately 0.1 %, therefore the A1 risk for first degree 
relatives of PsA probands, was 55 - a number significantly higher than that for 
relatives of psoriasis probands, as described above. 
More recently, two reports have published new data on the familial 
recurrence risk of PsA. Meyers et at. (149) examined 80 PsA probands and 112 
siblings who presented at the Rheumatology department of Freeman Hospital at 
Newcastle-Upon-Tyne, UK. Sibling prevalence was reported at 14.3% making the 
As 47. Chandran et at. (150) examined 100 consecutive probands who had 396 
total first degree relatives. 289 of these participated (73%) (130 sibs, 108 parents, 
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51 children). The authors assumed a population prevalence of 0.25% for PsA and 
2% for Ps as described previously by Gelfand et a/. (18) It was found that the 
prevalence of PsA was 7.6%, and the prevalence of psoriasis was 15.2% among 
first degree relatives. Therefore, }q was 30.4 for PsA and 7.6 for psoriasis. With 
respect to the siblings, the As was found to be 30.8 for PsA and 8.8 for psoriasis. 
To put these numbers into perspective, the As for RA is estimated to be between 
2 and 17 (151 ), and for Type 1 Diabetes is 15 (152). 
Interestingly, an epigenetic mode of inheritance has been observed in 
PsA. Rahman eta/. (153) observed excessive paternal transmission (i.e. , genetic 
imprinting) when it was discovered that the proportion of probands with an 
affected father (0.65) was significantly greater than the expected proportion of 0.5 
(p = 0.001 ). Similar trends were noted in the offspring and second degree 
relatives of the proband. Imprinting, exemplified by the Prader-Willi/Angelman 
syndromes, has been implicated in other auto-immune diseases such as insulin-
dependent diabetes mellitus (lOOM) and inflammatory bowel disease (lBO). This 
paternal transmission has also been reported in Icelandic PsA families (154 ). 
Taken cumulatively, these family data argue for a substantial genetic component 
to both psoriasis and PsA. 
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1.8 - Review of the Genetics of Psoriatic Arthritis 
1.8.1 -Genetic Basis of Psoriasis 
Psoriasis and PsA are interrelated disorders, as most PsA patients have 
psoriasis (1 ). Psoriasis is known to be an immunologically mediated disease, 
however the molecular events triggering this immune-activation remain unclear. 
Psoriasis has long been accepted as having a strong family history, and as 
described in section 1.6, Chandran et a/ recently demonstrated that psoriasis is 
highly heritable with a l\1 of 7.6 and a As of 8.8 (150). 
Several regions of the genome have been linked to susceptibility for the 
development of psoriasis, with the most consistently observed region being a 
locus within the Major Histocompatibility Complex (MHC) region at chromosome 
6p21.3 (155, 156). This locus has been named PSORS1 (Psoriasis Susceptibility 
region 1) and association studies have consistently demonstrated an association 
with the HLA-Cw6 allele across several different populations (157, 158). It is 
estimated that this region accounts for one-third to one-half of the genetic 
susceptibility to psoriasis (159). 
Recent analysis has confirmed that HLA-Cw6 is the variant in the MHC 
region which predisposes to psoriasis (160). Psoriasis affects males and females 
in equal proportions and can occur at any age (161 ). Carriage of the HLA-Cw6 
allele is most common in those with an early age of onset and family history (i .e., 
Type I Psoriasis) (162) (it is worth noting, however, that despite the strong 
association with HLA-Cw6, not all psoriasis patients carry the allele. In 
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independent sets of affected individuals/families it is only found in 40-80% of 
cases. Moreover the penetrance of HLA-Cw6 is 10%, implicating environmental 
effects or additional genetic susceptibility factors (163)). While the PSORS1 locus 
is generally understood to confer the most significant risk for the development of 
psoriasis, several other susceptibility loci also have been identified outside of the 
MHC region. Linkage scans have implicated other loci designated as PSORS2-
PSORS10; however in many of these replication has been difficult to achieve and 
statistical significance is often low (164 ). Of these, the PSORS2 (17q24-25), 
PSORS5 (3q21) and PSORS9 (4q28-31) loci show the strongest evidence for 
replication. Four independent linkage studies have shown significance (p < 0.01) 
for the PSORS2 region following the original report, while another reported 
significance at p = 0.05 (155, 165-169). PSORS5 has likewise been replicated 
(170, 171 ), while a meta analysis of four different genome wide linkage scans 
using Caucasian and Chinese Han populations observed significance in only the 
PSORS1 and PSORS9 loci (172). A summary of all implicated PSORS regions is 
included in Table 1-4. 
As will be described in more detail in section 1.7.4, the few genome-wide 
association studies performed in psoriasis have found significance for SNPs in 
the MHC region , as well as variants of the II-23R and 11-128 genes as well as two 
genes that act downstream of TNF-a and regulate NF-KB signalling (TNIP1 , 
TNFAIP3) . 
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Table 1-4: Summary of Known Psoriasis Susceptibility Regions 
Locus Lead Author and Year of Region Gene Candidates Publication of 
Psoriasis Susceptibility Studies 
HLA-Cw6; Samuelsson L, 1999; Lee YA, 2000; COSN, HCR, HERV-K, HCG2, 
PSORS1 6p21 .3 7PS04S1C3, POU5F1, Elder JT, 2001; Veal CD, 2001; 
TCF19, CCHCR1, LMP, Zhang XJ , 2002; Foerster J, 2004; 
SEEK1, SPR1 Sagoo GS, 2004 
Tomfohrde J, 1994; Nair RP, 1997; 
RUNX1; RAPTOR; Enlund F, 1 999; Samuelsson L, 1999; PSORS2 17q25 SLC9A3R1; NAT9; TBCD Helms C, 2003; ZhengY, 2003; Capon F, 2004; Stuart P, 2006; 
Capon F, 2007 
PSORS3 4q34 IRF-2 Matthews D, 1996; Hida S, 2000; Foerster J, 2004 
Loricrin; Filaggrin; Bhalerao J, 1998; Capon F, 1999; 
PSORS4 1q21 Pglyrp3,4; S100 genes within Semprini S, 2002; Giardina E, 2004; 
epidermal differentiation Giardina E, 2006; Sun C, 2006; Zhao 
complex Y,2007 
SLC 12A8; Cystatin A; Zn Enlund F, 1999; Samuelsson L, 1 999; PSORS5 3q finger protein 148 Hewett, 2002; Samuelsson L, 2004; Huffmeier U, 2005 
PSORS6 19e13 JunB Lee YA, 2000; Zenz R, 2005 
PTPN22 (1p13); IL-23R Veal CD, 2001; Tsunemi Y, 2002; 
PSORS7 1p (1p32.1-31 .2) Nistor I, 2005; Duerr RH, 2006; Huffmeier U, 2006; Capon F, 
2007;Cargill M, 2007 
PSORSB 16q CX3CL 1, CX3R1; Nair RP, 1 997; Karason A, 2003; NOD2/CARD 15 Young C, 2003; Plant D, 2006 
Bhalerao J, 1998; Samuelsson L, 
PSORS9 4q31 1/-15 1999; Zhang XJ , 2002; Bowcock AM, 2004; Sagoo GS, 2004; Sun LD, 
2007; Zhang XJ, 2007 
PSORS10 18p11 Veal CD, 2001; Asumalahti K, 2003 
5q31 .1- IL-128; SLC22A4; SLC22A5; Tsunemi Y, 2002; Duerr RH, 2006; 
33.1 IL-13; IL3, IL4, IL5, CSF2 and Friberg C, 2006; Capon F, 2007; IRF1 Cargill M, 2007, Nair et al, 2008 
9g33-34 Zhang XJ, 2002; Yan KL, 2007 
6p22 COKAL/ Wolf N, 2007 
19q34 KIR20S1, KIR2DL 1, Suzuki Y, 2004; Luszczek W, 2004 KIR2DL5 
Adapted from ( 176) 
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1.8.2- Genes in the MHC Region Associated with PsA 
The MHC locus spans approximately 4 Mb and contains roughly 250 
genes, of which approximately 60% have immune-related functions. The MHC 
region is characterized by extended LD blocks (up to 3 Mb), and by a strong and 
complicated LD pattern between the blocks (173). Nair et a/. 's work in 2006 
demonstrated conclusively that the PSORS1 gene is in fact the HLA-Cw*0602 
allele (160). While the strong association of HLA-Cw*0602 also exists for PsA, it 
is predominantly associated with a younger age at onset of psoriasis(< 40 years, 
i.e., Type I Psoriasis) in PsA patients, suggesting that the association is primarily 
with psoriasis rather than PsAperse (174,175). 
In addition to HLA-Cw6, both HLA-87 and -827 are associated with PsA 
associated with later onset of arthritis in PsA patients (46). (Interestingly, HLA-
827 is also the strongest reported association with Ankylosing Spondylitis, 
another seronegative spondyloarthropathy.) Further to these, other HLA markers 
identify increased or decreased risk for disease severity and progression: HLA-
839 alone, HLA-827 in the presence of HLA-DR7, and HLA-0Qw3 in the 
absence of HLA-DR7 predispose for additional risk for disease progression; 
independent of psoriasis (46, 177). Specifically, HLA-827 is associated with the 
spondyloarthritis (spinal involvement) form of PsA, and as well with distal 
interphalangeal (DIP) joint involvement (178). Conversely, the presence of HLA-
822 protects against disease progression (179). The RA 'shared epitope' (HLA-
DR81*01 and HLA-DR81 *04) and severity of PsA are associated: patients who 
possessed at least one copy of the shared epitope had significantly more erosive 
39 
disease than those who did not (180). Recently it was also found that carrying 
both HLA-Cw6 and HLA-DRB1*07 alleles predisposed PsA patients towards a 
less severe course of arthritis (181). 
Associations have been reported with two other non-HLA genes in the 
MHC region and PsA, both of which have been replicated . As evidenced through 
its involvement in multiple facets of the psoriatic and inflammatory pathways 
described earlier, variations in the TNF-a gene which is located 250kb 
centromeric from the HLA-8 locus are likely to play a role in PsA. Several studies 
examining promoter polymorphisms in TNF-a with conflicting results have been 
published (174,182,183). The most consistent results have been with the 
promoter SNPs at positions -238 and -308 relative to the start of transcription. 
The -238 and -308 SNPs have shown association across several Caucasian 
populations (174,182,184). Interestingly, other work has shown the -308 
polymorphism to be associated both with more erosive change in PsA patients 
(185), and with serum levels of circulating TNF-a. A recent study has reported 
that the -857 SNP may be a risk factor for PsA but not for psoriasis that is 
independent of the PSORS1 locus (186). 
The other replicated non-HLA MHC gene is the major histocompatibility 
complex class 1-related gene A (MICA) . The MICA gene is a highly polymorphic 
gene situated in the human leukocyte antigen (HLA) class I region, located 47 kb 
upstream from the HLA-B locus, and extensive linkage disequilibrium (LD) 
between HLA-B and MICA has been described (187-189). A triplet microsatellite 
repeat in the transmembrane region of exon 5 of the MICA gene was found to be 
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associated with a number of immunologically mediated disorders such as RA 
(190), Bechet's Disease (191 ), and AS (192-194 ). The location of the MICA gene 
and its extensive LD with HLA alleles associated with PsA, as well as its 
association with the previously described diseases indicate that it is an interesting 
candidate gene for PsA, and several studies have demonstrated an association 
between MICA and PsA across several populations (183, 195, 196). The reported 
association was found to be independent of HLA-Cw*0602 and psoriasis in a 
Spanish population (197), and was also replicated in an Israeli PsA cohort (198). 
MICA represents one of the few genetic associations that appears to be strictly 
involved with PsA and not psoriasis, as no evidence of an association with 
psoriasis has yet been published. 
Two other non-HLA MHC genes have been identified as potential 
candidate genes in PsA however the evidence is less well established. The gene 
known as PsorS1C1 (also referred to as SEEK1) has been suggested as a 
candidate gene, however, its theorized involvement is due entirely to location as 
it overlaps the 6p21 -23 region and is slightly telomeric to and in LD with the HLA-
C locus, was noted to have a strong association with psoriasis in the Swedish 
population and its effect was independent of HLA-Cw*0602 (199). However, the 
function of this gene remains unknown. The Corneodesmosin (COSN) gene is 
found roughly 160kb telomeric from HLA-C, and several reports have described 
associations with psoriasis (as well as LD with HLA-C) (200-202). COSN makes 
an interesting candidate gene in psoriasis and PsA as it is the only transcript from 
the PSORS1 region to be expressed in well differentiated keratinocytes (163), 
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and as well polymorphisms of this gene are known to increase mRNA stability, 
leading to a potential pathogenic mechanism (203). 
1.8.3- Non MHC Genes 
While there are many candidate genes in PsA based on either location or 
putative function in a biological pathway, there is a paucity of replicated candidate 
gene studies. The IL-1 gene cluster on chromosome 2q12-13 is an area of 
special interest as the expression of IL-1 is known to be upregulated in both the 
serum and synovium of patients with PsA (204 ). Ravindran et a/ (205) noted an 
association with the IL-1 alpha 889C polymorphism, however, while this specific 
SNP was not replicated (206), an association with PsA was noted with a 
haplotype of other SNPs in the extend IL-1 family gene cluster (207). 
The Killer Immunoglobulin-like Receptor (KIR) genes encode receptors on 
Natural Killer (NK) cells. The KIR gene cluster is highly polymorphic, nearing the 
level of variation observed in the MHC (208). The KIR receptors interact with 
MHC class I molecules, in particular those encoded by several HLA-C alleles 
(209). Once this interaction occurs, the threshold for triggering a T -cell by 
engagement of the classical T -cell receptor with an antigen presented by MHC 
molecules is lowered, while the presence of an inhibitory receptor will raise the 
threshold necessary for T-cell activation. An association has been observed 
between polymorphisms in the genes KIR2DS1 and KIR2DS2 with both PsA 
(21 0,211) and psoriasis (212), but only if the HLA ligand for the corresponding 
inhibitory receptors (KIR2DL 1 and KIR2DL2/3) were absent. Martin et a/ (213) 
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have proposed a model of how certain HLA and KIR genotypes can influence 
susceptibility to PsA, which postulates the mechanism for a pathogenic role for 
HLA-Cw*0602 in the development of psoriasis and PsA. 
A recent genome wide association study noted an association between 
psoriasis and a haplotype in the II-23R gene (214 ). This was quickly replicated 
(215,216). Interestingly, one of the SNPs in this haplotype is also associated with 
Crohn Disease as a protective allele (217). As there is evidence that IL-23 is 
involved in regulating Th1 pathway responses (218) and it has been detected in 
psoriatic skin (219), the II-23R gene made an obvious target for investigation in 
PsA. Two studies have replicated an association of II-23R with PsA (220,221 ). It 
is interesting to note, however that a recent study reports that synovial fluid, 
serum and synovial biopsies from 30 non-PsA SpA, 22 PsA and 22 RA patients 
do not show an increase in levels of IL-23R for SpA or PsA patients. An increase 
was observed in RA patients, suggesting that IL-23 is likely to be involved in 
psoriasis rather than PsA (222). 
The protein tyrosine phospatase non-receptor type 22 (PTPN22) gene is 
expressed only in hematopoietic cells, acts as a regulator of the negative 
regulatory kinase cytoplasmic tyrosine kinase (CSK) in T cells, and may play a 
role in suppression of T-cell activation (223). A functional SNP at nucleotide 
position 1858 C>T causing an Arg- Trp substitution (R620W) which disrupts the 
binding site for CSK is associated with lOOM (224), and other autoimmune 
diseases including RA (225) and systemic lupus erythematosus (SLE) (226) in 
Caucasian populations. To further examine the role of PTPN22 a collection of 
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265 multiplex families was assembled by the Multiple Autoimmune Disease 
Genetics Consortium (MADGC) {227). At least two of nine "core" autoimmune 
diseases (RA, SLE, IDDM, multiple sclerosis (MS), autoimmune thyroid disease 
(Hashimoto thyroiditis or Grave's disease), juvenile RA, inflammatory bowel 
disease (Crohn disease or ulcerative colitis), psoriasis, and primary Sjogren 
syndrome) were present in each of these families. They obseNed that the 
PTPN22 1858 C> T polymorphism confers risk of four separate autoimmune 
phenotypes in these families: T1 D, RA, SLE, and Hashimoto thyroiditis, 
suggesting a common underlying etiologic pathway for some, but not all, 
autoimmune disorders. No association was observed with psoriasis in the 
MADGC study, however, only 63 psoriasis patients were part of the study group. 
Since that time, several other studies have been conducted examining the 
association of PTPN22 with both psoriasis and PsA, and significant associations 
with both have been obseNed (228-231 ). The clearly evident association of 
PTPN22 with multiple autoimmune diseases makes it a strong candidate for 
continued investigation in PsA. 
1.8.4 - Genome Wide Scans 
Only one traditional genome wide linkage study has been performed in 
PsA, using a large Icelandic cohort. An initial LOD score of 2.17 on chromosome 
16q21 was found, however this was increased to 4.19 when conditioned on 
paternal transmission (154 ). A subsequent study and the use of additional 
markers further raised the LOD score to 5. 7 (232). The peak of this LOD score 
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was within 20Mb of the gene CARD15 which has been associated with Crohn 
Disease (233). One study found an association between this gene and PsA 
(234 ). While this finding has not been replicated {235-237), a recent study has 
shown evidence of an interaction between HLA-Cw6 and CARD15 in psoriasis 
families (238). 
Likewise, only one genome wide association study has been performed 
using a distinct PsA cohort (239). The study, which used both psoriasis and PsA 
cohorts from the US and the UK appears to have confirmed the associations with 
/L -12/23R and PsA. It is worth noting, however, that more recent reports suggest 
that these variants are not specific risk factors for arthritis, but relevant for 
susceptibility to psoriasis in general (240). A recent psoriasis genome wide 
association study that included two cohorts with high levels of PsA would appear 
to add further evidence to this contention (241 ). 
The results of the PsA genome wide association study also confirmed that 
the MHC is truly the most important risk factor for psoriasis and that it plays a 
very major role in PSA, as the most highly associated SNP from the study was 
found 34.7 kb upstream from HLA-C (U.K. PSA: p= 6.9 x 10-11) . The highest odds 
ratio was found for a coding SNP in the MHC class 1 gene HCP5 (OR PsA 3.2, 
Psoriasis 4.1) and the effect was independent of the upstream HLA-C SNP. A 
novel PsA (and potentially psoriasis) locus was also identified on chromosome 
4q27 (239). This region contains the //-2 and 11-21 genes and was recently shown 
to be associated with autoimmune diseases such Celiac disease, Type 1 
diabetes, Grave's disease and Rheumatoid Arthritis (242-245). 
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1.9 - Review of the Genetics of Related Diseases 
1.9.1 - Ankylosing Spondylitis 
Between 40 and 50% of PsA patients have spinal involvement, similar to 
ankylosing spondylitis (AS). AS is one of the most common forms of chronic, 
inflammatory arthritis: it is seronegative for rheumatoid factor (RF), affecting joints 
in the spine and sacroilium in the pelvis, causing eventual fusion of the spine 
(246). It has an estimated prevalence of 0.1-0.9%, and genetic factors have been 
strongly implicated in its aetiology, with a heritability estimated to be >90% (247). 
The mode of inheritance is unclear; however, the recurrence risk ratio suggests a 
multilocus, multiplicative model (248). A very strong association between AS and 
HLA-827 has been established for decades (249), and it is observed in over 90% 
patients with AS. However, HLA-827 is not the sole MHC molecule implicated in 
AS susceptibility. The entire genetic contribution of the MHC is estimated to be 
50% of which HLA-827 accounts for 16% of the effect (250). Only approximately 
8% of individuals with HLA-827 develop AS, and 1 0% of Caucasian AS patients 
do not carry HLA-827 (251 ). 
Three genome wide linkage studies have been performed in AS patient 
families. These data were re-analysed and then pooled for a meta-analysis by 
Carter et a/ (252). Not surprisingly, the MHC region showed the highest 
significance for linkage (p < 1 o-5) to a 37-75 eM region of chromosome 6, 
consistent for linkage with the location of HLA-827. The next strongest evidence 
of linkage was found at chromosome 16q (p = 1.8 x 1 0-4) overlapping the region 
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previously identified as displaying linkage to PsA. Other regions achieving 
moderate evidence of linkage (p < 0.01) were identified on chromosomes 3, 10 
and 19. Nominal evidence of linkage was found for the region containing the /L-1 
gene cluster on chromosome 2q, and with the CYP206 gene on chromosome 22. 
Both of these genes had previously reported associations with AS (207,253-256). 
While no true genome wide association study has been performed on AS 
patients, the Wellcome Trust Case Control Consortium (WTCCC) did examine 
14436 nonsynonymous SNPs and a further 897 SNPs in the MCH region, from 
1 000 AS cases and 1500 controls (242). This is by far the largest association 
study completed to date for AS, but nonetheless has only investigated a small 
proportion of the overall genetic diversity in relation to the disease (257). In 
addition to the expected associations of the SNPs from MHC region, significant 
associations were also identified with the genes IL-23R and ERAP-1 (also known 
as ARTS1). The finding of association with IL-23R is particularly interesting as it 
seems to provide evidence that variants of the gene are involved in bone 
disease, which counters the previously discussed contention that despite being 
associated with both PsA and psoriasis, IL-23R was more likely to be associated 
with psoriasis rather than PsA. Subsequent to the WTCCC study, the association 
of JL-23R with AS has been replicated in Spanish (258), Canadian 
(Newfoundland) (259) and UK (260) cohorts. 
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1.9.2- Crohn Disease/Inflammatory Bowel Disease 
It has long been recognized that patients with Crohn disease have an 
increased risk for the development of PsA and psoriasis (261-263). Both acute 
and chronic inflammation have been reported in the bowel of 15% of PsA patients 
(264) and 30% of psoriasis patients (265). These bowel lesions range from 
asymptomatic focal microscopic inflammation to inflammatory bowel disease 
(lBO) with macroscopic and histologic features indistinguishable from Crohn 
disease (266). As described previously, the only linkage study performed in PsA 
identified a linkage peak within 20 Mb of the known Crohn susceptibility gene 
CARD15 on chromosome 16q21 . Linkage studies in Crohn/IBD indicated that 
another strong susceptibility region was located at chromosome 5q31 known as 
the lBO 5 locus (267,268). Subsequent investigation of the organic cation 
transporter ( OCTN) gene cluster in this region revealed an association of a 
functional haplotype of two SNPs of the SLC22A4 and the adjacent SLC22A5 
genes with Crohn disease (269). Given the known association with Crohn and 
PsA, Ho eta/ examined this haplotype in a PsA cohort, a psoriasis cohort, and an 
undifferentiated inflammatory arthritis cohort, and observed an association only 
with PsA (270), lending evidence that there is commonality in the genetic 
predisposition for inflammatory diseases such as Crohn and PsA (269). 
At the time of this writing, there have been more than 30 replicated genes 
identified in Crohn Disease. The most common associations are the CARD15 
and /805 loci, but several others found through genome wise association studies 
have also been replicated. These associations are summarized in table 1-5. 
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Table 1-5: Summary of selected genetic associations with Crohn Disease, 
replicated by genome wide association studies 
Gene/Locus Region 
CARD15 16q12 
1805 5q31 
IL-23R 1 p31 
ATG1611 2q37 
MST1 3p21 
PTGER4 5p13.1 
IRGM 5q33 
TNFSF15 9q32 
PTPN2 18p11 
Adapted from (274) 
Lead Author and Year 
of Publication 
(Replication) 
Rioux, 2007 
Hampe, 2007 
Raelson, 2007 
Hampe, 2007 
Libioulle, 2007 
Franke, 2007 
WTCCC, 2007 
Libioulle, 2007 
Rioux, 2007 
WTCCC, 2007 
Parkes, 2007 
Raelson, 2007 
WTCCC, 2007 
Parkes, 2007 
Parkes, 2007 
WTCCC, 2007 
Parkes, 2007 
Several published studies based on a candidate gene hypothesis have 
identified an association between nuclear-factor kappa-beta 1 (NFKB1) and lBO 
(271 -273). NFKB1 is a subunit of the NF-KB protein. NF-KB is a pleiotropic 
transcription factor which is present in almost all cell types and is involved in 
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many biological processes such as inflammation, immunity, cell differentiation, 
cel l growth, tumourigenesis and apoptosis, and as described in section 1.5.3, it 
interacts directly with its receptor activator RANK in a central role in 
osteoclastogenesis (275-277). Interestingly, it has also been tentatively 
associated with psoriasis (278,279) and is directly involved in both the TNF-a 
receptor pathway (280,281) and in IL-23 mediated signalling (282,283). 
A total of seven different genome wide association studies in several 
different populations (Asian, North American Caucasian, UK Caucasian, French 
Canadian) have been performed in Crohn disease, and interestingly, several 
have detected associations with IL-23R. The results have indicated both 
protective associations as well as disease-predisposing alleles (284 ). The 
repeated association of /L-23R with interrelated inflammatory immunologically 
mediated conditions such as PsA, psoriasis, AS, and Crohn/180 clearly indicated 
that it is a multi-functional gene involved in systemic inflammation. 
1.9.3 - Rheumatoid Arthritis 
A detailed description of the genetics and pathogenesis of RA is not 
warranted as the disease and most implicated genes are substantially different 
from the disease process and genetics of PsA. The non-HLA genes which have 
been implicated in RA are summarized in table 1-6. A brief description of RA is 
included only to illustrate the difference between both diseases. For a 
considerable period of time, PsA was simply considered to be the co-occurrence 
of psoriasis and RA. RA is a chronic, systemic, inflammatory autoimmune 
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Table 1-6: Summary of selected genetic associations in RA. 
Gene/Locus Region lead author and year of 
eublication 
MMEL 1/TNFRSF14 1 p36.32 WTCCC, 2007 
PADI4 1p36.13 Suzuki, 2003 
PTPN22 1 p13.2 Begovich, 2004 
STAT4 2q32.3 Amos, 2006 
CTLA4 2q33.2 Plenge, 2005 
TNFAIP3/0LIG3 6q23.3 Thomson, 2007 
C5/TRAF1 9q33.2 Plenge, 2007 
PRKCQ 10p15.1 WTCCC, 2007 
KIF5A/PIP4K2C 12q13.3 WTCCC, 2007 
CD40 20q13 WTCCC, 2007 
Adapted from (285) 
disorder causing symmetrical polyarthritis of large and small joints, typically 
presenting between the ages of 30 and 50 years (286). Approximately 1% of the 
global population has RA, and it is found 3 times more frequently in females than 
in males. Like PsA the aetiology of RA is not fully understood but involves a 
complex interplay of environmental and genetic factors. The typical presentation 
is polyarticular, with pain, stiffness, and swelling of multiple joints in a bilateral, 
symmetric pattern . A minority of patients present with oligoarticular asymmetric 
involvement (287). As PsA is largely asymmetrical, the symmetry of the arthritis 
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present is one of the characteristics which helps differentiate PsA from RA, as 
well as the absence of the rheumatoid factor (RF) antibody, axial involvement, 
enthesopathy, and association with HLA-827 (288). While approximately 30% of 
RA patients will be RF seronegative (289), the previously described criteria for 
diagnosis of PsA (Moll & Wright, CASPAR) help distinguish these cases from RA. 
Variation in the HLA region has been associated with RA since the late 
1970's (290) and is the only region that has been consistently shown to be both 
linked and associated with RA across all populations. Whereas the association 
with PsA has been repeatedly shown to be with the HLA-Cw*0602, the HLA 
association with RA is with specific alleles of the class II gene, HLA-DRB1, that 
encode a conserved sequence of amino acids in the third hypervariable region 
(HVR3) of the class II DR-1 chain. These associated alleles are collectively 
referred to as the shared epitope (SE) (291 ). As described in section 1.7.3, the 
MADGC initially reported an association of RA with the PTPN22 gene, and this 
finding has been replicated several times in highly powered studies of 
populations of European descent (151,292-294 ). The WTCCC study also 
confirmed that the two strongest associations for RA are for HLA-DRB1 and 
PTPN22. Several recent reviews and genome wide association studies have 
reported extensive lists of SNPs associated with RA (285,295-298), however, of 
these the only overlap with reported associations with psoriasis or PsA remains 
the PTPN22 gene. While there are different HLA associations with RA and PsA 
reflecting the different pathogenesis of both diseases, the data regarding the 
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reported associations of both diseases with PTPN22 indicate that there may be 
common underlying pathways in inflammatory arthritis. 
1.9.4- Shared Genetics of Immune-related Diseases 
There exists a large spectrum of immunologically mediated diseases, from 
the seronegative spondyloarthropathies such as PsA and AS, as well as RA, to 
other non-arthritic diseases such as inflammatory bowel disease, type 1 diabetes 
and asthma. While genetic associations have long been reported for each of 
these diseases, an increase in co-morbidity and clustering of different 
autoimmune diseases in families suggest the existence of an overlap in the 
genetic background of these diseases (299,300). Until recently, only the HLA 
locus and a few candidate genes have consistently been associated with these 
immunologically mediated conditions, however, with the development of genome-
wide association studies, a growing number of candidate genes and loci have 
been and continue to be identified. 
Recently, Zhernakova et a/. reviewed 22 genome wide association studies on 
11 different immune mediated disorders (300). The authors observed that the 
major region linked to immune-related disorders was the HLA region, and also 
identified 23 genes that are shared by two or more diseases. While the prevailing 
line of thought has maintained that autoimmune disorders develop through 
different mechanisms from those that cause inflammatory disorders, many of 
these newly identified loci are shared by two or more immune-related diseases, 
and the majority of these shared genes belong to just a few immunological 
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pathways: T-cell signalling and differentiation, innate immunity, and TNF 
signalling. Further, many of the disease-specific associated genes are involved in 
the same pathways or were members of two functional groups - one group 
consisted of genes that are shared between ulcerative colitis and Crohn disease 
(lBO), and the other group encoded cytokines and chemokines. Several of the 
disease-specific genes identified also belong to the three immunological 
pathways. Interestingly, at least one associated gene was involved in each 
pathway for almost all of the immune diseases that were studied, which highlights 
the overlap in these immunological pathways between diseases. (The overlap of 
genes in selected immune-related diseases is shown in Figure 1-2). Fully 
elucidating the shared pathogenesis between various immunologically mediated 
diseases has the potential to clarify new targets for therapeutic intervention by 
focusing on pathways rather than genes. 
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Figure 1-2: The overlap of genes associated with multiple auto-immune 
diseases 
(The area of the overlap between PTPN22 and Psor and PsA is left 
transparent as this association has not yet been confirmed . All other 
associations shown have been replicated.) 
Adapted from Zhernakova et al., 2009 
Special thanks to Mr. Lance Doucette 
For his assistance in composing this figure 
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1.1 0 - Rationale and Goals for Study 
Broadly, the goals for this thesis are to confirm existing genetic 
associations with PsA, to identify novel gene associations and gene-gene 
interactions in PsA. As described previously, a large number of studies have been 
performed using several different ethnic populations from different locations 
around the world attempting to associate variations of the genes involved in 
different aspects of the pathogenesis of PsA. These studies have frequently 
produced conflicting results, due to such features as relatively small sample 
sizes, a low frequency of the gene variant being investigated, and ethnic 
heterogeneity of the populations being investigated. 
As PsA is a complex disorder, the genetic component of PsA is likely to be 
the result of a combined effect of a number of genes, with each playing only a 
small role. One of the largest and most common challenges facing case control 
studies is the ethnic heterogeneity of the investigated populations. Newfoundland 
presents an interesting and unique population structure which can help to 
overcome the heterogeneity frequently found in other studies. 
The island portion of the Canadian province of Newfoundland and 
Labrador is located in the Atlantic Ocean, off the eastern coast of Canada. The 
population of the island of Newfoundland consists mainly of descendants of 
English and Irish settlers who arrived in the late 18th and early 19th centuries, 
although settlements dating to the 1600's have been recorded (301 ). The settling 
of Newfoundland is unique when compared to colonization of other areas of the 
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New World, as the majority of those who immigrated to Newfoundland can be 
traced almost exclusively back to small regions in southwest England (the 
neighbouring counties of Cornwall, Devon, Somerset, Dorset, and Hampshire) 
and southeast Ireland (roughly a 30 mile radius from the city of Waterford). These 
areas were the principal ports of the United Kingdom's fishing industry at the time 
(302). The major migrations concluded in the mid-191h century at which point the 
population of the island was approximately 75,000 individuals. From this limited 
number of founding individuals, the population grew almost exclusively through 
expansion as the geographical and social isolation of this island has ensured very 
little inward migration since it was settled (303) and thus has lead to a small 
population (507 900 individuals; Statistics Canada 2008 - 50% of whom still live 
in communities smaller than 2500 individuals). While Newfoundland does not 
represent a true population isolate or founder population, showing levels of 
linkage disequilibrium comparable to that of an outbred European derived sample 
and the Afrikaner population of South Africa (304 ), there is evidence of relatively 
homogenous genetic background as demonstrated by a higher than expected 
prevalence of several Mendelian disorders (305). In addition, mating segregation 
between Irish Catholics and English Protestants, and geographical isolation of 
communities have resulted in several small population isolates, that have become 
more admixed as time and technology have allowed increased access into and 
out of the outports (303). In a review of the historical development of genetic 
isolation, it was observed that only 1% - 8% of breeding parents were immigrants 
to the area, and 60% of births had been to parents originating from the same 
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small community (306). As the Newfoundland population is almost entirely 
derived from settlers who shared a common geographic location and culture for 
several generations, the shared background combined with extensive genealogy 
from the current population are ideal for the study of complex disease such as 
PsA (305). The limitations of using a population such as Newfoundland in genetic 
studies are that the results may not be generalizable to more admixed population 
structures. In order to account for this, we have frequently used a PsA cohort 
from Toronto to validate our findings in the Newfoundland population. 
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2 
MATERIALS AND METHODS 
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2.1 - Patient and Control Ascertainment 
PsA was defined as an inflammatory arthritis in patients with psoriasis, in 
the absence of other aetiologies for inflammatory arthritis. All patients from the 
Newfoundland cohort were ascertained by a qualified rheumatologist (Dr. Proton 
Rahman). All patients were over the age of 18 years and were voluntary 
participants in this research study, who presented at rheumatology clinics under 
the Eastern Health management board in St. John's, NL, Canada. A protocol for 
clinical investigation for this study was approved by the Human Investigations 
Committee of the Faculty of Medicine of Memorial University of Newfoundland, 
and by the Eastern Health healthcare management board of St. John's, NL, 
Canada. All patients were Caucasians of northern European ancestry. All 
controls were ethnically matched, taken from the Newfoundland population, as 
well as matched for age and gender. Control subjects were originally participants 
in other research studies for conditions, that had had no pathological relationship 
to any form of skin disorder or arthritis, and were examined to sure there were no 
other auto-immune condition . 
All patients from the Toronto cohort were Caucasian, were also 
ascertained by a qualified rheumatologist (Dr. Dafna Gladman) and were over the 
age of 18 years and were voluntary participants in this research study. The 
Toronto controls either were ascertained from the local HLA laboratory DNA bank 
which includes healthy volunteers and organ donors, or were population based. 
No information regarding age or gender was available for control subjects from 
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the Toronto cohort, and ancestry was presumed to be Caucasian based on 
individual surname. 
2.2 - DNA Extraction from Whole Blood 
All DNA samples were extracted from white blood cells of venous blood 
which was collected from subjects in EDTA Vacutainer tubes. DNA was extracted 
from PsA probands and age and gender matched controls using the Promega 
Wizard Genomic DNA purification kit (307). Briefly, blood was added to a tube 
containing cell lysis solution and the components were mixed by inversion 
several times and allowed to incubate at room temperature for 10 minutes in 
order to lyse red blood cells. The mixture was then centrifuged at 2000 x g for 10 
minutes. The supernatant was poured off without disturbing the remaining pellet 
of white blood cells, until approximately 100 ~I of residual liquid remained. The 
pellet was then vortexed vigorously to resuspend the white blood cells, and nuclei 
lysis solution was added to the resuspended cells. The solution was pipetted 5-6 
times to lyse the white blood cells. RNase solution was then added to the nuclear 
lysate and mixed by inversion. The mixture was incubated at 3rC for 15 minutes 
and cooled to room temperature. Protein precipitation solution was added to the 
nuclear lysate and the solution was vortexed vigorously for 10-20 seconds, and 
centrifuged at 2000 x g for 10 minutes. A brown pellet containing the precipitated 
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protein was then visible. The supernatant containing the DNA was transferred to 
a clean 15 ml centrifuge tube containing room temperature isopropanol. This 
mixture was gently mixed by inversion until DNA was visible, and was then 
centrifuged at 2000 x g until it formed a small white pellet. The supernatant was 
carefully decanted so as to not disturb the DNA pellet, which was then gently 
washed 70% ethanol by inversion, and centrifuged at 2000 x g. The ethanol was 
gently aspirated using a pipette and the tube was inverted on clean absorbent 
paper leaving the pellet to air dry for 10-15 minutes. 250~1 of DNA Rehydration 
Solution was added to the tube and incubated for 1 hour at 65°C. Concentration 
of extracted DNA was determined by spectrophotometry, and was then 
transferred to a clean, labelled 2000~1 eppendorf tube and stored at -80°C. 
2.3 - Marker Selection 
The pathogenesis of PsA has been described in Chapter 1 as being the 
combination of several distinct mechanisms, involving components situated in 
cytokine-induced inflammation, enthesitis, bone remodelling, and angiogenesis. 
Thus, we have opted for a comprehensive approach to examine genetic markers 
potentially involved in all facets of the pathogenesis of PsA. A candidate gene 
approach is used to investigate novel associations, while meta-analysis is used to 
determine the proportion of involvement for markers which have been replicated 
in other populations. A haplotyping approach is employed in our admixed cohort 
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to attempt to validate an observed association across a gene cluster. Finally, a 
novel algorithm is employed to evaluate potential epistatic genetic interactions to 
determine whether the presence of multiple polymorphisms across several 
biological pathways from multiple chromosomes is a factor in the development of 
PsA. All SNPs chosen for the studies described here were selected on the basis 
of having been reported in previous association studies, or because they were 
non-synonymous - i.e., they caused an amino acid change in the protein for 
which the gene codes. As described by Risch, 2000, and summarized in Table 2-
1 there is an order in preference of SNPs used in genotyping studies, and we 
have chosen those deemed to be the highest priority for association study 
2.4- SNP Genotyping 
The detection of SNPs was performed by the analysis of primer extension 
products generated from previously amplified genomic DNA using a chip-based 
MALDI-TOF (Matrix Assisted Laser De-ionization - Time of Flight) mass 
spectrometry platform (Sequenom, Inc., San Diego, CA) (308-311 ). PCR and 
extension reactions were carried out by diluting the DNA sample to be analyzed 
to 2.5 ng/j..JI , following which 1 iJI of DNA was combined with 200 iJM of each 
dNTP, 0.1 units of HotStar Taq (Qiagen), 0.5 iJI of 1 Ox HotStar PCR buffer 
containing 15 mM MgCI2, PCR primers mixed together at a final concentration of 
200nM (for both multiplex and uniplex reactions), and 0.2 iJI of 25 mM MgCI2 in a 
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SNP Description Number (in thousands) 
Type 
I Coding, Non-synonymous, non-conservative 60-100 
II Coding, Non-synonymous, conservative 100-180 
Ill Coding, Synonymous 200-240 
IV Non coding , 5' UTR 140 
v Non coding , 3' UTR 300 
VI Other non-coding 2:1000 
Table 2-1: Typology of SNPs and their occurrence. 
(Adapted from Risch, 2000) 
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final reaction volume of 51JI. Reactions were heated at 95°C for 15 minutes 
followed by 45 cycles at 95°C for 20 seconds, 56°C for 30 seconds, and 72oC for 
1 minute and a final incubation at 72oC for 3 minute. PCR primers to amplify the 
region around each SNP as well as extension primers were designed using 
Sequenom's SpectroDesigner software. Unincorporated dNTP's were removed 
from the amplification products using 0.3 units of the shrimp alkaline phosphatase 
(Sequenom). The reaction was placed at 3rC for 20 minutes, and the enzyme 
was deactivated by incubating at 85°C for 5 minutes. After shrimp alkaline 
phosphatase treatment, the homogenous massEXTEND reaction was then 
performed. The massEXTEND SNP assays were designed to generate extension 
products of different masses by incorporating either one dideoxynucleotide or one 
deoxynucleotide and one dideoxynucleotide at the polymorphic site (depending 
on which SNP allele was present), to the antisense extension primer which 
annealed immediately 5 ' of the polymorphic site. 1.242 IJI of water, 0.2 IJI of 10x 
Termination mix (Sequenom), 0.018 IJI of 0.063 units/IJI Thermosequenase 
(Sequenom), and 0.54 IJI of 10 IJM extension primer was then added to the 
amplification products. The MassEXTEND reaction was carried out at 94 oc for 
2 minutes and then 55 cycles of 94 oc for 5 seconds, 52°C for 5 seconds, and 
72°C for 5 seconds. The reaction mix was desalted by adding 3 mg of a cationic 
resin, SpectroCLEAN (Sequenom), and resuspended in 16 IJI of water. Reactions 
were carried out in 384 well plastic plates, and where possible PCR reactions 
were multiplexed. All post-PCR sample preparation was performed using the 
Multimek 96 robotic system (Beckman Coulter, Fullerton, CA). Aliquots of the 
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samples were spotted using a SpectroJET nanolitre dispenser (Sequenom) onto 
a 384-element silicon chip preloaded with a 3-hydroxypicolinic acid matrix 
(SpectroCHIP, Sequenom). Mass spectra were generated by the MassARRAY 
spectrometer (Bruker Daltonik GmbH, Bremen, Germany; SEQUENOM). 
Genotypes were automatically determined with the aid of the SpectroTYPER-RT 
software (Sequenom). 
2.5- Fragment Analysis 
The MICA repeat polymorphism was genotyped using the fragment 
analysis module of a Beckman Coulter CEQ 8000 capillary electrophoresis 
automatic DNA sequencer (31 2). Samples were prepared for analysis by 
performing PCR reactions in a 96-well thin walled microplate. Amplification 
reactions were carried out as described in section 2.3, with the difference that 
cycling was as follows: 16 cycles of 94 oc for 45 seconds, 60°C for 45 seconds 
(decreasing temperature by 0.5°C/cycle such that the first annealing temperature 
was 60°C while the final annealing temperature was 52°C), and 72oC for 30 
seconds. This was then followed by 16 cycles of 94 oc for 45 seconds, 52°C for 
45 seconds, and 72oC for 30 seconds. The sample was then prepared for loading 
into the CEQ 8000 instrument by creating a 1:10 dilution in the CEQ Sample 
Loading Solution. A total of 39.51..JI of this dilution was added to 0.51..JI of the of the 
size standard for a final volume of 40.01JI. This solution is then loaded into the 
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instrument and the length of the fragments was calculated, and thus the number 
of repeats present in each sample was determined. 
2.6 - Quality Control 
Quality control measures employed to ensure that data used in the 
projects detailed in this thesis consisted of ensuring a 99% call rate for 
genotyping, as well as a 99.9% reproducibility of genotyping results. This was 
performed by randomly selecting 10% - 15% of samples for duplication in any 
PCR run to be performed in the same 384 plate as the primary reaction. Any 
genotypes not meeting these requirements were repeated until they met quality 
control criteria. Any samples which could not meet the quality control criteria were 
excluded from further analysis. All successful genotypes were investigated for 
fitness to the Hardy-Weinberg Equilibrium (HWE), and any that were not found to 
fit HWE were excluded. 
2.7- Statistical Analysis 
The statistical methodologies used in this work varied depending on the 
nature of the specific experiment being conducted and the required analysis. 
Broadly, all investigated genetic variants were tested to ensure fitness to the 
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Hardy-Weinberg Equilibrium. The specific statistical procedures employed for 
each experiment (univariate/multivariate analysis, haplotyping and sliding-window 
haplotyping, and meta-analysis) are described in detail in the appropriate chapter 
pertaining to that experiment. 
Statistical power was calculated according to the methodology proposed 
by Skol et a!., in Nature Genetics in 2006 (313). Assuming a sample size of 250 
cases and 250 controls, a population prevalence for PsA of 0.25% as described 
by Gelfand et a/., (18), and a disease allele frequency of 0.1 0, we have 96% 
power to detect a genotype relative risk of 2.0 at a significance level of p = 0.05, 
and 55% power to detect a genotype relative risk of 1.5. With a sample size of 
300 cases and 300 controls, we have 99% and 63% power to detect genotype 
relative risks of 2.0 and 1.5, respectively. 
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3 
Genetic Variation of the Major 
Histocompatibility Complex and 
Association with Psoriatic Arthritis 
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3.1 
TN F-a Polymorphisms and Risk of 
Psoriatic Arthritis in Caucasian 
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Introduction: 
Psoriatic Arthritis (PsA) is a complex immunologically mediated disorder 
that results from interplay between multiple genetic and environmental factors 
(23). Although the pathogenesis of PsA is still unclear, there is a substantial 
contribution of genetic factors to the aetiology of PsA (163). The MHC region has 
long been considered to harbour underlying PsA susceptibility gene(s) and it has 
been estimated that at least one third of the genetic contribution of PsA resides 
within this region (163). The tumour necrosis factor alpha (TNF-a) gene, which is 
located 250kb centromeric from HLA-8, has been proposed to be a high priority 
candidate gene in PsA (314). This premise is supported by studies noting 
significantly higher levels of TNF-a in serum, synovial fluid and synovial 
membrane of PsA patients as compared to OA patients and healthy controls 
(204,315). The importance of TNF-a in PsA is further strengthened by the 
marked clinical response of TNF-a blockade in PsA (316). Thus TNF-a appears 
to be a cytokine of critical importance in PsA. 
However, genetic studies of TNF-a polymorphisms and PsA have 
produced conflicting results (174,182-185,198). Selected studies have noted a 
significant association of TN F-a polymorph isms in PsA (182, 184 ), while other 
studies have failed to detect any such association (17 4, 183,185, 198). The 
inconsistencies in these results may reflect to the small effect size of TNF-a, 
insufficient sample size of PsA subjects and controls, differences in populations, 
the presence of linkage disequilibrium, or multiple testing . In view of the location 
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and proposed biologic effect of TNF-a, we felt it was prudent to further evaluate 
the relationship between TNF-a promoter polymorphisms and PsA in two well 
characterized Canadian PsA populations, a founder population from 
Newfoundland and a heterogeneous population from Toronto, Ontario. This was 
followed by a meta-analysis of the TNF-a association studies in Caucasian PsA 
populations. 
Methods: 
Patients 
This study was approved by the ethics committees at Memorial University 
of Newfoundland and the University of Toronto. Informed consent was obtained 
from all patients. PsA was diagnosed as an inflammatory arthritis in patients with 
psoriasis, in the absence of other aetiologies for inflammatory arthritis. 
Information was collected systematically and included age at onset of psoriasis, 
PsA and disease pattern. The control subjects were of similar ethnicity to the 
cases. Controls for the Newfoundland population were volunteers from 
Newfoundland who participated in our study as a result of a local campaign 
seeking population based controls for genetic studies. The Toronto controls were 
ascertained from the local HLA laboratory DNA bank which includes healthy 
volunteers and organ donors. 
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Laboratory Method 
Blood samples were collected from patient volunteers with PsA and 
healthy controls in EDTA anticoagulant. DNA was extracted from peripheral blood 
lymphocytes using the Wizard Genomic DNA Purification Kit from Promega 
(Madison, WI). DNA Samples were genotyped for five TNF variants by time-of-
flight mass spectrometry using the Sequenom platform. All five SNPs were in the 
51- flanking region of TN F-a gene at the following positions: -1031 (T ~C), -863 
(C~A), -857 (C~ T), -308 (G~A) and -238 (G~A) . Primer sequences were 
determined using Sequenom SpectroDESIGNER software v1.3.4 (Table 3-1 ). 
Table 3-1: Primer sequences for TN F-a SNPs 
rs number FORWARD REVERSE MASS EXTEND 
SNPID PRIMER PRIMER PRIMER 
-1031 rs1799964 5'- 5'- 5'-
ACGTIGGATGGG ACGTIGGATGTA GACCCTGACTTI 
GAAGCAAAGGAG CATGTGGCCATA TCCTIC-3' 
AAGCTG-3' TCTCCC -3' 
-857 rs1799724 5'- 5'- 5'-
ACGTIGGATGCT ACGTIGGATGTA CCTCTACATGGC 
ATGGAAGTCGAG TICCATACCTGG CCTGTCTIC-3' 
TATGGG-3' AGGTCC-3' 
-238 rs361525 5'- 5'- 5'-
ACGTIGGATGAC ACGTIGGATGAT AGAAGACCCCCC 
ACAAATCAGTCA CAAGGATACCCC TCGGAA TC-3' 
GTGGCC-3' TCACAC-3' 
-308 rs1800629 5'- 5'- 5'-
ACGTIGGATGGG ACGTIGGATGGA GAGGCTGAACCC 
TCCCCAAAAGAA TTIGTGTGTAGG CGTCC-3' 
ATGGAG-3' ACCCTG-3' 
-863 rs1800630 5'- 5'- 5'-
ACGTIGGATGCT ACGTIGGATGTA CGAGTATGGGGA 
ATGGAAGTCGAG TICCATACCTGG CCCCC-3' 
TATGGG-3' AGGTCC -3' 
For each sample, 2.5 ng of genomic DNA was amplified under standard 
conditions using the forward and reverse primer pairs. After DNA amplification, all 
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unincorporated nucleotides in the PCR product were deactivated using shrimp 
alkaline phosphatase. A primer extension reaction was then carried out using the 
mass extend primer and the appropriate termination mix. The Primer extension 
products were then cleaned and spotted onto a SpectroChip. The chip was 
scanned using a mass spectrometry workstation (Bruker), and the resulting 
spectra were analyzed using the Sequenom SpectroTYPER-RT software. 
With respect to the meta-analysis, the literature was searched up to and 
including October 2004. All articles pertaining to TNF-a polymorphisms in PsA 
were searched in Medline and Embase. As well the reference lists of the articles 
identified were also a searched . We then selected studies that examined 
Caucasian populations and provided enough data so that the number of minor 
alleles and the total number of alleles could be determined. The data was 
extracted by PR and then cross checked by CB. 
Statistical Analysis: 
Logistic regression was used to study the relationship between genotyping 
information and case/control status. The results are summarized in terms of odds 
ratios and significance tests. In addition an exploratory haplotype analysis based 
on EM imputation (317) was conducted. 
Pairwise linkage disequilibrium was assessed for all combinations of TN F-
a variants using Chi-squared tests. Strong associations were noted between -
1 031 and the other variants. The most notable association was between -863 and 
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-1031 (p < 0.001) which was present in separate populations, NF (p < 0.001) and 
Toronto (p < 0.001). For this reason -1031 was dropped from the haplotype 
analysis, which was based on the -238, -308, -857, and -863 variants. 
Meta-analyses were based on random effects analyses. 
Results: 
We examined 237 PsA subjects and 103 controls from Newfoundland and 
203 PsA subjects and 101 controls from Toronto. The mean age of the PsA 
patients in Newfoundland were 50.1 years (11 .3) and Toronto were 50.5 years 
(13.2). Forty-nine percent of PsA subjects were females in the Newfoundland 
cohort and 41% of PsA subjects were females in the Toronto cohort. With respect 
to the subtype of psoriatic arthritis, overall for both populations 61% had the 
polyarticular pattern, 27% the oligoarticular pattern, 5.2% the isolated 
spondyloarthropathy, and 7% were the remaining patterns. All probands had 
psoriasis vulgaris. 
For the genotypes in the controls, there was no evidence of a departure 
from Hardy-Weinberg equilibrium (HWE) in the Newfoundland control population 
(p values were 0.13, 0.31, 0.29, 0.43, and 0.15 for 238(A), 308(A), 857(T), 
863(A), and 1031 (C), respectively). For the Toronto control population the 
comparable p values were 0.16, 0.04, 0.08, 0.24, and 0.23. While there is some 
weak evidence of departure from HWE for the 308(A) and possibly the 857{T) 
polymorphisms, this evidence would not survive any form of adjustment for 
multiple testing. 
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The genotypes and allele frequencies for PsA subjects and controls for 
TNF-a polymorphisms in the Newfoundland and Toronto population are 
presented in Tables 3-2 and 3-3, respectively. For completeness these tables 
present significance levels based on Fisher's exact test for an association 
between allelic frequency and disease status in the separate populations but 
formal comparison of these must be based on tests of heterogeneity reported 
subsequently. 
A combined analysis of data from both populations, based on a stratified 
logistic regression of allelic frequencies, demonstrated a significant association 
between disease status and the -238(A) variant (p = 0.01 ). There was no 
evidence of heterogeneity of the association between the populations (p = 0.49). 
The observed frequencies in the Newfoundland PsA population versus controls 
for -238(A) variant were 10.7% vs. 5.3% respectively, while in the Toronto 
population these were 8.8% vs. 5.9%. 
For the -857(T} variant, there was no evidence of a relationship with 
disease status based on the combined analysis (p = 0.42}. However, there was 
marginal evidence of heterogeneity between the populations (p = 0.07). 
Observed allelic frequencies for the -857(T) variant in the Toronto population 
were 14.8% vs. 8.4% in cases and controls respectively, whereas no comparable 
marked difference was found in the Newfoundland population in which the 
frequencies were 6.8% vs. 7.8%. 
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Table 3-2: TNF-a genotypes and minor allele frequencies of the 
Newfoundland Population 
NF PsA Controls OR P value 
Genotype 
patients 
GIG 181 {79.4%) 93 (90.3%) 
TNF a -238 GIA 45 (19.7%) 9 (8.7%) 
A/A 2 (0.9%) 1 (1.0%) 
Allele F. (A) 10.7% 5.3% 2.13 0.03 
GIG 146 (64.9%) 67 (65.1 %) 
TNF a -308 GIA 75 (33.3%) 33 (32.0%) 
A/A 4 (1 .8%) 3 (2.9%) 
Allele F. (A) 18.4% 18.9% 0.97 0.91 
CIC 191 (86.8%) 88 (85.4%) 
TNF a -857 TIC 28 (12.7%) 14 (13.6%) 
TIT 1 (0.5%) 1 (1.0%) 
Allele F. (T) 6.8% 7.8% 0.87 0.74 
CIC 167 (72.3%) 70 (68.0%) 
TNF a -863 A/C 60 (26.0%) 30 (29.1 %) 
A/A 4 (1 .7%) 3 (2.9%) 
Allele F. (A) 14.7% 17.5% 0.82 0.36 
TNF a -1031 TIT 128 (58.2%) 63 (61 .2%) 
TIC 77 (35.0%) 33 (32.0%) 
CIC 15 (6.8%) 7 (6.8%) 
Allele F. (C) 24.3% 22.8% 1.09 0.69 
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Table 3-3: TNF-a Genotype and minor allele frequencies of the Toronto 
Population 
Toronto PsA Controls OR P value 
patients N=101 
Genotype n=199 
GIG 164 (82.4%) 90(89.1 %) 
TNF a -238 GIA 35 (17.6%) 10(9.9%) 
A/A 0 (0%) 1 (1.0%) 
Allele F. (A) 8.8% 5.9% 1.53 0.26 
GIG 144 (70.9%) 69 (68.3%) 
TNF a -308 GIA 53 (26.1%) 25 (24.8%) 
A/A 6 (3.0%) 7 (6.9%) 
Allele F. (A) 16.0% 19.3% 0.80 0.31 
CIC 148 (74.4%) 86 (85.1 %) 
TNF a -857 TIC 43 (21.6%) 13 (12.9%) 
TIT 8 (4.0%) 2 (2.0%) 
Allele F. (T) 14.8% 8.4% 1.89 0.03 
CIC 155 (77.5%) 71 (68.0%) 
TNF a -863 A/C 41 (20.5%) 26 (29.1 %) 
A/A 4 (2.0%) 4 (2.9%) 
Allele F. (A) 12.3% 16.8% 0.69 0.13 
TNFa-1031 TIT 126 (63%) 61 (61.6%) 
TIC 65 (32.5%) 32 (32.3%) 
CIC 9 (4.5%) 6 (6.1%) 
Allele F. (C) 20.8% 22.2% 0.92 0.67 
For the -308(A), -863(A) and -1031 (C) variants, there was no evidence of 
relationship with disease status (p values of 0.48, 0.28 and 0.64 respectively) or 
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heterogeneity of effects between populations (p values of 0.53, 0.61 and 0.57 
respectively). Results based on a more conservative genotype analysis (318) not 
influenced by HWE assumptions (319) were very similar. 
We then conducted a haplotype analysis for SNPs -238, -308, -857, and 
-863, in the two populations. The most notable result concerns the frequencies of 
the 1222 haplotype (where (1) indicates the presence of a minor allele, and (2) 
the presence of a major one) in patients and controls from Newfoundland (p = 
0.04 ). The analysis suggests a greater frequency of this haplotype in cases than 
in controls. In Toronto, no significance was attached to this haplotype (p = 0.27). 
In the Toronto population the haplotype that appeared to be associated with the 
disease expression was 2212 (p = 0.03). This relation was not evident in 
Newfoundland (p = 0.6). Adjustments for multiplicity are required for interpretation 
purposes, however. A simple Bonferroni adjustment would generate significance 
levels of 0.04x9 = 0.36 and 0.03x7 = 0.21 (as we have nine possible haplotypes 
in Newfoundland and seven in Toronto). Thus we report these haplotype 
frequencies as hypothesis-generating for future studies. Nevertheless, these 
haplotype analyses do support the univariate SNP analyses, as they indicate that 
the presence of minor alleles at -238 in Newfoundland and at -857 in Toronto 
may be of importance for disease expression. 
Meta-analysis 
Nine cohorts from eight studies (including our two Canadian cohorts) were 
identified in the meta-analysis (1 74, 182-185, 198,320). The leading author, year 
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of publication, population, TNF-a variants and the number of minor and total 
alleles for each of the variants are listed in Table 3.1-4. The results of the meta-
analysis are summarized in figure 3-1 for the TNF-a variants -238 and -308, 
which have been most extensively studied. The figures related to the other 
variants are not presented since they involve only three populations. Only the -
238 variant was noted to have a significant association (OR 2.29 (95% Cl 1.48, 
3.55)). If the Japanese study is excluded from the meta-analysis, the pooled 
estimates for all the TNF-a variants were: -238(A) OR 2.37 (95% Cl 1.52, 3.69); -
308(A) OR 0.92 (95% Cl 0.69, 1.23); -857 (T) OR 1.30 (95% Cl 0.61, 2.79); -
863(A) OR 0.75 (95% Cl 0.55, 1.04); and -1031(C) OR 1.00 (95% Cl 0.75, 1.33), 
the latter three being based only on the combined analysis of the Newfoundland 
and Toronto data. If, however, the Japanese study is included in the 
meta-analyses, this did not have a significant impact on the above results, 
leaving them practically unchanged (see fig 3.1-1 for -238(A) and -308(A)). Note 
that a test for heterogeneity in the -238 meta-analysis was associated with a 
marginal significance level of 0.05, likely associated with the higher ORs 
observed in the German studies (182, 184 ). A more significant result was 
associated with the -308 analysis (p=0.01) due to the German_2 study's outlying 
OR (184 ). This serves as justification for the use of a mixed effects model which 
adjusts for heterogeneity. 
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Table 3-4 - SummarY of TNF-a associations studies in PsA 
Author Year Population -238(A) -308(A) -857(T) -863(A) -1031( C) 488(A) 
Rahman 2005 NFLD Cases 49/456 83/450 30/440 68/462 107/440 
(10.7%) (18.4%) (6.8%) (14.7%) (24.3%) 
Controls 11/206 39/206 16/206 36/206 47/206 
(5.3%) (18.9%) (7.8%) (17.5%) (22.8%) 
Rahman 2005 Toronto Cases 35/398 65/406 59/398 49/400 83/400 
(8.8%) (16.0%) (14.8%) (12.2%) (20.8%) 
Controls 12/202 39/202 17/202 34/202 44/198 
(5.9%) (19.3%) (8.4%) (16.8%) (22.2%) 
Hohler 2002 German_1 Cases 30/174 9/174 
(17.2%) (5.2%) 
Controls 7/198 34/198 
(3.5%) (17.2%) 
Hohler 1997 German_2 Cases 20/124 19/124 
(16.1%) (15.3%) 
Controls 7/198 32/198 
(3.5%) (16.1%) 
Gonzalez 2002 Spanish Cases 15/162 25/162 
(9.3%) (15.4%) 
Controls 14/220 24/220 
(6.4%) (10.9%) 
Gonzalez 2001 Jewish Cases 7/104 8/104 
(6.7%) (7.7%) 
Controls 3/146 15/146 
(2.0%) (10.3%) 
AI-Heresh 2002 Irish Cases 23/248 52/248 17/248 
(9.3%) (21.0%) (6.9%) 
Controls 14/202 33/202 14/202 
(6.9%) (16.3%) (6.9%) 
Balding 2003 Irish Cases 70/298 
(23.5%) 
Controls 172/780 
(22.1 %) 
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Hamamot 2000 
0 
Japanese Cases 0/40 
(0%) 
Controls 4/174 
0/40 
(0) 
5/174 
(2.3%) (2.9%) 
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Figure 3-1: Meta Analysis: Fixed Effects Model for TNF-a -238 (A) and -308 
(A) variants. 
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Discussion: 
PsA has a strong heritability as reflected by a relative risk of 55 among first 
degree relatives with PsA ( 141 ). The TN F-a gene has long been considered a 
major susceptibility gene in immunologically mediated disease including PsA, as 
this cytokine is of critical importance in the pathogenesis of PsA (163). The 
associations between the two most widely cited TNF-a promoter polymorphisms 
(-238 and -308 variants) and PsA have been evaluated in several Caucasian 
populations (174, 182-185, 198). Prior to our study, a significant association for 
TN F-a and PsA was noted only in German populations (182, 184 ). In this study, 
we examined five common variants in the promoter region of the TNF-a gene, 
including -238 and -308. We noted a significant association between -238 variant 
and PsA in the Newfoundland population. The magnitude of our risk (OR=2) was 
not as high as reported in the German studies (OR=5). This may reflect a 
difference in population diversity, although it is well recognized that early 
association studies tend to overestimate the magnitude of the association 
conferred by a genetic polymorphism (321 ). 
Our pooled analysis of all TNF-a studies in Caucasian PsA populations 
also noted a significant association between -238(A) and PsA. The -238(A) 
variant increased the odds of PsA by two fold in Caucasian populations. The 
meta-analysis failed to support the association with the -308 (A) variant, which 
was previously reported in one of the German studies (182). The pooled 
estimates for the other variants revealed no significant association, although the 
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estimates for -857, -863 and -1 031 were based only on the combined analysis of 
the Canadian population and the small Japanese cohort. 
The differing results noted in the Irish (174,185) and Spanish {183,198) 
populations may be due to ethnic admixture resulting in population stratification, 
population specific gene-gene or gene-environment interactions, variable linkage 
disequilibrium between the polymorphisms and statistical fluctuations {322,323). 
Another possible explanation is the weak genetic effect of the underlying 
polymorphisms. In a meta-analysis of 370 studies addressing 36 genetic 
associations for various outcomes, it was noted that when the sample size of less 
than 150 patients were used, there is a 7 fold higher rate of discrepancy between 
the first and subsequent studies, as compared to studies with a sample size of at 
least 150 (321 ). Except for our studies in the Canadian cohorts, all other studies 
reported their finding using less than 150 PsA probands. As a result these studies 
may be underpowered to reliably assess the impact of TNF-a polymorphisms in 
PsA. 
As the previous studies were modest in size, we conducted a meta-
analysis to assist in estimating the population-wide genetic effect of the 
commonly cited TNF-a polymorphisms. Our pooled analysis demonstrated a 
significant association between -238(A) and PsA. Based on this finding along 
with the positional (i.e., close to the HLA-Cw6 locus) and functional 
characteristics of TNF-a, we feel that there is likely a genuine association 
between the -238{A) variant of TNF-a and PsA. However, we do acknowledge 
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that population stratification was not entirely avoided as family based controls 
were not used in these studies. Furthermore, publication bias may exist in the 
meta-analysis, as small negative association studies are often not published. As 
demonstrated in our study, since meta-analysis of association studies in complex 
diseases are helpful in estimating population-wide genetic effects, further efforts 
must be made to track all association data for a given polymorphism (positive or 
negative, small or large, published or not). 
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Introduction 
Psoriatic Arthritis (PsA) is an inflammatory form of arthritis usually 
seronegative for rheumatoid factor (6), It may affect as many as 30% of patients 
with psoriasis (7,8). PsA is a complex immunologically mediated disorder which 
likely results from the interplay of several genetic elements and environmental 
factors. Although psoriasis and psoriatic arthritis (PsA) are interrelated disorders, 
PsA is a distinct entity with its own epidemiological clinical and genetic features. 
Furthermore, PsA demonstrates much greater heritability than does psoriasis 
among first degree relatives (A1 30.4 vs. 7.6) and among siblings of PsA and 
psoriasis patients (As 30.8 vs. 8.8) (150). 
The most common genetic association for both psoriasis and PsA has 
been shown to be the HLA-Cw*0602 allele, however, other strong associations 
have been demonstrated for HLA-813, -827, -837, and -857 (52,145). The MICA 
(major histocompatibility complex class 1-related chain A) gene is a highly 
polymorphic gene situated in the human leukocyte antigen (HLA) class I region, 
located 4 7 kb upstream from the HLA-8 locus, and extensive linkage 
disequilibrium between HLA-8 and MICA has been described (187-189). The 
MIG genes represent a second lineage of mammalian MHC class I genes, and 
include seven members (MICA- MICG); five of these are pseudogenes and gene 
fragments, whereas MICA and MIC8 are functional genes closely related to each 
other (188). The MICA gene is expressed primarily in gastrointestinal epithelium 
(as well as keratinocytes and fibroblasts), and appears to act as a stress induced 
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signal for the NKG2D receptor causing activation of natural killer (NK) cells and 
T-cells {324,325). 
MICA encodes a cell surface glycoprotein of 383 amino acids, composed 
of three extracellular domains coded for by exons 2,3 and 4, a transmembrane 
domain coded for by exon 5 and a carboxy-terminal cytoplasmic tail (326,327). 
There is a triplet microsatellite repeat in the transmembrane region of exon 5 of 
the MICA gene. These repeat alleles are named A4, A5, A6, A9, A 10 reflecting 4, 
5, 6, 9, or 10 GCT repeats, or A5.1 reflecting 5 GCT repeats with the insertion of 
an additional G nucleotide. This repeat polymorphism has been associated with 
several autoimmune disorders such as RA (190), Bechet's Disease (191 ), 
Ankylosing Spondylitis (192-194) and PsA (183,195-198,328), across several 
populations. In order to evaluate the contribution of the MICA repeat 
polymorphism we analyzed PsA patients and healthy controls from the relatively 
homogeneous Newfoundland population, and then performed a meta-analysis of 
MICA alleles and PsA using previously reported data. 
Methods 
Patients 
This study was approved by the ethics committee at Memorial University 
of Newfoundland. Informed consent was obtained from all patients. Study 
participants were evaluated by a rheumatologist, and PsA was diagnosed as an 
inflammatory arthritis in patients with psoriasis, in the absence of other 
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aetiologies for inflammatory arthritis. Information was collected systematically and 
included age at onset of psoriasis, PsA, and disease pattern. The control subjects 
were ascertained from the Newfoundland population, and were all unrelated. 
Laboratory Methods 
Blood samples were obtained from 309 patient volunteers with PsA and 
310 healthy controls in EDTA anticoagulant blood collection tubes. DNA was 
extracted from peripheral blood lymphocytes using the Wizard Genomic DNA 
Purification Kit from Promega (Madison, WI). DNA Samples were genotyped for 
the MICA exon 5 repeat polymorphism using the Beckman Coulter CEQ 8000 
automatic sequencer with primers designed using lOT's PrimerQuest program 
(www.idtdna.com). 
With respect to the meta-analysis, the literature was searched up to and 
including January 2009. All articles pertaining to MICA repeat polymorphism in 
PsA were searched in Pubmed/Medline and Embase. As well, the reference lists 
of the articles identified were searched . We limited our selections to studies that 
examined Caucasian populations and provided enough data so that the number 
of individual repeat alleles (A4, A5, etc) as well as the total number of alleles 
present in both PsA patients and controls could be determined. The data was 
extracted by CB and then cross checked by DH and MU. 
Statistical Analysis 
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Logistic regression was used to study the relationship between genotyping 
information and case/control status. The results are summarized in terms of odds 
ratios and significance tests. Pairwise linkage disequilibrium was assessed for all 
combinations of MICA repeat variants using Chi-squared tests. Meta-analyses 
were also based on logistic regression analyses and present results for individual 
studies and overall estimates of disease/genotype relationships from fixed effect 
stratified regression analyses. 
Results 
The results of the MICA genotyping in the Newfoundland population is 
summarized in table 3-5. The MICA A9 allele was detected in 102/309 PsA 
patients vs. 71/310 control subjects (OR 1.66, 95% Cl1.16- 2.37, p=0.005), and 
was found to be significantly associated with PsA in the Newfoundland 
population. MICA A6 was found in 79/309 patients vs. 101/310 controls (OR 0.71, 
95% Cl 0.50- 1.01, p=0.05). For the remaining alleles, MICA A5.1 was observed 
in 226/309 vs. 218/310 (OR 1.14, 95% Cl 0.81 - 1.16, p=0.43); for MICA A5 it 
was 51/309 vs. 72/310 (OR 0.65, 95% Cl 0.44- 0.97, p=0.04) and for MICA A-4 it 
was 72/309 vs. 59/310 (OR 1.29, 95% Cl 0.88- 1.90, p=0.19). 
For the meta-analyses, a total of six studies with six different cohorts 
(including our own) met the inclusion criteria for analysis of the MICA A9 allele 
(195-198,328), while five were included for analysis of the MICA A4, A5, A6 
alleles (196-198,328), and four were retained for analysis of the MICA A5.1 allele 
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Table 3-5 - MICA triplet repeat polymorphism frequency in the 
Newfoundland population 
MICA NF PsA Controls OR (95% Cl) P value 
Repeat patients n=310 
allele n=309 
A4 72 (23.3%) 59 (19.0%) 1.29 (0.88-1.90) 0.19 
A5 51 (16.5%) 72 (23.2%) 0.65 (0.44-0.97) 0.04 
A5.1 226 (73.1%) 21 8 (70.3%) 1.14 (0.81-1 .16) 0.43 
A6 79 (25.6%) 101 (32.6%) 0.71 (0.50-1 .01) 0.05 
A9 102 (33.0%) 71 (22.9%) 1.66 (1.16-2.37) 0.005 
(196-198). The meta-analysis appears to reveal a strong association between the 
MICA A9 allele and PsA. 
A total of 884 PsA cases and 1 023 controls from six studies were 
genotyped for the MICA A9 allele. The overall OR and 95% Cl for the association 
between PsA and MICA A9 was 1.89 (1 .55 - 2.31; p < 0.0001 ). There was no 
significant heterogeneity between these studies. For the remainder of the MICA 
alleles, the meta-analysis revealed ORs of; A4 - 1.24 (0.98 - 1.57); A5 - 0.76 
(0.58- 0.98); A5.1 - 0.91 (0.73 - 1.13); A6 - 0.79 (0.64 - 0.98) [See Figs 3.2-1 a-
e). 
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Figure 3-2(a-e): Meta Analysis - Fixed Effects Models for MICA 
A9, A4, AS, A5.1, and A6. 
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Figure 3-2a: Meta Analysis - Fixed Effects Model for MICA A9 
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Figure 3-2b: Meta Analysis - Fixed Effects Model for MICA A4 
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Figure 3-2c: Meta Analysis - Fixed Effects Model for MICA A5 
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Figure 3-2d: Meta Analysis- Fixed Effects Model MICA A5.1 
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Figure 3.2-1e: Meta Analysis- Fixed Effects Model MICA A6 
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Discussion 
The strongest genetic association for both psoriasis and PsA has 
repeatedly been shown to be the HLA-Cw*0602 allele, although other significant 
associations with HLA-8 alleles have been demonstrated. Even in the absence of 
HLA-Cw*0602, genome wide association studies of psoriasis and PsA indicate 
that the strongest associations are with the MHC region (239,241 ). As MICA is 
located 47kb from the HLA-8 locus, the possibility exists that MICA may simply 
be in linkage disequilibrium with a true risk allele; however, previous studies have 
indicated that when MICA alleles are associated with PsA, it is independent of 
HLA-Cw*0602 (195-198). We have observed a higher prevalence of the MICA A9 
allele in our Newfoundland PsA cohort when compared to controls (33% vs. 
22.9%), and through an extensive meta-analysis have demonstrated that the 
presence of the MICA A9 allele imparts a highly significant odds ratio 1.89 (95% 
Cl 1.55 - 2.31; p < 0.0001) indicating that the MICA A9 allele is a risk factor for 
PsA. 
PsA is thought to beaT cell mediated disease (92,93). It has been shown 
that the MICA protein is recognized as a ligand by intestinal epithelium NKG2D 
receptors of natural killer (NK) T -cells (329), although evidence suggests that 
MICA is not involved in antigen presentation (330). The recognition of MICA by 
NKG2D receptors is interesting as it has been reported that PsA is associated 
with variation of another family of NK receptors, the killer immunoglobulin-like 
receptors (KIR) (21 0,213,331 ). It has long been recognized that patients with 
Crohn Disease/Ulcerative Colitis have an increased risk for the development of 
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PsA {263,265). There have been reported associations of MICA repeat 
polymorphisms and ulcerative colitis (332,333) as well as several other 
immunologically mediated diseases such as type I diabetes {lOOM) (334) and 
another seronegative spondyloarthropathy, ankylosing spondylitis (193,335). 
Cumulatively, the function of the MICA gene product and the reported disease 
associations suggest a direct involvement in PsA. Further studies exploring the 
functional role of MICA in PsA are warranted. 
Finally, it is worth mentioning that upon completion of this work, another 
report regarding MICA repeat polymorphisms was released (336). While the 
authors did detect a higher frequency of the MICA A9 allele in PsA and PsA with 
type II psoriasis versus controls (46.0% and 58.6% vs. 30.8%, respectively) this 
difference did not achieve statistical significance after correction for multiple 
testing. However, as the sample size was small (200 PsA patients and 188 
control subjects) we feel that it is unlikely these results would change the finding 
from our meta-analysis showing the MICA A9 allele is a significant risk factor for 
PsA. 
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l 
Based on association studies and genome wide linkage scans in psoriasis, 
there is convincing evidence for a major psoriasis susceptibility locus within the 
MHC complex [as reviewed in (163)]. The primary area of interest resides in a 
200 kb region between HLA-C and corneodesmosin (CDSN) that is in strong 
linkage disequilibrium (LD). Despite widely reported associations between HLA-
Cw*0602 and psoriasis, there is ongoing debate about role of HLA-Cw*0602 as 
the causative allele, as this allele is neither necessary nor sufficient to develop 
psoriasis. Meanwhile, the CDSN gene, which is 160 kb from HLA-C, has been 
proposed as a candidate gene in psoriasis as it is the only PSORS1 transcript to 
be expressed in well differentiated keratinocytes, and is responsible for 
corneocyte adhesion and desquamation (163). However, association studies 
between CDSN and psoriasis have reported conflicting results and the data have 
been difficult to interpret due to LD with HLA-Cw6 (163,200-202,337-339). The 
association between CDSN polymorphisms and psoriatic arthritis (PsA) has not 
been systematically evaluated. Thus, based on the inter-relationship between 
psoriasis and PsA, and the location and proposed function of CDSN, we 
examined the association between CDSN polymorphisms and PsA in two distinct 
populations, a founder population from Newfoundland, Canada, and an admixed 
population from Toronto, Canada. 
This study was approved by the local ethics committees at Memorial 
University of Newfoundland and the University of Toronto. Informed consent was 
obtained from all patients. PsA was diagnosed as an inflammatory arthritis in 
patients with psoriasis, in the absence of other aetiologies for inflammatory 
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arthritis. The control subjects were ascertained from their respective regions, and 
were all unrelated. 
Blood samples were collected from volunteers in EDTA anticoagulant and 
DNA was extracted from peripheral blood lymphocytes using the Wizard 
Genomic DNA Purification Kit from Promega (Madison, WI). The following four 
SNPs in the COSN gene [619 (rs707913); 1215; 1236 (rs1042127); 1243 
(rs3132554 )]. were evaluated in our study. PsA subjects and controls were 
genotyped for the COSN polymorphism by time-of-flight mass spectrometry, 
using the Sequenom platform. The PCR primers were designed using 
MassARRAY assay design software v1 .3.4. Logistic regression was used to 
study the relationship between genotyping information and case/control status. 
The results are summarized in terms of significance tests. 
We examined 226 PsA subjects and 1 07 controls from Newfoundland and 
210 PsA subjects and 99 controls from Toronto. The genotypes for the controls 
satisfied the Hardy-Weinberg equilibrium. The allele frequencies for PsA subjects 
and controls for COSN polymorphisms in the Newfoundland and Ontario 
population are presented in Table 3-6. We observed no association between 
CDSN polymorphisms (619, 1215, 1236 and 1243), and PsA in either the 
Newfoundland or Ontario cohorts. 
Our results contrast those of Ahnini et al, who first reported an association 
between CDSN allele (+1243) and Type I psoriasis (337) and Capon et al, who 
noted a cluster of three COSN polymorphisms to be associated with psoriasis, in 
differing ethnic populations (200) as well as Schmitt-Egenolf et al. who observed 
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Table 3-6: Allele Frequencies of CDSN polymorphisms in Newfoundland and 
Toronto Population 
SNP Newfoundland Toronto 
PsA Control P value PsA Control P value 
619 (C) 35.4% 40.6% 0.44 36.3% 32.2% 0.58 
1215 (G) 4.9% 1.5% 0.37 8.9% 6.2% 057 
1236 (G) 27.4% 30.8% 0.61 38.2% 34.3% 0.60 
1243 (T) 70.4% 75.2% 0.44 64.5% 69.4% 0.48 
that Corneodesmosin was more closely associated with psoriasis than HLA-
Cw6*0602 (338). However, the interpretation of these results is difficult as it is 
confounded by LD across th is region. More recently, there has been heightened 
interest in the CDSN gene in psoriasis as a synonymous SNP in the CDSN gene 
has shown to increase mRNA stability and is associated with psoriasis across 
diverse populations (340). However, other investigators have failed to detect an 
association between CDSN polymorph isms and PsA (202,339). 
In summary, we did not detect an association between CDSN 
polymorph isms and PsA in two distinct Canadian cohorts. However the possibility 
still remains that novel SNPs of these genes, or genes further up- or down-
stream of CDSN may play a role in PsA. Alternatively, the CDSN may be in LD 
with the true susceptibility gene as a locus in a 70Kb interval around the CDSN 
gene has recently been mapped for psoriasis (201 ). 
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INTRODUCTION 
As psoriasis and psoriatic arthritis (PsA) are interrelated disorders, these 
entities, at times, share common genetic determinants (163). The association of 
the HLA-Cw*0602 allele with psoriasis and PsA is one such example. HLA-
Cw*0602 has long been considered to be the major predisposing factor for 
psoriasis (140, 163), and the prevalence of this allele is also increased among 
subjects with PsA (341 ). Furthermore, in both these entities, the presence of 
HLA-Cw*0602 predicts an earlier age of onset of psoriasis (157,158,174). 
However, whether the HLA-Cw*0602 allele actually represents the true psoriasis 
gene or is in linkage disequilibrium with the true gene has not been adequately 
elucidated (140, 163). SEEK1 {also known as PSORS1C1), which overlaps the 
6p21 -23 region and is in close proximity to the HLA-C locus, was recently noted 
to have a strong association with psoriasis in the Swedish population (199). In 
that study of 87 subjects with uncomplicated psoriasis, the +39604 polymorphism 
(rs3815097) in exon 2 of SEEK1 was found in 66% of patients with psoriasis as 
compared with 22% of controls (p = 0.000001 ). This polymorphism exhibited the 
strongest association with psoriasis and its effect was independent of HLA-
Cw*0602. Because of the striking association of rs3815097 in SEEK1 and 
psoriasis, we set out to determine the prevalence of this SEEK1 polymorphism in 
two distinct Canadian populations. 
105 
PATIENTS AND METHODS 
Patients 
This study was approved by the ethics committees at Memorial University 
of Newfoundland and the University of Toronto. Informed consent was obtained 
from all patients. PsA was diagnosed as an inflammatory arthritis in patients with 
psoriasis, in the absence of other causes for inflammatory arthritis. Information 
was collected systematically and included age at onset of psoriasis, PsA, and 
disease pattern. The control subjects were obtained from their respective regions, 
and were all unrelated. 
Laboratory methods 
Blood samples were collected from volunteers in EDTA anticoagulant, and 
DNA was extracted from peripheral blood lymphocytes using the Wizard Genomic 
DNA Purification Kit from Promega (Madison, WI). Subjects with PsA and controls 
were genotyped for the SEEK1 polymorphism by time of flight mass 
spectrometry, using the Sequenom platform. The polymerase chain reaction 
(PCR) primers were designed using MassARRAY assay design software, version 
1.3.4. Mass array assay design was as follows: PCR primer 1: 
ACGTTGGATGTGCAACAGAAACCATCACCC; PCR primer 2: 
ACGTTGGATGTATGTGCTGGGAACTCAGTG. The primer sequences were 
obtained from Integrated DNA Technologies (Coralville, lA). For HLA genotyping, 
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200 ng of genomic DNA was amplified using the Dynal RELI SSO HLA-Cw* 
typing kit. PCR amplicons were identified by a reverse line assay using 
sequence-specific oligonucleotide probes. Assay results were interpreted using 
the pattern matching program provided by Dynal. 
Statistics 
Logistic regression was used to study the relationship between genotyping 
information and case-control status. The results are summarised as odds ratios 
(ORs) and significance tests. The association between age at onset of psoriasis 
and age at onset of PsA was examined semiparametrically (342). A l test was 
used to examine the relationship between the SEEK1(T) polymorphism and 
disease pattern. 
RESULTS 
One hundred and three patients with PsA (42% women) and 105 ethnically 
matched controls from Newfoundland were assessed. The mean (SO) age of the 
patients with PsA from Newfoundland was 49.6 (1 0.7) years, mean (SO) age of 
onset of psoriasis was 31.0 (14.1) years and of PsA 38.0 (1 0.8) years. Of the 103 
patients with PsA cases who were genotyped for rs3815097, there were 3 
homozygotes for the mutant T allele {TT), 4 7 heterozygotes {TC), and 53 
homozygotes for wild-type C allele (CC). Of the 105 Newfoundland controls 
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genotyped, there were 3 homozygotes for the mutant T allele (TT), 31 
heterozygotes (TC), and 71 homozygotes for the wild-type C allele (CC). The 
frequency for the minor (T) allele for the rs3815097 was 48.5% in the 
Newfoundland patients with PsA compared with 32.4% in controls (OR= 2.0; p = 
0.02). Two hundred and two patients with PsA (41% women) and 100 ethnically 
matched controls from Ontario were genotyped. The mean (SO) age of the 
patients with PsA from Ontario was 50.5 (13.2) years, mean (SO) age of onset of 
psoriasis was 26.9 (12.2) years and of PsA 32.5 (1 0.8) years. Of the 202 patients 
with PsA who were genotyped for rs3815097, there were 17 homozygotes for the 
mutant T allele (TT), 77 heterozygotes (TC), and 108 homozygotes for wild-type 
C allele (CC). Of the 100 Ontario controls genotyped, there were 6 homozygotes 
for the mutant T allele (TT), 32 heterozygotes (TC), and 62 homozygotes for the 
wild-type C allele (CC). The frequency for the minor (T) allele for the rs3815097 
was 46.5% in the Ontario patients with PsA compared with 38.0% in controls (OR 
1.4; p = 0.16). The results are summarized in table 3-7. 
A combined analysis of the Newfoundland and Ontario data demonstrated 
an overall association between the SEEK1(T) allele and PsA (p = 0.009). 
Additionally, there was no evidence for a SEEK1(T) allele and geographic 
location interaction (p = 0.39). Thus it cannot be established that the role of the 
SEEK1(T) allele in the incidence of PsA differs in the two populations. In separate 
analyses, the effect of HLA-Cw*0602 is strong in the Newfoundland population (p 
= 0.0004) but is not noted in the Ontario population (p = 0.41 ). In contrast with the 
SEEK1 analysis, however, a multivariate analysis does provide evidence for an 
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Table 3-7 Allele frequency of minor SEEK1 and HLA-Cw*0602 
Newfoundland Ontario 
PsA Controls OR p Value PsA Controls OR p Value 
SEEK1(T) 48.5 32.4 
HLA-Cw*0602 35.9 14.4 
2.0 0.02 46.5 38.0 
3.3 0.0004 28.2 23.5 
1.4 0.16 
1.3 0.41 
interaction between HLA-Cw*0602 and geographic location (p = 0.02), 
demonstrating that the effect of HLA-Cw*0602 on the incidence of PsA is 
significantly different in the two populations. Furthermore, when HLA-Cw*0602 
and its interaction with location is included in a multivariate model, addition of the 
SEEK1(T) allele does not improve the model significantly (p = 0.26). Therefore, 
although SEEK1(T) is associated with PsA, SEEK1 does not appear to be a 
further susceptibility factor if the HLA-Cw*0602 status is already known. Table 1 
presents a summary of the allele frequency for the minor SEEK1 allele (T) and 
the presence of the HLA-Cw*0602 allele. Linkage disequilibrium between HLA-
Cw*0602 and SEEK1(T) is reflected in the fact that in the Newfoundland 
population, 18/75 (24%) of control subjects without HLA-Cw*0602 have the 
SEEK1(T) allele, whereas 20/23 (87%) with HLA-Cw*0602 have the SEEK1(T) 
allele. The parallel numbers in the Ontario population are 38/107 (36%) versus 
56/57 (98%). There is some evidence of a different level of disequilibrium in the 
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two populations (p = 0.03). When we explored the genotype/phenotype 
correlations for the minor {T) allele compared with the corresponding wild-type 
variant for SEEK1, no differences in the age of onset of psoriasis, PsA, or pattern 
of arthritis were noted. 
DISCUSSION 
Presently debate exists about whether HLA-Cw*0602 is the causative 
allele in psoriasis or PsA as it is neither necessary nor sufficient to develop the 
disease. Thus it is prudent to investigate the role of neighbouring genes, such as 
SEEK1 . At first glance, rs3815097 in SEEK1 may not appear to be a strong 
candidate for PsA susceptibility as the function of SEEK1 is not yet known and 
rs3815097 does not code for any amino acid change. However a striking 
association was noted between rs3815097 in exon 2 of SEEK1 and psoriasis in 
the Swedish population (p<0.000001) (199). This association was independent of 
HLA-Cw*0602. An efficient way to validate the importance of SEEK1 in PsA is to 
study multiple case-control populations, with the expectation that any important 
association will be seen in all populations. We examined two complementary 
populations. Newfoundland is a white founder population known to exhibit 
homogeneity comparable to the Hutterites (306). An advantage in examining this 
population is that it may allow the detection of small to modest genetic 
associations as a result of an increased "signal to noise ratio". Meanwhile, the 
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Ontario population is a well characterised heterogeneous PsA population that 
greatly enhances the generalisability of results. 
In our study a statistically significant association was shown between 
SEEK1 and PsA in the Newfoundland population alone. There was a trend for 
increased prevalence of SEEK1 in the Ontario PsA population as compared with 
controls (46.5 v 38.0%) but this was not significant. However, there was also no 
evidence for a different relationship in the two separate populations, but when 
both populations were combined the evidence for an association was 
considerable (p = 0.009). Further analysis showed, however, that this association 
was not independent of HLA-Cw*0602 status. The association noted in the 
Newfoundland population can probably be attributed to the extended linkage 
disequilibrium that exists in this young founder population. 
A puzzling finding in our study was the lack of association between HLA-
Cw*0602 and PsA in the Ontario population, especially because previous studies 
from this cohort have confirmed this association (46, 158). The allele frequency for 
the Ontario controls in this study (23.5%) was higher than previously reported for 
Ontario controls (9-15%) (46, 158). This group of controls and patients was 
different from groups previously reported and may highlight the heterogeneity 
within the Ontario population. A further limitation of our study is the inability to rule 
out the possibility that an association exists for other SNP variants in the SEEK1 
gene, as only one SNP variant was studied. Finally, we are unable to decipher 
the independent contribution of psoriasis and inflammatory arthritis to SEEK1, as 
all our patients with PsA had both psoriasis and inflammatory arthritis. In 
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conclusion, data from our study does not support the premise that the rs3815097 
SNP in SEEK1 is an independent genetic determinant leading to susceptibility to 
PsA in the Newfoundland and Ontario populations. 
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Common genetic variants in auto-
immune diseases: association with 
psoriatic arthritis. 
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Introduction: 
Recently, a novel gene has attracted attention in the investigation of auto-
immune disease. The PTPN22 gene encodes a functional protein tyrosine 
phosphatase known as lymphoid phosphatase which acts as a regulator of the 
negative regulatory kinase cytoplasmic tyrosine kinase (CSK) in T cells, and may 
play a role in suppression of T -cell activation (223). A functional SNP 1858 C> T 
causing an Arg-+ Trp substitution (R620W) which disrupts the binding site for 
CSK was recently found to be associated with Type-1 diabetes (lOOM) (224). 
Subsequently associations have also been shown with other autoimmune 
diseases including rheumatoid arthritis (RA) (225) and systemic lupus 
erythematosus (SLE) (226) in Caucasian populations. A large study in psoriasis 
involving 1,146 affected individuals (343) and a smaller study in psoriasis in 265 
families with multiple autoimmune diseases, with only 63 psoriasis patients, 
revealed no association of the 1858 C>T variant of PTPN22 and psoriasis (227). 
Although psoriasis and psoriatic arthritis (PsA) are interrelated disorders, 
PsA is a distinct entity with its own epidemiological, clinical and genetic features. 
Furthermore, PsA demonstrates much greater heritability among first degree 
relatives (A1 48) than psoriasis (A1 5-1 0) (145). Thus we set out to examine the 
association of these two high priority candidate genes in two well characterized 
Caucasian PsA cohorts. 
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Materials and Methods: 
This study was approved by the ethics committees of Memorial University 
of Newfoundland and University of Toronto. Informed consent was obtained from 
all patients. All PsA probands were Caucasians. Information was collected 
systematically and included age at onset of psoriasis and PsA, and disease 
pattern. The control subjects were of similar ethnicity to the cases. Controls for 
the Newfoundland population were volunteers from Newfoundland that 
participated in our study as a result of a local campaign seeking population based 
controls for genetic studies. The Toronto controls were ascertained from the local 
HLA laboratory DNA bank which includes healthy volunteers and organ donors. 
Whole blood samples were obtained from PsA probands and control 
subjects. DNA was extracted using the Promega Wizard Genomic DNA 
purification Kit. The detection of SNPs was performed by the analysis of primer 
extension products generated from previously amplified genomic DNA using a 
Sequenom chip-based MALDI-TOF mass spectrometry platform. In brief, PCR 
and extension reactions were designed using MassARRA Y design software, and 
were carried out using 2.5 ng of template DNA. Unincorporated nucleotides in the 
PCR product were deactivated using shrimp alkaline phosphatase. The 
amplification of the SNP site was carried out using the MassExtend primer and 
involved the use of specific deoxy/dideoxy-nucleotide triphosphate {d/ddNTP) 
termination mixes which were also determined using MassARRAY assay design 
software. The primer extension products were then cleaned and spotted onto a 
SpectroChip. The chips were scanned using a mass spectrometry workstation 
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(Bruker) and the resulting spectra were analyzed and genotypes were 
determined using the Sequenom SpectroTYPER-RT software. We genotyped 
PsA probands and control subjects for the PPTN22 1858 C> T polymorphism 
(rs2476601 ). 
To determine differences in allele and genotyping frequencies, 2 X 2 
contingency tables were used. Power calculations were performed by simulating 
cases and controls assuming a multiplicative model for disease risk, and varying 
the genetic risk associated each copy of the high-risk variant. Observed allele 
frequencies among controls were used to generate genotypes, together with an 
assumed baseline risk of PsA between 0.005 and 0.01. For each candidate gene, 
100 simulated data sets were created, the trend test was performed, and we 
counted the number of simulations where the p-value was less than 0.05. 
Results: 
Two hundred and thirty eight Newfoundland PsA patients and 149 healthy 
Newfoundland controls were studied. With respect to the Newfoundland PsA 
patients, 53% were male and their mean age at the onset of the study was 49.7 
years. The mean age of onset of psoriasis was 29.3 years (sd 14.2 years) and 
the mean age of onset of PsA was 38.1 years {sd 11.0 years). Sixty percent of 
the PsA patients had polyarticular disease 32% had oligoarticular disease and 
7% had an isolated spondyloarthropathy. For the Toronto population, 207 PsA 
patients and 203 control subjects from the Toronto population were genotyped. 
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With respect to the Toronto PsA patients, 61% were male and their mean age at 
the onset of the study was 39.6 years (sd 11.3 yrs). The mean age of onset of 
psoriasis was 26.8 years (sd 12.1 years) and the mean age of onset of PsA was 
33.0 years (sd 10.8 years). Forty-four percent of the PsA patients had 
polyarticular disease, 40% had oligoarticular disease and 2.9% had isolated 
spondyloarthritis. 
Of the 238 PsA patients genotyped for the 1858 C> T variant of PTPN22 in 
the Newfoundland cohort, the C/C, CIT, and TIT genotypes for cases were 191, 
44, and 3 respectively. For the 149 controls, the C/C, CIT, and TIT genotypes for 
controls were 121, 25, and 3 respectively. There was no difference in the minor 
allele (T) frequencies for the cases (10.5%) and controls (10.4%) for this PTPN22 
variant, p=0.96. 
203 PsA patients and 199 control subjects were genotyped in the Toronto 
population for the 1858 C> T variant of PTPN22. For the PsA patients, the GIG, 
G/A, and AJA genotypes were 153, 43, and 7 respectively, while the Toronto 
control subjects were shown to be 167, 30, and 2. The minor allele (A) showed a 
frequency of 13.8% in PsA subjects versus 8.5% in controls. This was statistically 
significant when tested for the minor (T) allele (p=0.018) and for a trend in the 
genotypes (p=0.024 ). The rheumatoid factor (RF) was positive in 9% and 10% of 
the Newfoundland and Toronto cohorts respectively. After stratification for the 
presence of RF, we noted no association with RF positivity and the minor (T) 
allele for the PTPN22 variant in either population . 
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All control genotypes satisfied the Hardy-Weinberg equilibrium. Using the 
minor allele frequency of 0.1 0, observed among the controls for the PTPN22 
gene, this study had over 85% power to detect a genotype relative risk of 2.0 or 
greater at PTPN22 and power near 0.67 to detect a genotype relative risk of 1.75. 
Discussion: 
This is the first study to assess the association of the high priority 
candidate gene variant PTPN22 1858 C> T specifically in PsA. With respect to the 
Newfoundland population , our results are consistent with the reported studies in 
psoriasis (227,343). However, a modest association was noted between this 
PPTN22 variant and PsA in the Toronto cohort. As the Toronto cohort is the first 
population to report a significant association between PTPN22 and PsA and 
contradicts previous larger studies in psoriasis (227,343), this result should be 
interpreted with caution until it is independently validated in another PsA 
population. It is conceivable that a true association exists and this association is 
disease (PsA) and population {Toronto) specific. It is worthwhile to note that the 
lymphoid-specific phosphatase encoded by PTPN22 is among the most powerful 
inhibitors of T-cell activation, thus there is a potential rationale for this 
association. Alternatively, a false positive association may have occurred in the 
Toronto PsA cohort due to population stratification. As the reported RA 
associations with PTPN22 are almost exclusively with seropositive RA 
(225,227,344,345) we stratified our population based on seropositivity for 
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rheumatoid factor (RF), and found no association between the presence of RF 
and PTPN22. 
Conclusions: 
In conclusion, we obtained different results regarding the association of 
PTPN22 in two PsA cohorts. A moderate association was noted in a well 
characterized, admixed PsA cohort, however this was not validated in a 
homogenous Caucasian cohort. Further studies in additional PsA populations are 
warranted to more definitively determine the role of PPTN22 in PsA. 
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Introduction 
Psoriatic arthritis (PsA} is an inflammatory arthritis associated with 
psoriasis. The disease presents with a variety of pathogenic subtypes. While the 
triggers for the disease have not yet been elucidated, it has a strong genetic 
component (145, 150). PsA is largely an inflammatory disease, and the 
inflammatory cytokine IL-1 is expressed at increased levels in the serum, synovial 
fluid and skin of PsA patients (204,346). Recently, several reports have found an 
association between the /L-1 gene cluster and ankylosing spondylitis including 
amongst a cohort from Newfoundland (254,347). A large clinical and immunologic 
overlap exists between PsA and AS; thus based on the known role of IL-1 and 
the observed association between the /L-1 gene cluster and AS, our laboratory 
examined the association of SNPs in the /L-1 gene cluster with PsA in a cohort 
from Newfoundland (207). 
A significant association was noted in PsA with 2 adjacent IL 1 B markers 
(rs1143627 and rs16944) and an IL 1F7 marker (rs3811047) in the Newfoundland 
PsA cohort. Using adjacent 3-marker haplotype windows two regions in the /L-1 
gene cluster (markers rs3783547, rs3783543, and rs17561 in IL 1A, and a region 
near the end of IL 1 B, through IL 1 F7, IL 1 FB, and into IL 1 F1 0, containing markers 
rs3811047, rs1562304, and rs3811058) were found to be associated with PsA. 
While these results are interesting, findings in a small founder population may not 
be generalizable to larger, more admixed populations. Thus, we set out to 
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validate our observation of association in the /L-1 gene cluster in an admixed 
population from Toronto. 
Methods 
This study was approved by the ethics committee of Memorial University 
of Newfoundland and the University of Toronto. Informed consent was obtained 
from all patients and participation was voluntary. Controls were volunteers from 
the Toronto area who participated in our study as a result of a local campaign 
seeking controls for genetics studies. Samples of whole blood were obtained 
from PsA probands and controls. DNA was extracted using the Wizard Genomic 
DNA Purification kit (Promega, Madison, WI). In total, Two hundred fifty PsA 
patients and two hundred forty seven controls were genotyped for 16 SNPs: 9 
SNPs in /L-1A, 3 SNPs in /L-18, and 2 SNPs each in IL-1F7 and IL-1F8. The 
SNPs used and results for this study are summarized in Table 4.1. SNP 
determination was performed using the chip-based matrix-assisted laser 
desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry platform 
(Sequenom, San Diego, CA). Briefly, polymerase chain reaction (PCR) and 
extension reactions were designed using MassArray design software 
(Sequenom). Primers were obtained from Integrated DNA Technologies 
(Coralville, lA). The PCR primers were used to amplify 2.5 ng of genomic DNA 
using standard conditions for MassArray genotyping. Unincorporated nucleotides 
in the PCR product were deactivated using shrimp alkaline phosphatase. 
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Amplification of the SNP site was carried out using the MassExtend primer and 
involved the use of specific d/ddNTP termination mixes that were also determined 
using MassArray design software. The primer extension products were then 
cleaned and spotted onto a SpectroChip (Sequenom). The chip was scanned 
using a mass spectrometry workstation (Bruker Analytik, Rheinstetten, Germany), 
and the resulting spectra were analyzed using SpectroTyper-RT software 
(Sequenom). Single marker associations and 2, 3 and 4 marker sliding window 
haplotypes were calculated using the Plink software package (348), and 2, 3 and 
4 marker sliding window haplotypes were calculated using PHASE version 2.1 
(349) 
Results 
All markers tested fit Hardy-Weinberg Equilibrium. The SNP rs3917348 
was excluded from analysis as it had a minor allele frequency of < 0.01. None of 
the remaining 15 markers tested displayed any significant associations. We 
estimated differences in haplotype frequencies between cases and controls for all 
overlapping windows of size 2, 3 or 4 markers across the region genotyped, 
using PHASE software, version 2.1 Parameter settings for PHASE were 300 
burn-in, 300 runs, and 10000 permutations. To evaluate the number of significant 
results expected by chance, we permuted case and control labels and repeated 
the univariate 2-df tests, counting the number of significant results obtained in 
each permutation . Similarly, we permuted case and control labels and repeated 
the haplotype analyses, counting the number of significant case-control 
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associations within each gene. These permutation tests adjusted significance for 
the number of markers or windows tested . No combination of markers displayed 
significance following permutation testing. The results are summarized in Table 
4-1. 
Table 4-1 - SNPs from the 11-1 gene cluster and significance levels after 
permutations of sliding-window haplotypes. 
SNP Marker 2-marker P-Value 3-marker P-Value 4-marker P-Value 
Number ha~lot;t~e ha~lot;t~e ha~lot;t~e 
rs2856836 1 1-2 0.9292 1-2-3 0.9837 1-2-3-4 0.9770 
rs3783550 2 2-3 0.9948 2-3-4 0.9933 2-3-4-5 0.9708 
rs3783547 3 3-4 0.9935 3-4-5 0.9717 3-4-5-6 0.9741 
rs3783543 4 4-5 0.9108 4-5-6 0.9722 4-5-6-7 0.9555 
rs17561 5 5-6 0.9729 5-6-7 0.9542 5-6-7-8 0.9500 
rs1533463 6 6-7 0.9680 6-7-8 0.9222 6-7-8-9 0.9565 
rs3783526 7 7-8 0.9640 7-8-9 0.9801 7-8-9-10 0.7926 
rs1800587 8 8-9 0.8415 8-9-10 0.8569 8-9-1 0-11 0.7726 
rs1800794 9 9-10 0.8157 9-10-11 0.6812 9-10-11-12 0.3920 
rs1143627 10 10-11 0.4644 10-1 1-12 0.5144 10-11-12-13 0.5399 
rs16944 11 11-12 0.5228 11-12-13 0.4996 11-12-13-14 0.6467 
rs3811047 12 12-13 0.7899 12-13-14 0.8387 12-13-14-15 0.6832 
rs2723187 13 13-14 0.5931 13-14-15 0.4333 
rs1562304 14 14-15 0.3026 
rs1900287 15 
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Discussion 
Recently two reports of an autosomal recessive autoinflammatory disease 
caused by mutations affecting IL 1 RN, referred to as deficiency of the interleukin-
1-receptor antagonist, or DIRA, have brought attention to the role of the /L-1 
gene cluster in inflammatory disease (350,351 ). The patients carrying mutations 
to IL 1 RN were described as having life-threatening systemic inflammation with 
skin and bone involvement, which was resolved with the administration of 
recombinant IL-1 receptor antagonist Anakinra (Biovitrum). The IL 1RN gene lies 
just proximal to the /L-1gene cluster and codes for the interleukin-1 receptor 
antagonist. The IL 1 RN cytokine regulates IL-1 ~ by binding tightly to the 
interleukin-1 receptor, thereby blocking access of interleukin-1 to the receptor. IL-
1 and IL 1 RN are produced in patients with infection, trauma, or inflammatory 
conditions, where they compete for occupancy of the interleukin-1 receptor. Thus, 
it is likely that an inflammatory process may be affected by the relative amounts 
of interleukin-1 and interleukin-1- receptor antagonist circulating, a view which is 
supported by several animal models (352). Thus, the /L-1 gene cluster is an 
attractive target in the investigation of an inflammatory disease such as PsA. 
In this study, we set out to replicate the observed finding of association 
between the /L-1 gene cluster in a PsA cohort from Newfoundland (207), using 
the same markers in a second PsA cohort from Toronto. Genetic studies of this 
gene cluster and the seronegative spondyloarthropathies have garnered 
considerable attention as several reports have noted an association between the 
/L-1 gene cluster and AS across Caucasian (including a Newfoundland cohort) 
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and Asian populations (253,254,347,353,354). However, aside from the reported 
association in the Newfoundland population, a positive association between 
certain SNPs in the /L-1 gene cluster and PsA has been published only one other 
time (205), however when we attempted to replicate the findings of Ravindran et 
a/. in our Newfoundland PsA cohort, we observed no association with those 
specific polymorphisms (206). The fact that no significance was observed in 
single marker or 2, 3 and 4 marker sliding window haplotypes in the Toronto 
cohort could be due to population specific variation in our Newfoundland cohort. 
As the population of Newfoundland is relatively small, the reported results for 
both AS and PsA could be explained by a founder effect, or due to cryptic 
relatedness between patients of both diseases, or due to the result of positive 
selection or genetic drift. The repeated associations of the /L-1 gene cluster with 
AS argue for this region's involvement in the seronegative spondyloarthropathies. 
As our Newfoundland PsA cohort has roughly 40% of patients who have been 
diagnosed with the spondylitis form of PsA (234) the reported association with the 
/L-1 gene cluster may represent an association with spondyloarthropathy rather 
than PsA per se. Further investigation in additional PsA cohorts is warranted. 
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Psoriatic Arthritis (PsA) is a complex immunologically mediated disorder 
that results from interplay between multiple genetic and environmental factors. 
Epidemiological studies implicate a substantive role for genetic factors in disease 
susceptibility and expression in PsA (23, 140). Although association of PsA and 
alleles in the MHC region are well established, this region appears to contribute 
only one third of the total genetic variance to other forms of autoimmune 
inflammatory arthritis (355). Thus, it is prudent to investigate high priority 
candidate genes outside the MHC region in PsA. 
Nuclear Factor-KB (NF-KB) exists as a multi-protein complex and is a 
pleiotropic transcription regulator that regulates key cytokines involved in 
regulating immune response including TN F-a and IL-1 ~ (356). These cytokines 
are important in the pathogenesis of PsA (356). Recently, the first potentially 
functional polymorphism of the NFKB1 gene on chromosome 4q24 was 
described: an ATTG ins/del polymorphism in the promoter region of the gene, 
which decreases promoter activity in ulcerative colitis (271 ). NF-KB has also been 
implicated in the pathogenesis of rheumatoid arthritis as the affinity for NF-KB 
binding in rheumatoid arthritis synovium is significantly higher than osteoarthritis 
synovium (357). Thus, based on the proposed function of NFKB 1 and its 
association with inflammatory arthritis and colitis we set out to investigate the role 
of this NFKB1 promoter ins/del polymorphism as well as other SNPs in the 
NFKB1 gene, and two genes in the NF-KB functional complex (RELA and 
NFKBIA) in subjects with PsA from our founder population. 
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Methods 
Patients 
This study was approved by the local ethics committee at Memorial 
University of Newfoundland. Informed consent was obtained from all patients, 
who were all from the Newfoundland population. PsA was diagnosed as an 
inflammatory arthritis in patients with psoriasis, in the absence of other 
aetiologies for inflammatory arthritis. The control subjects were also ascertained 
from Newfoundland and were all unrelated to each other, or to our patients. 
Laboratory 
Whole blood samples were obtained from PsA probands and control 
subjects. DNA was extracted using the Promega Wizard Genomic DNA 
purification Kit. The detection of SNPs was performed by the analysis of primer 
extension products generated from previously amplified genomic DNA using a 
chip-based MALDI-TOF mass spectrometry platform (Sequenom, Inc. , San 
Diego, CA) (31 0). In brief, PCR and extension reactions were designed using 
MassARRAY design software, and were carried out using 2.5 ng of template 
DNA. Unincorporated nucleotides in the PCR product were deactivated using 
shrimp alkaline phosphatase. The amplification of the SNP site was carried out 
using the MassExtend primer and involved the use of specific d/ddNTP 
termination mixes which were also determined using MassARRAY assay design 
software. The primer extension products were then cleaned and spotted onto a 
SpectroChip. The chips were scanned using a mass spectrometry workstation 
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(Bruker) and the resulting spectra were analyzed and genotypes were 
determined using the Sequenom SpectroTYPER-RT software. 
We genotyped PsA probands and control subjects for the following 
polymorphisms: NFkB1 : in the promoter region, -94deiATTG; and the non 
synonymous coding SNPs rs4648065, rs4648072, rs4648085, rs4648086, 
rs4648099; RELA promoter SNP rs11568292, coding SNP rs7116571, and 3' 
SNPs rs2009453, rs6591183; and NFKBIA promoter SNPs -410 (rs2233409), -
642 (rs2233408), -673 (rs2233407), -949 (rs2233406) and 3' SNPs 2643 
(rs8904 ), 2758 (rs696) and 3053 (rs2273650). 
Statistical Analysis 
Chi-square analysis was used to test the single locus associations 
between SNPs in NF-KB complex and PsA. Associations between multi-locus 
haplotypes and case or control status were tested using the software PHASE, 
version 2.1 (http://www.stat.washington.edu/stephens/software.html). This 
software uses a haplotype reconstruction method that assesses similarity 
between haplotypes using arguments based in coalescent theory (349,358). A 
permutation test is performed to examine the similarity of the haplotype 
distributions between cases and controls. Since the algorithm considers 
haplotype similarity, the permutation test has power even when the number of 
haplotypes is large. 
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Results 
Two hundred and twenty four PsA probands (52% males) and 88 
ethnically matched controls (62% males) were studied. All subjects were 
Caucasian of North European descent and considered to be native 
Newfoundlanders. The mean age of the PsA probands was 50.0 years (SO 10.9 
years), age at onset of psoriasis 29.4 years (SO 14.3 years) and age at onset of 
PsA 37.9 years (SO 11 .3 years). All of the genotypes for the controls satisfied the 
Hardy-Weinberg equilibrium. Not all SNPs were successfully genotyped in every 
individual. The genotyping results of all non-homozygous polymorphisms are 
summarized in table 4-2. 
With respect to single locus associations, none of the SNPs tested were 
found to be associated with PsA in the Newfoundland population. In particular, 
the allele frequency for the NFKB1 -94deiATTG was 41.7% in the cases and 
41.6% in the controls (p=0.97). For the five non-synonymous coding SNPs of 
NFKB1 (rs4648065, rs4648072, rs4648085, rs4648086, rs4648099), the 
genotypes were all homozygous for all probands and controls, with the exception 
of one control that was heterozygous for SNP rs4648072. 
For RELA the 3' SNP rs2009453 the minor allele © had a frequencies of 
42.2% vs. 40.3% in cases and controls respectively (p=0.67); while for the 3' SNP 
rs6591183 the minor allele (A) frequencies were 44.1% vs. 38.6% in cases and 
controls respectively (p=0.23); The RELA promoter SNP rs11568292 and coding 
SNP rs7116571 , were found to be homozygous in all PsA probands and controls, 
except for one patient who was heterozygous for rs11568292. 
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The NFKBIA promoter SNP -410 (rs2233409) was found to have minor 
allele (T} frequencies of 25.0% vs. 28.1% in cases and controls respectively 
(p=0.45); for SNP -673 (rs2233407), the minor allele (T} frequencies were 5.8% 
vs. 4.2% respectively (p=0.42); for SNP -949 (rs2233406) the minor allele (T} 
frequencies were 31 .3% vs. 34.5% respectively (p=0.60); and finally for SNP 
2578 (rs696) the minor allele (A) frequency was 28.4% vs. 30.5% in cases and 
controls respectively (p=0.21 ). For the remaining NFKBIA promoter SNP -642 
(rs2233408) as well as the 3 ' SNPs 2643 (rs8904), and 3053 (rs2273650) the 
genotypes were all homozygous for all probands and controls. 
Haplotypes were formed with two markers for RELA (rs2009453 and 
rs6591183) and four markers for NFKBIA [-41 0 (rs2233409), -673 (rs2233407); -
949 (rs2233406) and (rs696)]. No associations were found for haplotypes for 
RELA (0.37) and NFKBIA (0.90). We then re-analyzed all these markers as well 
as NFKB1 -94deiATTG for gene/gene interaction and again found no association 
(p=0.82). 
Results were further analyzed to determine if there was any relationship 
between the minor allele frequency of each genotype, gender and early onset of 
psoriasis (defined as onset of psoriasis prior to age 40 years). No such 
association was observed. 
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Table 4-2- Frequency of polymorphisms in the NFKB1, RELA and NFKBIA 
genes in the Newfoundland population 
Genotype NF PSA Controls pValue 
Patients 
NFk81 n=224 n=83 
94deiATTG ATTG 75(33.5%) 26 (31 .3%) 
rs28362491 ATTG/DEL 111(49.5%) 45 (54.2%) 
DEL/DEL 38 (17.0%) 12 (14.5%) 
Allele F. {del} 41 .7% 41 .6% NS 
n=196 n=88 
NFk81 AA 196 (100%) 86 (98.9%) 
rs4648072 AG 1 (1.1%} NS 
RELA rs6591183 n=194 n=88 
AA 36 (18.6%) 14 (15.9%) 
AG 99 (51.0%) 40 (45.5%) 
Allele F. (A) GG 59 (30.4%) 34 (38.6%) 
44.0% 38.6% NS 
RELA rs2009453 n=193 n=88 
cc 32 (16.6%) 15 (17.0%) 
CT 99 (51.3%) 41 (46.6%) 
Allele F. (C) TT 62 (32.1%) 32 (36.4%) 
42.2% 40.3% NS 
RELA n=182 n=71 
rs11568292 GG 182 (100%) 70 (98.6%) 
AG 1 (1.4%} NS 
NFKBIA -949 n=211 n=84 
rs2233406 c 96 (45.5%) 40 (47.6%) 
CT 98 (46.4%) 30 (35.7%) 
T 17 (8.1%) 14 (16.7%) 
Allele F. (T} 31.3% 34.5% NS 
NFKBIA -673 n=216 n=84 
rs2233407 A 191 (88.4%) 77 (91.7%) 
AT 25 (11.6%) 27 (32.1 %) 
T 0 0 
Allele F. (T} 5.8% 4.2% NS 
NFKBIA -410 n=220 n=84 
rs2233409 c 120 (54.5%) 47 (56.0%) 
CT 90 (41.0%) 27 (32.1%) 
T 10 (4.5%) 10 (11.9%) 
Allele F. {T} 25.0% 28.0% NS 
NFKBIA 2578 n=222 n=88 
(rs696) A 20 (9.0%) 8(9.1%) 
AG 86 (38.7%) 37 (42.0%) 
G 116 (52.3%) 43 (48.9%) 
Allele F. (A) 28.4% 30.5% NS 
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Discussion 
As noted in a recent editorial, NF-KB serves as a "master switch" for the 
inflammatory cascade in rheumatic disease, as it is critically linked to many 
genes that result in synovitis such as pro-inflammatory cytokines and 
metalloproteinases (359). The NFKB1 protein is found most often bound with 
ReiA to form the NF-KB complex (360). The complex is found inactive in the 
cytoplasm bound to an 1-kappa-B inhibitory protein (NFKBia), and is activated 
when the 1-kappa-B kinases (IKBKA or IKBKB) phosphorylate serine residues on 
the NFKBia protein, marking it for destruction via ubiquitination. The active NF-KB 
complex then is transported to the cell nucleus and binds DNA at kappa-S-
binding motifs, thereby activating gene expression (361 ). Inappropriate activation 
of NF-KB has been linked to inflammatory events associated with autoimmune 
arthritis, asthma, septic shock, lung fibrosis, and atherosclerosis (275,362). There 
are no previous studies that have examined the role of NF-KB in PsA. 
In our study, an association between PsA and SNPs of components of the 
NF-KB complex- NFkB1, RELA, and NFKBIA was not observed. In particular we 
did not detect any association between the NFKB1 -94deiATTG polymorphism 
and PsA. This study strongly suggests that the major NFKB1 -94deiATTG 
variant, which is associated with UC, is not associated with PsA. However, we 
cannot rule out the possibility that an association exists for other SNP variants in 
genes in the NF-KB pathway or that there is an association in other populations, 
as the Newfoundland population may not be representative of other admixed 
Caucasian populations (303). Furthermore, we also acknowledge that because of 
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our sample size we are unlikely to detect small differences in allele frequencies. 
Based on our observations, we conclude that there is no association between 
SNPs of components of the NF-KB complex- NFkB1 , RELA, and NFKBIA in the 
Newfoundland population. The possibility remains that novel SNPs of these 
genes, or genes further up- or down-stream in the NF-KB pathway may contribute 
to dysfunction of the inflammatory process leading to PsA. 
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INTRODUCTION 
Psoriasis is a chronic inflammatory hyperproliferative skin disorder that 
affects 1-3% of the population (7). Up to a th ird of the patients with psoriasis may 
develop an inflammatory form of arthritis, referred to as psoriatic arthritis (PsA). 
Extensive epidemiological evidence supports the concept of PsA as a distinct 
entity (23). PsA is a heterogeneous disease with articular and extra-articular 
features. Moll and Wright described five clinical patterns of PsA, including 
symmetrical polyarthritis, a subtype that resembles rheumatoid arthritis (6). 
Various extra-articular features also occur in PsA including psoriasis (which is 
seen in the majority of subjects with PsA) and inflammatory bowel disease, such 
as Crohn disease. A significant overlap exists in the therapeutic approach for 
PsA, psoriasis, rheumatoid arthritis and Crohn disease including an excellent 
clinical response to TNF blockade. Thus there are shared epidemiological 
features, clinical manifestations and therapeutic strategies for these autoimmune 
diseases. 
With respect to aetiology of these complex, immunologically mediated 
disorders, PsA, psoriasis, rheumatoid arthritis and Crohn disease appear to result 
from an interplay between multiple genetic and environmental factors. Common 
genetic elements to autoimmune diseases have been proposed as there is co-
localization of susceptibility loci for autoimmune diseases in mouse (363) and 
also overlapping of susceptibility loci among autoimmune diseases in humans 
(364 ). Thus, when searching for susceptibility genes for PsA it is prudent to 
examine high priority candidate genes in related autoimmune disorders. 
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Recently, there have been major advances in the genetics of complex 
autoimmune diseases, with novel candidate genes being identified in psoriasis 
(SLC9A3R1) (365), rheumatoid arthritis (SLC22A4 and RUNX1) (366), and Grahn 
disease (a haplotype of SNPs in SLC22A4 and SLC22A5) (269). As SLC22A4, 
SLC22A5, SLC9A3R1 and RUNX1 have a proposed role in chronic inflammatory 
disease, the phenotypes of which frequently overlap with PsA, we set out to 
examine the association of these genes with PsA in the Newfoundland founder 
population. 
MATERIALS AND METHODS 
This study was approved by the local ethics committee at Memorial 
University of Newfoundland. Informed consent was obtained from all PsA 
patients, who were all from the Newfoundland founder population. PsA was 
diagnosed as an inflammatory arthritis in patients with psoriasis, in the absence 
of other aetiologies for inflammatory arthritis. The control subjects were also 
ascertained from Newfoundland and were all unrelated to each other, or to our 
patients. 
Whole blood samples were collected from PsA probands and control 
subjects in EDTA anticoagulant tubes and DNA was extracted from peripheral 
blood lymphocytes using the Wizard Genomic DNA Purification Kit from Promega 
(Madison, WI). In total , 259 PsA patients and 238 controls from Newfoundland 
were genotyped for three SNPs in SLC22A4 (rs3792876, 1050152, rs3763112), 1 
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SNP in SLC22A5 (rs2631367), 1 SNP in SLC9A3R1 (rs734232), and 1 SNP in 
RUNX1 (rs2268277) using the Sequenom MassArray platform using time-of-flight 
mass spectrometry (Sequenom, Inc., San Diego, CA) (310). All PCR primers and 
extension primers were designed using SpectroDESIGNER assay design 
software v1 .3.4. All PCR and extension reactions were carried out using 2.5ng of 
template DNA. The primer extension products were then cleaned and spotted 
onto a SpectroChip. The chips were scanned using a mass spectrometry 
workstation (Bruker) and the resulting spectra were analyzed and genotypes 
were determined using the Sequenom SpectroTYPER-RT software. Not all 
samples were successfully genotyped for each SNP. 
Chi square analysis was used to test the single locus associations 
between SNPs in our selected candidate genes and PsA. Associations between 
multi-locus haplotypes and case or control status were tested using the software 
PHASE, version 2.1 (http://www.stat.washington.edu/stephens/software.html). 
This software uses a haplotype reconstruction method that assesses similarity 
between haplotypes using arguments based in coalescent theory (349,358). A 
permutation test is performed to examine the similarity of the haplotype 
distributions between cases and controls. Since the algorithm considers 
haplotype similarity, the permutation test has power even when the number of 
haplotypes is large. Physical distances between the SNPs on the same 
chromosome were used in the PHASE analysis. 
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RESULTS 
Two hundred and fifty-nine PsA probands and 238 ethnically matched 
controls were studied. All subjects were Caucasian of North European descent 
and considered to be native Newfoundlanders. The mean age of PsA patients at 
the time of study was 49.67 years, SO 10.95 years, and 48.5% of subjects were 
females. The mean age of onset of psoriasis in our cohort was 29.27 years, SO 
14.16 years. All of the genotypes for the controls satisfied the Hardy-Weinberg 
equilibrium. Not all SNPs were successfully genotyped in every individual. 
With respect to single locus associations, none of the variants examined from 
SLC22A4, SLC22A5, SLC9A3R1 and RUNX1 were significantly associated with 
PsA in the Newfoundland population either by genotype or minor allele 
frequencies. These results are summarized in table 4-3. We then analyzed two 
marker haplotypes for markers of interest in rheumatoid arthritis [ SLC22A4 
(rs3792876) and RUNX1 (rs2268277)] and Crohn disease [SLC22A4 
(rs1 050152) and SLC22A5 (rs2631367)] and noted no association [(p=0.342), 
(p=0.81) respectively]. We also examined 2 marker combinations for the 
remaining SNPs in SLC22A4 [(rs3792876 and rs1 050152; p=0.48); (rs3792876 
and rs3763112, p=0.580] as well as haplotypes for all four SNPs in SLC22A4 on 
chromosome 5 (p=0.90). Finally we assessed the relationship of all 6 markers on 
three different chromosomes and again found noted no association (p=O. 7 4 ). 
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Table 4-3- Genotype and allele frequency of SLC9A3R1, SLC22A4, 
SLC22A4, and RUNX1 polymorphisms in the NL population. 
Genotype NF PsA Controls OR P value 
patients (95% Cl) 
SLC9A3R1 
(rs734232) 
Genotype Freq GG 89 (35.0%) 74(31 .8%) 0.32 
GA 115 (45.3%) 100 (42.9%) 
AA 50 (19.7%) 59 (25.3%) 
Allele Freq (A) 42.3% 46.8% 0.16 
OCTN1/ 
SLC22A4 
(rs1050152) 
Genotype Freq cc 80 (30.9%) 75 (32.2%) 0.58 
CT 119 (45.9%) 113 (48.5%) 
TT 60 (23.2%) 45 (19.3%) 
Allele Freq (T) 46.1% 43.6% 1.11 0.42 
(0.86-1 .43) 
OCTN11 
SLC22A4 
(rs 3763112) 
Genotype Freq GG 80 (31.6%) 76(31.9%) 0.99 
GA 131 (51 .8%) 122 (51.3%) 
AA 42 (16.6%) 40 (16.8%) 
Allele Freq (A) 42.5% 42.4% 0.99 
OCTN11 
SLC22A4 
(rs3792876) 
Genotype Freq cc 226 (87.6%) 196 (84.5%) 0.61 
CT 31 (12.0%) 35(15.1%) 
TT 1 (0.4%) 1 (0.4%) 
Allele Freq (T} 6.4% 8.0% 0.34 
OCTN 
2/SLC22A5 
(rs2631367) 
Genotype Freq GG 74 (28.7%) 56 (24.9%) 0.62 
GC 115 (44.6%) 108 (48.0%) 
cc 69 (26.7%) 61 (27.1%) 
Allele Freq (G) 51 .0% 48.9% 0.52 
RUNX1 
(rs2268277) 
Genotype Freq GG 114 (44.4%) 98 (42.8%) 0.23 
GC 116 (45.1%) 95 (41.5%) 
cc 27 (10.5%) 36 (15.7%) 
Allele Freq (C) 33.1% 36.5% 0.27 
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DISCUSSION 
The chromosome 5q31 region is a region of interest in various forms of 
autoimmune disease as it contains a cytokine gene cluster that has been 
implicated in Crohn disease and rheumatoid arthritis (268,367). Rioux eta/. (267) 
found significant association of the 5q31 region with Crohn disease using 
microsatellite analysis of 256 Crohn disease trios. Further analysis using TOT 
identified two SNPs, one in the OCTN1 gene and one in the OCTN2 gene as 
being significantly associated with Crohn disease, a finding which has since been 
confirmed (269). Given that Crohn disease has a pathogenesis associated with 
inflammation and autoimmunity, Tokuhiro et at. investigated the cytokine gene 
cluster on 5q31 to determine if an association existed between this region and 
rheumatoid arthritis and determined that a SNP within SLC22A4/ 0CTN1 was 
significantly associated with rheumatoid arthritis (366). This SNP was shown to 
affect the expression of SLC22A4/0CTN1 by altering the binding affinity to the 
transcription factor RUNX1 . Notably, it has been previously shown that mutation 
of a RUNX1 binding site was associated with systemic lupus erythematosus 
(368). Tokuhiro et at also observed an association of an intronic RUNX1 SNP 
with rheumatoid arthritis, however this association was determined to be 
independent of the observed SLC22A4/0CTN1 association, rather than epistatic 
(366). Interestingly, the disruption of a RUNX1 binding site in the putative 
PSORS2 locus on 17q25, less than three hundred bp downstream of the gene 
SLC9A3R1 was recently associated with psoriasis (365). 
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We noted no association between the organic cation transporter genes 
and PsA in the Newfoundland population. This is in contrast to a recent British 
study that investigated 471 Caucasian PsA patients and 605 population controls 
for similar variants in SLC22A4 and SLC22A5 (369). They noted two SNPs, 
rs3763112 mapping to SLC22A4 and rs2631367 mapping to SLC22A5, to be 
significantly associated with PsA (p=0.001 and p=0.007) respectively. 
Furthermore, a haplotype which was associated with Crohn disease (SNPs 
rs1 050152 and rs2631367) was also strongly associated with PsA (p=0.0002) in 
their population. The lack of association of these SNPs and the Crohn disease 
haplotype in our study may reflect a difference in the PsA populations, as 
Newfoundland is a homogenous founder Caucasian population, while the 
population from Manchester is admixed. A potential benefit of studying the 
Newfoundland population is the possibility of an amplified genotype relative risk 
due to the enhanced signal to noise ratio that exists in the population as a result 
of genetic and relative environmental homogeneity. However, as locus 
homogeneity is also likely to exist in the Newfoundland population, not all genes 
of potential importance to PsA will be implicated in the Newfoundland population. 
We also cannot rule out the possibility that an association exists for other SNPs 
within these genes, or to other recently described organic cation transporter 
genes in the 1805 locus (OCTN3) (370). Furthermore, we also acknowledge that 
because our sample size is modest we are unlikely to detect small differences in 
allele frequencies. 
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Despite the observation that SLC9A3R1 has a plausible biologic role in 
psoriasis (365), as it is expressed in polarized epithelial cells, we found no 
association between the rs734232 variant of SLC9A3R1 examined and PsA in 
the Newfoundland PsA population. All patients with PsA in our population had 
psoriasis. 
Thus, although there is significant epidemiological clinical and 
immunological overlap between PsA, psoriasis, rheumatoid arthritis and Crohn 
disease, we were unable to implicate SLC22A4, SLC22A5, SLC9A3R1, and 
RUNX1 in the aetiology of PsA in Newfoundland. 
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Background 
Psoriatic Arthritis (PsA) is an inflammatory form of arthritis usually 
seronegative for rheumatoid factor (6), which may affect as many as 30% of 
patients with psoriasis (7,8). Although psoriasis and psoriatic arthritis (PsA) are 
interrelated disorders, PsA is a distinct entity with its own epidemiological clinical 
and genetic features. Furthermore, PsA demonstrates much greater heritability 
among first degree relatives (} .. 1 48) than psoriasis (}-.1 5-1 0) (145). 
Angiogenesis appears to be a first-order event in both psoriasis and PsA 
(127). Abnormalities in the vascular morphology of the nail-folds of psoriasis 
patients without nail disease have been observed (128), as well as an increase in 
the number of synovial membrane blood vessels in PsA joint tissue (90). 
Recently, the peroxisome proliferator activated receptor-y (PPARy) agonist 
pioglitazone, which inhibits angiogenesis, has shown efficacy in the treatment of 
PsA in a small open-label study (132). Modest significance between a coding 
SNP of PPARy and PsA patients has been observed (371 ), suggesting that 
angiogenesis may be an important area of investigation in PsA. 
Among angiogenic factors, the cytokines vascular endothelial growth 
factor (VEGF), epidermal growth factor (EGF), and fibroblast growth factors 1 and 
2 (FGF1 and FGF2) are powerful mitogens and play a central role in the initiation 
of angiogenesis. VEGF is the only mitogen that specifically acts on endothelial 
cells, and has been shown to stimulate the elongation, network formation, and 
branching of nonproliferating endothelial cells in culture that are deprived of 
oxygen and nutrients. As endothelial cells in tumours are routinely exposed to 
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periodic or constant hypoxia, it has been proposed that VEGF contributes to the 
formation of blood vessels in tumourigenesis (372). FGF1 has been shown to 
play a role in both angiogenesis and tumourigenesis (373), while FGF2 has been 
shown to play a crucial role in both skin and carti lage wound healing (374,375), 
and in combination with another pro-angiogenic factor synergistically induces 
vascular networks which remain stable for more than a year even after depletion 
of angiogenic factors (376). EGF likewise is important in wound healing and plays 
a role in tumour growth and development (377). 
High levels of the cytokine VEGF have been found in the synovial joints of 
both early and established rheumatoid arthritis (RA), PsA (130), AS, (378), and 
psoriasis plaques (379). The treatment of PsA with TNF-a inhibitors has been 
shown to significantly reduce levels of circulating VEGF and FGF1 (380). 
Several VEGF polymorphisms have been associated with the 
development of psoriasis (379,381 ). The 936 T allele (rs3025039) of the VEGF 
gene, and haplotypes of SNPs at positions -2578 (rs699947), -1154 (rs1570360), 
-634 (rs2010963) and 936 have been associated with younger age of onset of RA 
in a Korean population (382). Furthermore a haplotype of SNPs at positions -
2578, -1154 and -634 has been associated with disease severity for ankylosing 
spondylitis in the same population (383). 
Both FGF1 and FGF2 have been observed to be upregulated in the 
synovial tissue of human subjects with RA (384) and significantly worsened 
clinical symptoms in a rat adjuvant-induced model of arthritis (385), while at least 
one polymorphism of the EGF gene (rs4444903) has been shown to significantly 
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affect EGF production (386). At the time of this report, genetic variations in the 
FGF1, FGF2 or EGF genes have not been studied in either RA or the 
spondyloarthropathies. 
Given the previously reported associations of VEGF in both RA and AS, 
and the role that VEGF, FGF1, FGF2 and EGF play in angiogenesis, we 
examined genetic variants of each of these genes in PsA subjects from 
Newfoundland. 
Methods 
This study was approved by the ethics committee of Memorial University 
of Newfoundland. Informed consent was obtained from all patients. All PsA 
probands were Caucasians from the Newfoundland population. PsA was 
diagnosed as inflammatory arthritis in patients with psoriasis, in the absence of 
any other aetiology for inflammatory arthritis. Information was collected 
systematically and included age at onset of psoriasis, PsA and disease pattern. 
The ethnically matched, healthy control subjects were also obtained from the 
Newfoundland population, and were unrelated to the cases. 
Whole blood samples were obtained from PsA probands and control 
subjects. DNA was extracted using the Promega Wizard Genomic DNA 
purification Kit. The detection of SNPs was performed by the analysis of primer 
extension products generated from previously amplified genomic DNA using a 
Sequenom chip-based MALDI-TOF mass spectrometry platform. In brief, PCR 
and extension reactions were designed using MassARRA Y design software, and 
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were carried out using 2.5 ng of template DNA. Unincorporated nucleotides in the 
PCR product were deactivated using shrimp alkaline phosphatase. The 
amplification of the SNP site was carried out using the MassExtend primer and 
involved the use of specific deoxy/dideoxy-nucleotide triphosphate (d/ddNTP) 
termination mixes which were also determined using MassARRA Y assay design 
software. The primer extension products were then cleaned and spotted onto a 
SpectroChip. The chips were scanned using a mass spectrometry workstation 
(Bruker) and the resulting spectra were analyzed and genotypes were 
determined using the Sequenom SpectroTYPER-RT software. We genotyped 
PsA probands and control subjects for the following polymorphisms: in the VEGF 
gene rs3025039, rs69994 7, rs1570360, and rs201 0963; in the FGF1 gene 
rs34011 ; in the FGF2 gene rs1 048201 ; and in the EGF gene rs4444903, 
rs11568943 and rs2237051 . 
For 2 x 2 contingency tables of allele frequencies, Fisher's exact tests 
were conducted to calculate the exact p-values, and odds ratios were also 
calculated . As supporting exploratory analyses, genotype frequencies were also 
examined: for each of the 2 x 3 contingency tables of genotype frequencies, two 
different statistical methods that require somewhat different modeling 
assumptions were used to generate p-values: one was Fisher's exact test, and 
the other was the Cochrane-Armitage trend test, which may have more power 
than Fisher's exact test if a trend exists across genotype categories under the 
additive genetic effect model. 
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Haplotype estimation was conducted in several stages using two software 
packages (Haploview (387) and Phase v2.1 (349,358)): Haploview was first run 
on the markers for each multi-marker gene to identify the linkage disequilibrium 
structure and check to ensure that the markers were appropriate for inclusion in 
the haplotype estimates. Once the markers for which haplotypes were to be 
constructed were identified for each gene, then Haploview was re-run to identify 
the likely haplotypes and determine their relative frequencies. In order to predict 
the haplotypes for each subject, the Phase software was run on the markers 
used for Haploview. Haplotyping was performed on the genes EGF and VEGF 
only, as there was only one genotyped marker in each of FGF1 and FGF2. 
Haplotype odds ratios for disease associations were calculated using the mixture 
logistic regression method proposed by Sham et al. (2004) (388), fitted by using 
WinBUGS 1.4 (Medical Research Council Biostatistics Unit, Cambridge) (389), 
which estimates Bayesian model parameters by using Markov chain Monte Carlo 
methods. 
Results 
Two hundred and fifty-eight PsA probands and 154 ethnically matched 
controls were studied. All subjects were Caucasian of North European descent 
and considered to be native Newfoundlanders. The mean age of PsA patients at 
the time of study was 49.67 years (sd 10.95 years), and 48.5% of subjects were 
females. The mean age of onset of psoriasis in our cohort was 29.27 years (sd 
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14.16 years). Not all SNPs were successfully genotyped in every individual. The 
results of the genotyping experiments are given in Table 5.1-1. 
Chi squared (X2) tests for a departure from the Hardy-Weinberg equilibrium 
were performed on each marker by Haploview. The only marker that attained 
statistical significance in the control sample is rs4444903 in EGF gene (p < 0.01 ), 
and this marker was removed from further analysis; all the other markers satisfied 
H-W equilibrium. 
Single Marker Association Tests 
The marker VEGF +936 (rs3025039) yielded a statistically significant 
result when Fisher's exact test was performed to compare allele frequencies 
between cases and controls (see Table 5-1). There was a higher proportion ofT 
alleles among controls than cases (cases 11.6% vs. 16.8% in controls); Fisher's 
exact p value was= 0.042, OR for the T allele: 0.653 (95% Cl: 0.434, 0.982). This 
finding is consistent with those of the statistical tests on the genotype frequencies 
(Fisher's exact test p = 0.082; Trend test p = 0.035). The marker VEGF -634 
(rs201 0963) also appears to yield a statistically significant result when Fisher's 
exact test was performed on the genotype frequencies (p = 0.037). However, 
neither the Fisher's exact test on the allele table (p = 0.74) nor the trend test on 
the genotype table (p = 0.71) was statistically significant. The remaining two 
SNPs in the VEGF gene, VEGF -1154 (rs1570360) and VEGF -2578 (rs699947) 
displayed no evidence of an association with PsA. For the FGF1 and FGF2 
markers (rs34011 
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Table 5-1: Genotype frequencies of SNPs in VEGF, FGF1 , FGF2 and EGF in PsA 
patients and controls 
Genotype NF PsA patients Controls 
VEGF+936 cc 200/258 (77.5%) 100/146 (68.5%) 
rs3025039 CT 56/258 (21.7%) 43/146 (29.5%) 
TT 2/258 (0.8%) 3/146 (2.0%) 
Allele Freq (T) 11.6% 16.8% 
VEGF-1154 GG 69/257 (26.8%) 35/147 (23.8%) 
rs1570360 GA 121/257 (47.1%) 69/147 (46.9%) 
AA 67/257 (26.1%) 43/147 (29.3%) 
Allele Freq (A) 49.6% 52.7% 
VEGF-2578 AA 68/257 (26.5%) 45/150 (30.0%) 
rs699947 AC 124/257 (48.2%) 70/150 (46.7%) 
cc 65/257 (25.3%) 35/150 (23.3%) 
Allele Freq (C) 49.4% 46.7% 
VEGF-634 GG 118/255 (46.3%) 64/127 (50.4%) 
rs201 0963 GC 118/255 (46.3%) 45/127 (35.4%) 
cc 19/255 (7.4%) 18/127 (14.2%) 
Allele Freq (c) 30.6% 31 .9% 
FGF1 cc 110/242 (45.5%) 74/154 (48.0%) 
rs34011 CT 108/242 (44.6%) 64/154 (41 .6%) 
TT 24/242 (9.9%) 16/154 (10.4%) 
Allele Freq (T) 32.2% 31.2% 
FGF2 cc 167/254 (65.7%) 99/154 (64.3%) 
rs1048201 CT 79/254 (31 .1%) 47/154 (30.5%) 
TT 8/254 (3.2%) 8/154 (5.2%) 
Allele Freq (T) 18.7% 20.5% 
EGF AA 209/248 (84.3%) 122/153 (79.7%) 
rs4444903 GA 4/248 (1.6%) 1/153 (0.7%) 
GG 35/248 (14.1%) 30/153 (19.6%) 
Allele Freq (G) 14.9% 19.9% 
EGF GG 78/256 (30.5%) 55/154 (35.7%) 
rs2237051 GA 138/256 (53.9%) 72/154 (46.8%) 
AA 40/256 (15.6%) 27/154 (17.5%) 
Allele Freq (A) 42.6% 40.9% 
EGF GG 233/243 (95.9%) 140/149 (94.0%) 
rs11568943 GA 10/243 (4.1%) 9/149 (6.0%) 
AA 0 0 
Allele Freq (A) 2.1% 3.0% 
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and rs1 048201 respectively), there were no statistically significant findings in any 
of the tests (p > 0.5) that would suggest an association with PsA. For the two 
EGF SNPs, there was no evidence of association for either rs2237051 or 
rs11568943 in PsA. 
Haplotyping 
The VEGF marker +936 (rs3025039) is physically far from, and has low LD with, 
the other 3 markers in the gene (see Figure 5-1). Thus, it was decided that 
rs3025039 should be excluded when estimating multi-marker haplotypes within 
this gene, (this decision is consistent with the VEGF haplotyping work of Seo et al 
(383)) and only rs699947, rs1570360, and rs201 0963 were considered for 
haplotyping. There are 3 main haplotypes (AAG, CGC, and CGG) at the loci 
rs69994 7, rs1570360, and rs201 0963, and haplotype frequency estimates are 
shown in Table 5.1-2. Haploview performed x2 tests comparing frequencies of 
haplotype CGC and CGG, respectively, in cases and controls. For CGC, the 
haplotype frequency was 0.325 in controls and 0.308 in cases, while the x2 test 
gave a p value of 0.612. For CGG the haplotype frequency was 0.138 in controls 
and 0.186 in cases, while the l test gave a p value of 0.077. 
In order to calculate haplotype odds ratios (HOR), Phase v2.1 was used to 
make haplotype predictions for individuals. The haplotype frequencies generated 
by Phase and Haploview were compared and it was determined that the results 
from the two software packages were consistent with each other. A logistic 
regression model was then fitted to the case-control data to determine the odds 
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Figure 5-1: Linkage Disequilibrium in VEGF Markers 
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Table 5-2: Haplotype frequencies for VEGF rs699947, rs1570360, and 
rs201 0963, estimated by using PHASE version 2.1. 
Haplotype Frequency in PsA cases Frequency in controls 
(N=516) No. {%) (N=300) No. (%) 
CGC 159.0 (30.8%) 97.6 (32 .5%) 
CGG 96.0 (18.6%) 41.4 (13.8%) 
AAG 256.0 (49.6%) 156.9 (52.3%) 
All other haplotypes 5 (0.97%) 4.1 {1.4%) 
ratio associated with each haplotype. Since haplotypes for some individuals 
cannot be precisely determined due to phase ambiguities, the mixture logistic 
regression method (388) was used to account for the probabilistic determination 
of haplotypes for individuals. This was implemented in WinBUGS 1.4. Note that 
this implementation does not yield p-values due to its Bayesian nature, but 
statistical significance can still be assessed by checking whether the 95% Cl of 
HOR spans 1.0. 
The results of the HOR analysis for the EGF and VEGF markers are given 
in Tables 5-3 and 5-4. Neither of the haplotypes for either gene was found to be 
strongly related to the disease status. It was decided that the marker rs4444903 
of the EGF gene should be excluded from haplotyping as it was not in Hardy-
Weinberg equilibrium in the control sample. Thus, only EGF markers rs11568943 
and rs2237051 were considered for haplotyping (See figure 5.1-2: The 2nd block 
of figure 1 corresponds to the haplotyping of our interest). No evidence of a 
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haplotype association with PsA for EGF markers (rs11568943 and rs2237051) 
was observed. 
Table 5-3: Haplotype Odds Ratios (HOR) for PsA associated with EGF 
rs11568943 and rs2237051. The baseline haplotype for reference is GG. 
EGF 
haplotype 
GA 
AA 
HOR (95% Cl) 
1.106(0.824,1 .504) 
0.702 ( 0.264, 1.844) 
Table 5-4: Haplotype Odds Ratio (HOR) analysis for VEGF rs699947, 
rs1570360, and rs201 0963. The reference haplotype is AAG. 
VEGF 
haplotype 
CGC 
CGG 
HOR (95% Cl) 
0.946 ( 0.687, 1.294) 
1.481 ( 0.932, 2.340) 
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Of the 258 PsA probands, 164 had polyarticular disease (63.6%); 79 had 
oligoarticular disease (30.6%); 5 patients had isolated DIP variant (1.9%), 5 had 
isolated spondyloarthropathies (1.9%) and 3 had arthritis mutilans (1 .1 %). 
Due to the low frequency of the isolated DIP, isolated spondylitis, and arthritis 
mutilans variant, we assessed differences in allele frequencies for our markers in 
between the oligoarticular and polyarticular subtypes of PsA, (data summarized 
in Table 5-5). 
With respect to axial involvement, as noted above isolated spondylitis was 
relatively rare in our cohort. Most of the cases of spondylitis occurred in 
conjunction with either oligoarthritis or polyarthritis. Thus we stratified our PsA 
probands as having spondylitis or no spondylitis irrespective of peripheral 
involvement. We noted that 40 (15.5%) of our patients had a concomitant 
spondyloarthropathy and 201 patients (78.0%) had no axial involvement. For the 
remaining 17 patients there was insufficient information to properly assess for the 
presence of spondylitis (data summarized in Table 5-6). As noted in tables 5.1-5 
and 5.1-6, no significant differences in minor allele frequencies were noted 
between variants of PsA and any of the SNPs examined in our study using 
Fisher's exact test. 
Discussion 
The proposed physiological role of the cytokines coded for by the VEGF, 
FGF1, FGF2 and EGF genes, along with the increased levels of these angiogen-
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Table 5-5: Minor allele frequencies in ol igoarticular and polyarticular 
subsets of PsA. 
No significant differences were found between these two subgroups for any 
marker. 
SNP Minor allele frequency Minor allele frequency 
for for Polyarticular disease 
Oligoarticular disease [N= 164; 63.6% of 
[N= 79; 30.6% of cases] cases] 
VEGF +936 (T) 0.12 0.11 
rs3025039 
VEGF -1154 (A) 0.52 0.48 
rs1570360 
VEGF -2578 (C) 0.47 0.51 
rs699947 
VEGF -634 (C) 0.30 0.31 
rs2010963 
FGF1 (T) 0.32 0.33 
rs34011 
FGF2 (T) 0.21 0.18 
rs1048201 
EGF (G) 0.16 0.15 
rs4444903 
EGF (A) 0.46 0.42 
rs2237051 
EGF (A) 0.01 0.03 
rs11568943 
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Table 5.6: Minor allele frequencies in the spondyloarthritis subgroups of 
PsA. 
No significant differences were found between these two subgroups for any 
marker. 
SNP 
VEGF +936 (T) 
rs3025039 
VEGF -1154 (A) 
rs1570360 
VEGF -2578 (C) 
rs699947 
VEGF -634 (C) 
rs2010963 
FGF1 (T) 
rs34011 
FGF2 (T) 
rs1048201 
EGF (G) 
rs4444903 
EGF (A) 
rs2237051 
EGF (A) 
rs11568943 
Minor allele frequency 
for cases with NO 
spondylitis 
[N=201; 78.0% of cases] 
0.12 
0.48 
0.5 
0.31 
0.32 
0.21 
0.15 
0.42 
0.02 
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Minor allele frequency 
for cases with 
Spondylitis present 
[N=40; 15.5% of cases] 
0.11 
0.53 
0.45 
0.29 
0.36 
0.21 
0.20 
0.50 
0.05 
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-ic factors in arthritic synovium, make these worthy targets for evaluation of 
genetic association. 
We have observed an increased frequency in the T allele of VEGF +936 
(rs3025039) in control subjects when compared to our PsA patients [Fisher's 
exact p-value = 0.042; OR 0.653 (95% Cl: 0.434, 0.982)] indicating that this SNP 
may play a protective role against the development of PsA. This is in contrast to 
Han et al. (382) who observed an association of the T allele with the development 
of RA. It is worth noting that the pattern of increasing vascularity in PsA synovial 
tissue has been shown to be markedly distinct from that observed in RA: PsA 
patients were shown to have predominantly tortuous, bushy vessels while RA 
patients had mainly straight, branching vessels (1 01 ). This potentially indicates 
differing mechanisms of angiogenesis, lending further evidence to the idea that 
there are indeed different pathogenic mechanisms in RA and PsA, which is not 
necessarily surprising. 
Although the -1154 G-+A (rs1570360) and -634 G-+C (rs2010963) VEGF 
variants were not associated with rheumatoid arthritis in a white population from 
Spain (390), interesting observations were found in assessing patients with 
primary systemic vasculitides from North-western Spain. With respect to this, 
biopsy-proven giant cell arteri tis (GCA) patients, who had severe ischemic 
complications exhibited a significantly increased frequency of VEGF -634 G allele 
compared with GCA patients not affected by ischemic complications or with 
healthy controls. Interestingly, patients carrying the VEGF -634 C allele, 
associated with high production of VEGF had significantly reduced frequency of 
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severe ischemic events in the setting of this large and middle-sized blood vessel 
vasculitis. In this regard, the carriage rate of the risk allele G showed statistically 
significant skewing comparing GCA patients with severe ischemic events with the 
remaining GCA patients (GG + GC compared with CC). These results suggest a 
potential implication of the VEGF gene -634 G-->C polymorphism in the 
development of severe ischemic manifestations of GCA. High VEGF levels may 
have a compensatory effect supporting neoangiogenesis mechanisms that may 
protect GCA patients from the development of severe ischemic complications 
such as irreversible visual loss (391 ). In contrast, in Henoch-Schonlein Purpura 
(HSP), a small-sized blood vessel vasculitis involving skin, gut and kidney, the 
high VEGF producing -1154 G allele was increased in HSP patients with nephritis 
compared with healthy controls. Similarly, the high VEGF producing -634 C allele 
was also increased in patients with nephritis compared to controls. The -1154G/-
634C haplotype was also associated with susceptibility to HSP nephritis. 
Moreover, a protective effect against nephritis in patients with HSP was observed 
for the -1154AI-634G VEGF promoter haplotype. These results also suggest a 
potential implication of the VEGF -1154 G-->A and -634 G-->C polymorphisms in 
the development of nephritis in patients with HSP (392). It is also worth noting 
that in several instances the frequency of disease-associated and other alleles 
have been shown to be markedly different between Caucasian and Asian 
populations (393,394) including alleles associated with RA and other auto-
immune conditions (395 ), therefore, our observed differences in the allele 
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frequency of VEGF +936 (rs3025039) from other published reports is not 
surprising. 
Conclusions 
Thus, the first investigation of genetic variations of the pro-angiogenic 
cytokines VEGF, FGF1, FGF2, and EGF in PsA has produced some interesting 
results. We observed that the T allele of VEGF in +936 (rs3025039) may act as a 
protective allele in the development of PsA, in contrast to other reports which 
have observed a higher frequency of the allele in RA patients. The possibility 
does remain that an association exists for novel SNPs in these genes which may 
affect transcription levels or cause other functional changes, or within regulatory 
genes for VEGF, FGF1 , FGF2 and EGF. It is also quite possible that variants in 
genes for other molecules which function in angiogenesis may be involved with 
PsA. Further studies regarding the association of pro-angiogenic markers in PsA 
would be beneficial to help elucidate pathogenic pathways in this disease. 
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Introduction 
Recently, Bongartz et a/. reported on the use of a novel class of insulin-
sensitizing drugs (thiazolidinediones) in the treatment of active psoriatic arthritis 
(PsA) (132). Specifically, in this open labelled trial, six out of 10 patients with 
active PsA improved sufficiently to satisfy the psoriatic arthritis response criterion 
(PsARC) after pioglitazone was instituted. Pioglitazone was developed for the 
treatment of type II diabetes mellitus and acts as a ligand for the peroxisome 
proliferator-activated receptor y (PPARy). The PPARy gene is expressed in many 
human tissues and its activation has previously been shown to play a role in 
suppressing both angiogenesis and inflammation (133,396). Specifically, PPARy 
activation can decrease proinflammatory cytokine expression and suppress 
neoangiogenesis in models of inflammatory disease (133). 
PPARy is a potential candidate gene for susceptibility in PsA, as Mingrone 
et al. demonstrated that abnormal lipid metabolism often co-exists with glucose 
intolerance in subjects with psoriasis (397). Secondly, epidemiological studies 
have noted increased prevalence of type I diabetes (lOOM) in subjects with 
psoriasis. Also, the Pro12Aia SNP of PPARy has previously been associated with 
type 2 OM (398) and biomarkers of systemic inflammation (399). Finally, several 
animal models have shown that peroxisome proliferator-activated receptor y 
agonists significantly reduced the progression of experimentally induced 
osteoarthritis in guinea pigs (400), and clinical disease activity scores as well as 
histological scores of joint destruction in a mouse model of collagen-induced 
arthritis (401 ). 
167 
Given the potential physiological role of PPARy activation and the 
apparent success of PPARy-agonist in the treatment of active PsA and in animal 
models of arthritis, we decided to examine four known coding polymorphisms in 
the PPARy gene in our PsA population: Pro12Aia (rs1801282), Pro40Aia 
(rs1805192), Pro115Gin (rs1800571), and C161T (rs3856806). The PPARy 
Pro12Aia SNP has previously been associated with reduced transcriptional and 
receptor activity of PPARy (402) and the presence of the Ala isoform has been 
linked to higher insulin sensitivity and both higher and lower body mass index 
(403,404 ), while the Pro12Pro isoform has been associated with both higher 
levels of biomarkers of inflammation as well as shorter survival times in patients 
with end-stage renal disease (399). The Pro40Aia, Pro115Gin and C161 T 
polymorphisms have all previously been inconsistently associated with diabetes, 
insulin sensitivity and obesity (402,404,405). 
Methods 
PsA was diagnosed as an inflammatory arthritis in patients with psoriasis, 
in the absence of other aetiologies for inflammatory arthritis. All PsA probands 
were Caucasians from the Newfoundland population, and were unrelated to each 
other. Information was collected on a standardized protocol and included age at 
onset of psoriasis, PsA and disease pattern. Control subjects were healthy 
volunteers from Newfoundland who responded to an advertisement seeking 
controls for genetic studies. As the control subjects were examined we verified 
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that they did not have PsA at the time of the study nor did they have a history of 
psoriasis or inflammatory arthritis. This study was approved by the local ethics 
committee of Memorial University of Newfoundland. Informed consent was 
obtained from all patients. 
The island portion of the Canadian province of Newfoundland and 
Labrador is located in the Atlantic Ocean, off the eastern coast of Canada. The 
population of the island of Newfoundland consists mainly of descendants of 
English and Irish settlers who arrived in the 1 y!h and 181h centuries. The 
geographical and social isolation of this island has ensured very little inward 
migration for several hundred years and thus has lead to a small population (530 
000 individuals; Statistics Canada 2001) which has grown mostly through internal 
expansion, with a relatively homogenous genetic background ideal for the study 
of complex disease. 
Whole blood samples were obtained from PsA probands and control 
subjects. DNA was extracted using the Promega Wizard Genomic DNA 
purification Kit. The detection of SNPs was performed by the analysis of primer 
extension products generated from previously amplified genomic DNA using a 
Sequenom chip-based MALDI-TOF mass spectrometry platform. In brief, PCR 
and extension reactions were designed using MassARRAY design software, and 
were carried out using 2.5 ng of template DNA. Unincorporated nucleotides in the 
PCR product were deactivated using shrimp alkaline phosphatase. The 
amplification of the SNP site was carried out using the MassExtend primer and 
involved the use of specific deoxy/dideoxy-nucleotide triphosphate (d/ddNTP) 
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termination mixes which were also determined using MassARRAY assay design 
software. The primer extension products were then cleaned and spotted onto a 
SpectroChip. The chips were scanned using a mass spectrometry workstation 
(Bruker) and the resulting spectra were analyzed and genotypes were 
determined using the Sequenom SpectroTYPER-RT software. 
Samples were genotyped for all four PPARy variants by time-of-flight 
mass spectrometry using the Sequenom platform. All four SNPs were previously 
reported coding variations, three of which caused an amino-acid change: 
Pro12Aia, Pro40Aia, Pro115Gin, while the fourth SNP C161 T was synonymous, 
resulting in no amino acid change in the final protein. All primers were designed 
using Sequenom SpectroDESIGNER software, scanned using a mass 
spectrometry workstation (Bruker), and analyzed using the Sequenom 
SpectroTYPER-RT software. Statistical analysis of all PPARy variants was 
performed using chi-square tests. 
Results 
Of the four PPARy SNPs examined, two (Pro40Aia and Pro115Gin) were 
found to be non-polymorphic in our population. The genotype frequencies of the 
remaining SNPs are given Table 5-7. For the Pro12Aia (rs1801282) SNP, an 
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Table 5-7: Genotype frequencies in PPARy in PsA patients from 
Newfoundland 
Genotype PsA patients Controls p-value 
N=251 N=235 
PPARy cc 208 (82.9%) 177 (75.3%) 
Pro12Aia GC 41 (16.3%) 51 (21 .7%) 
rs1801282 GG 2 (0.8%) 7 (3.0%) 
Allele Freg (G) 9.0% 13.8% 0.017 
PPARy cc 207(80.9%) 185 (79.4%) 
C1431T TC 43 (16.8%) 40 (17.2%) 
rs3856806 TT 6 (2.3%) 8 (3.4%) 
Allele Freg (T) 10.7% 12.0% 0.56 
association was noted for the minor allele between PsA cases and controls (9.0% 
vs. 13.8% respectively, p=0.017; OR: 0.62, 95% Cl: 0.45 - 0.93), and this 
association remained significant (p=0.034) in multiple testing using Bonferroni's 
correction . Meanwhile, no association was noted for the C161T (rs3856806) SNP 
(1 0.7% vs. 12.0%, respectively, p=0.56). No haplotype associations were noted 
and there was no correlation between the genotypes and age of onset of 
psoriasis, age of onset of PsA or disease pattern. 
Discussion 
In our study a modest association was noted for the Pro12Aia (rs1801282) 
SNP, which results in an amino acid change from proline to alanine. To our 
knowledge, cases and controls were not related to each other. Even though 
selection of cases and controls was not limited to one geographic region, it is 
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conceivable that cryptic relatedness exists in the Newfoundland population, 
resulting in an ascertainment bias. 
Interestingly, a previous study noted no association between PPARy 
polymorphisms and uncomplicated psoriasis (406). This would appear to suggest 
that the Pro12Aia variant of the PPARy gene confers susceptibility specifically to 
PsA rather than psoriasis. However we would use caution in interpreting this 
result, as 2 separate populations were studied in the psoriasis and PsA reports. 
Thus, further investigation of this gene from PsA and psoriasis subjects from our 
population as well as other independent populations is now warranted. 
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Psoriatic Arthritis (PsA) is a complex immunologically mediated disorder 
that results from interplay between multiple genetic and environmental factors. 
One of the pathological hallmarks of PsA is the presence of extensive bone 
resorption with concomitant new bone formation (49). Osteoclasts are the primary 
cells responsible for bone resorption, and there is a significant increase in the 
amount of osteoclast precursor cells (OPCs) observed in PsA patients (112). 
Signalling of OPCs to begin maturation to osteoclasts is initiated when the 
receptor-activator of NF-KB (RANK)- an OPC surface receptor molecule - binds 
to its ligand (RANKL). Osteoprotegerin (OPG) is a natural antagonist to RANKL, 
acting as a soluble decoy receptor for RANKL that blocks osteoclast formation by 
inhibiting RANKL binding to RANK helping to maintain balanced bone 
remodelling (407). Imbalances in any of these three molecules could affect 
normal bone remodelling leading to the pattern of simultaneous bone loss and 
gain observed in PsA, thus we decided to examine some known SNPs in RANK, 
RANKL and OPG to determine if an association existed with PsA in a founder 
population. 
This study was approved by the local ethics committee at Memorial 
University of Newfoundland. All patients were unrelated, and informed consent 
was obtained from all participants. PsA was diagnosed as an inflammatory 
arthritis in patients with psoriasis, in the absence of other aetiologies for 
inflammatory arthritis. The control subjects were ascertained from our founder 
population, and were all unrelated to each other and our patient group. DNA 
Samples were genotyped for three OPG SNPs (rs2073618, rs2073617, 
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rs3102735), two RANKL SNPs (rs922996, rs12721445), and one RANK SNP 
(rs1805034 ), by time-of-flight mass spectrometry using the Sequenom platform. 
All OPG and RANKL SNPs have previously reported associations with arthritic or 
bone-loss conditions, while the RANK SNP is the only identified coding SNP in 
that gene that results in an amino acid change present at a high heterozygosity 
level. All primers were designed using Sequenom SpectroDESIGNER software, 
scanned using a mass spectrometry workstation (Bruker), and analyzed using the 
Sequenom SpectroTYPER-RT software. Statistical analysis of all OPG, RANK, 
and RANKL variants was performed using chi-square tests. 
Of the six SNPs examined, none were observed to have significant 
differences in minor allele frequencies between our patient and control 
populations (rs2073618 48.8% vs. 50.2%; rs2073617 50.0% vs. 45.5%; 
rs3102735 14.3% vs. 14.4%; rs1805034 48.0% vs. 51.9%; rs922996 50.0% vs. 
45.1% ), while rs12721445 was found to be completely non-polymorphic in our 
founder population {Table 5-8), and no differences were observed when analyzed 
by early-onset patients, gender, or type of arthritis (all p values > 0.05). All 
genotypes satisfied the Hardy-Weinberg equilibrium. 
An association between PsA and known SNPs of the genes RANK, 
RANKL and OPG was not observed in our founder population, suggesting that 
variants in these genes are not involved in the pathogenesis of PsA. The 
possibility does remain that an association exists for novel SNPs in these genes 
which may affect transcription levels or cause other functional changes, or that 
variants in genes for other molecules which play a role in osteoclast maturation or 
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bone resorption/formation may play a role. Furthermore, we also acknowledge 
that because of our sample size we are unlikely to detect small differences in 
allele frequencies. 
Table-5-8: Association of selected SNPs in the OPG, RANK, and RANKL genes 
in PsA. 
Genotype # of PsA patients # of Controls with each 
with each genot~~e genot~~e 
OPG cc 67/252 (23.8%) 54/238 (22. 7%) 
rs2073618 GC 124/252 ( 49.2%) 129/238 (54 .2%) 
GG 61/252 (24.2%) 55/238 {23 .1%) 
Allele Freq (G) 48.8% 50.2% 
OPG TT 61/252 (24.2%) 67/236 (28.4%) 
rs2073617 CT 130/252 (51 .6%) 123/236 (52.1%) 
cc 61/252 (24.2%) 46/236 (19.5%) 
Allele Freq (C) 50.0% 45.5% 
OPG TT 195/259 (75.3%) 172/236 (72.9%) 
rs3102735 CT 54/259 {20.8%) 60/236 {25.4%) 
cc 10/259 (3.9%) 4/236 (1.7%) 
Allele Freq (C) 14.3% 14.4% 
RANK TT 76/259 (29.3%) 50/235 (21 .3%) 
rs1805034 CT 117/259 (45.2%) 126/235 (53.6%) 
cc 66/259 (25.5%) 59/235 (25 .1%) 
Allele Freq (C) 48.0% 51.9% 
RANKL cc 61/256 {23.8%) 76/235 (32.3%) 
rs922996 TC 134/256 (52.4%) 106/235 (45.1%) 
TT 61/256 {23.8%) 53/235 {22.6%) 
Allele Freq {T) 50.0% 45.1% 
RANKL TT 252/252 ( 1 00%) 236/236 ( 1 00%) 
rs12721445 
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Introduction 
The genetic contribution to complex disease is thought to be the result of 
multiple variants of several genes across multiple pathways, each with low 
penetrance (408). The predisposition imparted by individual gene variants may 
act independently or interact with other genes to result in an additive effect or a 
synergistic co-effect. As well, disease susceptibility and severity can vary across 
populations of differing ethnic backgrounds. This variance is likely due to the 
result of a shared genetic background within ethnic groups, or due to the 
interaction of specific gene variants with local environmental factors. 
The advent of the International HapMap project (409) has enabled 
researchers to take advantage of knowledge of linkage disequilibrium (LD) 
present in the genome to elucidate the relationship between SNPs and their 
nearest neighbours, as well as the frequency of the these variants across several 
populations. The hoped-for end result is a small set of variants (tagSNPs) that 
capture most variation in the genome. 
The data obtained from the HapMap has enabled several significant 
findings, from fine mapping small regions implicated in disease (221 ,410,411) to 
larger genome wide scans (239,242,412). Despite the prevailing wisdom that 
complex disease is the result of interplay of multiple variants, the majority of 
these studies do not examine potential epistatic interactions between the 
genotyped markers. Conventional haplotyping may not pick up associations of 
markers separated by great distances and thus not affected by LD on the same 
chromosome. Further, as multiple genes from different chromosomes interacting 
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to form a biological effect are the norm rather than the exception (i.e., cytokines 
and cytokine receptors, blood coagulation cascade) foregoing this type of intra-
and intergenic marker analysis may result the underestimation of the contribution 
of combined gene variants to disease phenotype. 
In recent years, much effort has been put into genome-wide association 
studies (GWAS). Frequently, such studies fail to detect associations of relevant 
biological pathways to disease phenotypes. One of the reasons for such failures 
is the use of single-locus association analyses that ignore or down-play the 
effects of multi-gene interactions (413). Most proposed methods and analyses for 
capturing epistatic effects are limited to small numbers of genes (414 ). One of the 
most prominent and commonly used methods is non-parametric multifactorial 
dimensionality reduction (MDR), which is a constructive induction algorithm (415). 
This algorithm uses 90% of the data as training data and the remaining 10% is for 
validation. In simulation on 10 SNPs, the MDR approach detected gene-gene 
interactions in the presence of 5% genotyping error and 5% missing data (416). 
Unfortunately, the MDR approach is limited to very small numbers of SNPs, i.e., 
less than 50 and is not scalable to large datasets (417,418). 
Another proposed method employs multi-locus tests which use a 1 degree 
of freedom (1-d.f) model of interaction (419). This method has been tested 
successfully in simulation on 12 SNPs for two genes relative to a very small 
sample size and on a real dataset consisting of 6 SNPs for N-acetyltransferase 2 
(NAT 2) relative to a moderately large case-control colorectal adenoma cohort 
(420). However, this method only detects interactions between two loci and does 
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not handle missing data. The most comprehensive method to date was proposed 
by Zhang et al. {421) in which they introduced a Bayesian epistasis association 
mapping (BEAM) model that computes the posterior probability of a disease 
associated marker set using Monte Carlo Markov chains. The method was 
successfully tested on an age-related macular degeneration genome-wide case-
control data set genotyped for 96 cases and 50 controls. This method computes 
interactions based on six statistical models and handles interactions of up to six 
genes. However, it is not clear if larger groups of interactions or missing data can 
accommodated in this method. Common problems of existing methods are the 
inability to detect interactions among multiple loci, poor scalability to even 
moderate size datasets, and poor handling of missing data {which is very 
common in real datasets). The need for novel methods that solve all of these 
problems has been recently acknowledged as of being of great importance (422). 
In order to analyze interactions such as these, we have made use of a 
novel algorithm developed by Mohammed Uddin (423) to examine multi-marker 
epistasis in PsA. The details of the algorithm and results of algorithm validation 
experiments are included in Appendix 1. 
Methods 
Data 
The PsA cohort was taken from the Newfoundland population. Markers for 
analysis were chosen as SNPs from genes which we had previously reported 
significant associations (221 ,371 ,424,425), with additional inclusion criteria being 
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that the markers were bi-allelic and were hypothesized as being involved in three 
primary events in PsA - namely, cytokine-driven inflammation (II-23R; GeneiD 
149233, Chromosome 1 p31 .3; TNF-a; GeneiD 7124, Chromosome 6p21.3), T-
cell activation (PTPN22; GeneiD 26191 , Chromosome 1 p13.1 ), and angiogenesis 
(PPAR-v, GeneiD 5468, Chromosome 3p25). 
This study was approved by the ethics committee of Memorial University 
of Newfoundland. Informed consent was obtained from all patients, and 
participation was on a purely voluntary basis. All PsA probands were Caucasians 
from the Newfoundland population, and were diagnosed by a rheumatologist. 
PsA was diagnosed as inflammatory arthritis in patients with psoriasis, in the 
absence of any other aetiology for inflammatory arthritis. Information was 
collected systematically and included age at onset of psoriasis, PsA and disease 
pattern. The ethnically matched, healthy control subjects were also obtained from 
the Newfoundland population, and were unrelated to the cases. There were a 
total of 240 PsA patients and 129 control subjects. The PsA case-control 
haplotypes includes 0.33% and 0.20% missing data, respectively 
Genotyping Methods 
Whole blood samples were obtained from PsA probands and control 
subjects. DNA was extracted using the Promega Wizard Genomic DNA 
purification kit. The detection of SNPs was performed by the analysis of primer 
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extension products generated from previously amplified genomic DNA using a 
Sequenom chip-based MALDI-TOF mass spectrometry platform (310). 
Results 
The results of the analysis with our Competitive Co-Evolutionary Algorithm 
are displayed in Figure 6-1 . After 10000 permutations, 40 SNP interactions 
displayed significance with p < 1.0 X 1 0"-4.. Of these, 22 were composed 
exclusively of SNPs from //-23R. The highest haplotype risk ratios were observed 
in an AC epistatic genotype of PPAR-y rs1801282 and IL-23R rs6660226 (HRR 
2.92, 95% Cl 2.04 - 4.18). The next highest HRR was observed in an AAC 
'haplotype' which contained PPAR-y rs1801282 and IL-23R rs6660226 and an 
additional II-23R SNP of rs1857292 (HRR 2.89, 95% Cl 2.02 - 4.14). PPAR-y 
rs1801282 was observed in 18 epistatic genotypes - 6 of these included IL-23R 
rs6660226, while the remaining 12 included II-23R rs11209081 (all but 1 of these 
12 also included II-23R rs1857292). The PTPN22 SNP rs2476601 was only 
observed in three epistatic genotypes, all of which also contained PPAR-y 
rs1801282 and IL-23R rs6660226. Of the 5 TNF-a SNPs included in this data set, 
only one (rs1800630, also referred to as TNF-a -863) was ever observed, 
appearing in a single CGAA epistatic genotype consisting of TNF-a rs1800630, 
PPAR-y rs1801282, IL-23R rs6660226, II-23R rs1857292 which provided the 
lowest observed HRR of 2.37. It remains possible that different interactions or 
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Figure 6-1: Results of the Competitive Co-Evolutionary algorithm in PsA. 
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different HRR may have been observed had our PsA patients been stratified 
according to the 5 different clinical subtypes (145). 
Discussion 
The results obtained here show the presence of only IL-23R SNPs in 22 of 
the 40 observed PsA epistatic genotypes and the involvement of at least one IL-
23R SNP in all of the 40 PsA epistatic genotypes adds further evidence to the 
recently observed association of this gene with PsA (221 ,241 ). Functionally, IL-
23R has a plausible biological role in PsA, as IL-23 is a proinflammatory cytokine 
and may account for pathologic T cell responses. IL-23 is also expressed on the 
surface of both macrophages and dendritic cells and thus may have a roll in 
controlling barrier function and immune response (426) IL-23 can directly induce 
the production of IL-22 from both murine and human naive T cells. These results 
suggest that Th17 cells, through the production of both IL-22 and IL-17, might 
have essential functions in host defence and in the pathogenesis of autoimmune 
diseases such as psoriasis (427). 
The observation of PPAR-y appearing in nearly 50% of observed 
significant epistatic genotypes (and always in conjunction with at least one II-23R 
SNP) is interesting as it speaks directly to the multiple pathogenic processes 
(both inflammation and angiogenesis, as well as others) which must occur 
simultaneously in the development of PsA. TNF-a has been repeatedly 
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associated with PsA, and a recent meta-analysis of 8 populations recently 
showed that the -238 allele is significantly associated with PsA (424). The fact 
that this allele does not appear in any of our 'haplotypes' coupled with its central 
role in driving many inflammation processes argues that it may be an 
independent risk factor for PsA. 
While PTPN22 has been repeatedly associated with several 
immunologically mediated diseases (227) the evidence for its association with 
PsA has been mixed (229,425). As the gene functions in the inhibition of T cell 
activation, it does suggest a plausible biologic mechanism for the epistatic 
interactions observed here. Increased levels of the IL-23 cytokine brought about 
due to variation in the receptor (encoded by the IL-23R gene) can lead to 
differentiation of type 17 and type 1 helper T cells (Th17 and Th1 ). These 
activated T cells will then secrete further inflammatory cytokines which feedback 
into the inflammatory cycle (428). The specific PTPN22 SNP examined here 
(rs2476601) introduces an Arg---+ Trp substitution, which disrupts a binding site for 
a negative regulatory kinase in T cells. Thus, a normal suppression mechanism 
for T cell activation is abrogated, which could further perpetuate the cycle of T-
cell over-activation in psoriatic skin and joints. 
It must be noted that there are some significant issues that the current 
iteration of our algorithm design did not consider. One such issue was the 
population stratification bias. Our proposed CCA algorithm is designed to detect 
SNPs and the underlying haplotypes from a case-control cohort that is ethnically 
matched. A cohort with mixed ethnicity will disrupt the accuracy of the algorithm 
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as mixed ethnicity will introduce a stratification bias which this algorithm does not 
consider while computing haplotype frequencies. Hence, using a mixed 
population in a cohort might produce false positive results . 
Our results show the power of detecting interactions which are not 
restricted to a fixed number of loci, hence demonstrating the advantages of our 
CCA-based method over other proposed methods that use models to detect 
interactions from a limited number of loci. For example, while the BEAM algorithm 
is computationally sound, it is likely that more than 6 distinct loci can interact in 
complex diseases. Moreover, our CCA proposes a novel algorithm that can 
quickly and reliably estimate the likelihood of haplotype frequencies in the 
presence of up 15% missing data. This suggests that our CCA should scale well 
for larger datasets. There is no proposed multiple correction test that can be 
applied to the large number of tests we are performing in our CCA. Multiple 
correction tests for single locus association commonly use Bonferroni tests when 
all tests are considered independent. To identify gene-gene interaction from 
multiple loci, the LD structure can introduce dependency. Hence, the permutation 
test (which is applied in our CCA) is more appropriate (429). The significance 
level of the test was considered based on the number of permutation-iterations. 
As the permutation test is computationally expensive, we only apply it on 
haplotypes whose significance is greater than a given threshold. Further, we 
acknowledge that the small sample size used in each of our disease cohorts may 
contribute to a false-positive result. Methods of power calculation for multiple 
gene-gene interactions from different chromosomes are yet to be identified. 
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Commonly used methods (i.e. Quanto) for power computation are limited to 
compute for pair of genes (430). The power computation for detecting 
interactions from multiple genes located in different chromosome needs more 
research to suffice the growing need for gene-gene interactions. Finally, it is a 
drawback that the current iteration of the algorithm can only accommodate bi -
allelic SNPs. To fully account for variation that may contribute to disease, it will 
be necessary to include multi-allelic SNPs, and Copy Number Variants (CNVs), 
such insertion/deletion or repeat polymorphisms in an analysis. 
This report is meant to be a pilot study to gauge the applicability of the 
algorithm to single-gene and multi-gene/multi-chromosomal complex disease. As 
we have now shown that the model has been validated, we will soon begin to 
apply our software to larger datasets, and attempt to include methods for dealing 
more fully with other types of human genetic variation. 
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7 
Summary, Critique, and 
Future Directions 
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7.1 -Study Design 
PsA is clearly a disease with a significant genetic component. Heritability 
within family units is quite high, as the recurrence risk ratio for first degree 
relatives of a PsA patient (A1) is 30.4 and for siblings (As) is 30.8 (150). While it is 
likely a disease that involves the interaction of multiple environmental and genetic 
factors, identifying the genetic basis of the disease will contribute to 
understanding the many pathways involved in this complex disease, and help to 
determine an individual's susceptibility risk, or the severity of disease they are 
likely to experience. Establishing this would allow for earlier and more specifically 
targeted intervention to mitigate the effects of the disease. 
Genetic studies which are designed to identify genes or polymorphisms 
involved with disease, or to identify genes at least in LD with a causative allele 
are typically carried out as either linkage studies or association studies. Linkage 
studies are employed when large families with multiple generations are available 
for analysis (431-433). Linkage analysis works well for Mendelian diseases; 
however, it is not as successful when used to examine complex diseases which 
display incomplete penetrance, genetic heterogeneity, or have multiple causative 
loci or an environmental trigger. In order to properly undertake linkage analysis 
assumptions must be made regarding such things as the mode of inheritance, 
disease penetrance, and candidate gene frequency. These assumptions can lead 
to error in the analysis if they are incorrect (144 ). As PsA is a complex disease, 
and we are have unrelated case subjects with little available family history, 
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linkage would be an ineffective manner in which to investigate the genetics of 
PsA in our patient cohort. 
When large families are not available, association studies are frequently 
employed to evaluate genetic risk factors. Association studies are typically 
executed as either transmission disequilibrium tests {TOT), family based 
association tests (FBAT) or case-control studies. The TOT is an application of the 
McNamara's test statistic which measures the over-transmission of an allele from 
heterozygous parents to affected offspring. It requires trios consisting of parents 
and an affected offspring, but can also be used if there is more than one affected 
offspring (434 ). Variations have been devised which require the genotyping of 
only one parent (435). Compared with conventional tests for linkage, the TOT has 
the advantage that it does not require data either on multiple affected family 
members or on unaffected sibs. 
The FBAT allows analysis of possibly incomplete nuclear families. (435) 
This test conceptualises TOT tests as a two stage procedure. In the first stage, a 
statistic to test for association between the trait locus and the marker locus is 
specified. In the second stage, the distribution of the genotyped marker data is 
computed by treating the offspring genotype data as random. The first stage 
allows flexibility in modeling while the second stage ensures correct false positive 
rates regardless of population admixture, genetic model misspecification or the 
ascertainment strategy (435). Our PsA patient cohorts consist of unrelated 
individual probands with no additional family members. Thus, as with traditional 
linkage, the TOT and FBAT would be inappropriate to analyse our subjects. 
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Genetic case-control association studies use subjects who already have a 
disease or trait to determine if the frequency of alleles or genotypes of these 
patients differ from controls who do not have the disease or trait. The case 
subjects are patients who have been definitively diagnosed with the disease 
being investigated ; the controls are known to be unaffected. If a difference in the 
frequency of an allele or genotype of the polymorphism being tested between the 
two groups is observed, it indicates that the genetic marker may increase or 
decrease risk of the disease or likelihood of the trait, or be in linkage 
disequilibrium with a genetic variant which does. Likewise, the analysis of a case-
control association study makes use of a simple approximation in the odds ratio. 
However, while case-control association studies are relatively easy to design and 
implement, they are prone to bias and confounding. In order to minimise bias, 
care must be taken in the selection of both cases and controls, in establishing 
definitions of disease, risk factors and in ensuring there are no confounding 
associations between detection of disease and risk factor exposure. Confounding 
factors must be identified prior to the start of the study. Individual cases can be 
matched to controls where is it thought that other factors, aside from the 
genotype of interest, might contribute to the development of disease and 
confound the causal association under investigation (436). Cases and controls 
are commonly matched by age and sex, and care must be taken to avoid 
population stratification unduly influencing the result of the analysis (population 
stratification will be discussed in more detail in section 7.2). The single largest 
drawback to a case-control association study is that the results, by definition, only 
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reveal an association of the variable being investigated with the disease. If a 
genetic association is noted with a disease, it does not provide evidence of 
causation between the disease and the genetic variant (437). 
If the limitations inherent to case-control study design are adequately 
addressed, then association studies are very useful when searching for genes 
which confer a relative risk of between 1.5 and 4.0. The sample size required in 
order to detect an effect of that magnitude is much smaller than would be 
required through linkage (438). As illustrated in Figure 7-1, assuming an allele 
frequency of 0.2 in the population being tested, you would require approximately 
500 samples in order to detect an allele with a genotype relative risk of 2.0. 
Approximately 3500 would be required in order to capture an allele of the same 
frequency with a genotype relative risk of 2.0 via linkage. Thus, based on the 
composition and size of the patient cohort available, a case-control association 
study is clearly the optimal study design for experiments conducted in this thesis. 
7.2 - Cohort Selection and Utilization 
Throughout the experimental work presented in this thesis, there has been 
repeated use of a PsA cohort from Newfoundland, and a second PsA cohort from 
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Figure 7-1 :Comparison of sample sizes required to detect a 
genetic effect via linkage (dashed lines) and 
association (solid lines). 
Adapted from Risch, 2000 
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Toronto. While combining both patient cohorts into one group for genotyping 
would have provided the studies presented here with a larger sample size and 
thus increased the statistical power of the findings, it was decided to analyze 
them separately in order to control for the possibility of population stratification. 
Population stratification refers to differences in allele frequencies between 
cases and controls due to differences in ancestry rather than association of 
genes with disease. Stratification can be a problem for association studies, as an 
observed association could be due to the underlying structure of the population 
rather than a genuine disease associated locus. Conversely, a true association 
might not be found if the locus is less prevalent in the population where the case 
subjects are chosen. While it has been shown that the Newfoundland population 
does not represent a true population isolate or founder population, with levels of 
linkage disequilibrium comparable to that of an outbred European derived sample 
and the Afrikaner population of South Africa (304 ), the fact remains that 
Newfoundland was founded by a limited number of settlers and the population 
grew largely through internal expansion rather than in-migration (305). This 
combined with religion-influenced mating segregation in early Newfoundland 
history, and geographical isolation of communities could potentially lead to 
population stratification. 
One proposed method of controlling for population stratification has been 
to genotype unlinked markers. When this method was tested on 44 unlinked 
markers in four case-control studies, stratification was detected in only one study, 
although the signal was no longer apparent after more stringent matching of 
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cases and controls based on the birthplaces of the individuals' grandparents. This 
has been interpreted as evidence that stratification may be less of a concern than 
originally anticipated (439). A larger study by Freedman eta/, in Nature Genetics 
in 2004 analyzed unlinked SNPs in 11 different studies (440). None of the 11 
studies showed statistically significant evidence of stratification after correcting 
for multiple hypotheses testing, however the authors did state that assessments 
based on a few dozen markers lack power to rule out moderate levels of 
stratification that could cause false positive associations. Other evidence, 
however, has shown that the effects of stratification can be largely overcome by 
carefully matching cases and controls according to self-reported ancestry and 
geographical origin (441 ). Therefore, based upon the cumulative evidence of 
these studies regarding the nature and likelihood of population stratification, and 
despite the potential loss of statistical power, the experiments detailed here were 
performed by using both PsA cohorts separately - the Newfoundland cohort was 
used for initial investigation, and the Toronto PsA cohort was used for replication. 
7.3 - Marker Selection 
At the time the experiments detailed in this thesis began in 2004, case-
control association studies were usually carried out as hypothesis-testing 
research . Variants in a single gene or small number of genes with a known or 
putative role in a disease process were genotyped in patients and control 
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subjects usually from within one centre. As the sample sizes in these studies 
were typically small, the need for statistical correction was minimal. Results often 
overestimated the true genetic effect size as a consequence of the "winner's 
curse" phenomenon. Simply put, the genetic effect in an association study is 
biased upward, conditional on that study being the first to reach statistical 
significance and be published (442). 
The first genome-wide association study (GWAS) was published in 2002, 
and used 65,761 SNPs in 94 cases (443). GWAS were thought to be especially 
useful in the study of complex disease, as it changed the focus from hypothesis-
driven research to hypothesis-generating research. As the pathogenesis of many 
common diseases was not fully elucidated, it was hoped that finding genetic 
associations would yield clues towards disease process and progression. 2005 
marked the first year that multiple GWAS were published (444,445), and with the 
introduction of large, highly accurate (0%-2% missing data; <0.5% errors) 1 
million marker "SNP chips" from Affymetrix and lllumina in 2007-2008, the cost 
of performing a GWAS has dropped immensely (approximately $500 (U.S.] per 
subject; an approximate 2,000-fold reduction of cost per genotype in just under 
10 years), (446) making them much more feasible . While performing a GWAS 
has become more feasible, the number of SNPs now being tested means that 
after corrections for multiple testing even GWAS using 2000-5000 samples are, 
in fact, underpowered to detect genetic effects of even modest sizes (447). Were 
the studies described in this thesis initiated today, they would undoubtedly 
contain a greater SNP density due to the lower cost of genotyping, and efforts 
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would be made to collaborate with other groups in order to initiate well powered 
GWAS of PsA. The studies presented here have attempted to fully utilize the 
technology available to us at the time they were conducted by performing 
association studies in accordance with the literature standards of the time, and by 
later using large numbers of SNPs to fine-map and haplotype regions associated 
with PsA (See chapters 4.2 and 6). 
7.4- Patient History, Lifestyle and Environmental Factors 
A potentially large source of confounding error in the studies presented in 
this thesis is the lack individual patient medical histories, and their environmental 
exposures. There is considerable evidence that infection may play a role in the 
development of PsA. Acute episodes of guttate psoriasis have been associated 
with streptococcal infection (448), and one study indicated that the prevalence of 
positive streptococcal throat swabs in HLA-Cw*0602 positive patients was twice 
the prevalence among HLA-Cw*0602 negative patients, while no difference was 
observed among HLA-Cw*0602 positive versus negative controls. In sub-
Saharan Africa PsA is almost universally associated with HIV infection, even 
though prior to the HIV epidemic, seronegative spondyloarthropathies were 
considered uncommon in Africans (449,450). Genetic factors responsible for the 
immune response to infection, or the nature of the infectious agent may play a 
role in the development of PsA. 
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Trauma has long been associated with psoriasis (the "Koebner 
phenomenon" (1 07)), and several articles have reported on the triggering role of 
trauma in inducing arthritis in patients with psoriatic disease (451-453). As 
reviewed in McGonagle et a/, 2009 (1 06) the recent recognition of a synovio-
entheseal complex (SEC) may help resolve the relationship between synovitis 
and enthesitis in PsA, while also advocating a role for a localized Koebner 
phenomenon. The SEC model shows how enthesis fibrocartilage could derive 
lubrication and nourishment from adjacent synovium in a manner identical to the 
long appreciated interaction between articular cartilage and synovium. Hence, all 
sites of disease in PsA could potentially be linked to the common denominator of 
enthesitis. Several micro-anatomical studies have shown that there appears to be 
an 'enthesis organ' which is prone to microdamage at insertion sites and adjacent 
tissues, microscopic inflammatory and vascular changes both at and near the 
insertion itself and the immediately adjacent synovium. Given the known link with 
skin psoriasis and trauma, these findings of clinically unrecognized trauma at 
insertions sites are especially noteworthy. It is a distinct possibility that genes 
involved with the structure of tendon and ligament insertion points, or which 
control the marrow fluid that occupies the spaces between the bone and insertion 
points, or genes responsible for the response to such microtrauma may be quite 
important in the pathogenesis of PsA. 
Smoking has also been linked to a large number of immunologically 
mediated diseases. In the western world, smoking is the most well established 
environmental risk factor for lBO, increasing the risk by approximately two-fold 
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(454 ), and at least one study has shown that the expression of certain genes is 
upregulated in the descending colon mucosa in smoking Crohn patients versus 
patients who have never smoked (455). Tobacco use has also been shown to be 
associated with the risk of development of psoriasis (456) and with poor long 
term outcome in AS patients (457,458). Direct gene-environment interactions 
have also been observed with respect to smoking and rheumatic disease: one 
study has reported a significant multiplicative interaction between the 1858 C> T 
SNP of the PTPN22 gene and smoking for more than 10 pack-years (459), and a 
history of smoking has been shown to interact with the presence of /L-13 
polymorph isms to increase the risk of PsA (460). 
Clearly, patient history and lifestyle play a role in the development of 
diseases and may modulate the course of autoimmune disease. Analysis of 
patient history along with genotypes could provide interesting data with respect to 
gene-environment interactions. 
7.5- DNA Source May Contribute to Genotype Results 
All DNA samples used in the studies presented in this thesis were 
extracted from white blood cells of venous blood. This method is the most 
commonly used manner of obtaining DNA from patients who do not require 
invasive medical interventions. However, a growing body of evidence suggests 
that DNA obtained from sources other than those primarily involved in disease 
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processes (i.e., in PsA, from the sites of psoriatic skin lesions, or from synovium 
inflamed joints, or enthesis sites) may not be the most appropriate for analysis for 
genetic association. 
One recent study established that there is tissue-specific splicing of DNA 
(461 ). The authors studied the genetic control of both exon-level and whole-
transcript level variation in expression in two cell types (white blood cells, and 
cortical brain tissue from a set of control individuals), combined with parallel 
genome-wide genotyping of these samples. Using identical genome-wide 
screens in two primary tissue types allowed them to identify polymorphisms with 
clear effects on both overall expression and splicing, and to show that these 
effects are often tissue specific. A total of 23 high confidence associations with 
total expression and 80 with alternative splicing as reflected by expression levels 
of specific exons were identified. Fewer than 50% of the implicated SNPs showed 
effects in both tissue types, reflecting strong evidence for distinct genetic control 
of splicing and expression in differing tissue types. When the results were 
compared to reported associations of SNPs in genome wide scans of diseases, 
the authors noted several overlaps, including an over-representation of 
autoimmune diseases such as AS, Crohn, RA, and T1 D. Most of these 
connections appeared to relate to alternative splicing as opposed to overall 
expression changes, suggesting that changes in splicing patterns may be more 
consequential for disease than those which affect only gene expression. Of 
specific interest to the work presented in this thesis, splicing effects of a SNP in 
the PTPN22 gene were observed. The authors postulate that excess of 
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representation of autoimmune disease in these tissue-specific splicing variants 
may be due to the growing recognition of the importance of rare genetic variants 
in common disease (462,463). Specifically, the authors state that: "It is generally 
assumed that when a common SNP is associated with disease in a genome-wide 
study, that it, or some other common variant in LD with it, is responsible for the 
association. It is theoretically possible, however, that many of the associations 
observed are not due to single common variants, but rather due to a constellation 
of more rare disease-causing variants that happen to occur, by chance, more 
frequently along with one of the common alleles at given SNP as opposed to the 
other. In such a case, the signal of association credited to a common SNP is 
actually a synthetic association resulting from the contributions of multiple rare 
SNPs. In such cases a screen for a common SNP associated with an underlying 
biological effect (such as expression or splicing) is not likely to identify a causal 
site." 
Further to differential control of splicing in various tissue types, another 
study has shown that there are significant differences in the SNPs observed in 
DNA from diseased tissue versus non-diseased tissue and blood (464 ). While 
this study was examining the genetic contribution to abdominal aortic aneurysm 
(a multifactorial, although non-autoimmune disease), the results are interesting 
and relevant to the critique of this thesis. The authors observed specific BAK1 
SNP alleles in both aneurysmic (31 cases) and healthy aortic tissue (5 cases) 
without seeing them in the matching blood samples. These same BAK1 SNPs 
have been reported , although rarely (average frequency < 0.06%), in reference 
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BAK1 DNA sequences. The potential that rare variants from reference sequences 
could be more frequent in diseased tissue presents an interesting challenge to 
the current methods of performing association studies or fine mapping of regions. 
At the current time, common variants (typically with a minor allele frequency 
greater than 5%) are chosen from the HapMap data for genotyping in order to 
capture other variants through LD, while rarer variants are typically not used. The 
authors of this study hypothesize that multiple variants of genes may pre-exist in 
"minority" forms within specific tissue in the non-diseased state, and may be 
selected for when intra- and/or extracellular conditions change, leading the 
tissues to be predisposed to an increased genetic susceptibility to disease. This 
tissue specific increased predisposition would not be identified in a routine 
genetic analysis of DNA from blood, and thus could easily lead to false-negative 
results for genes with plausible biological mechanisms in disease pathogenesis. 
7.6- Results Summary 
This thesis has attempted to take a comprehensive genetic approach 
towards the study of PsA and have examined polymorphisms in genes involved 
in the several different pathogenic aspects of the disease. The research 
presented here has identified significant associations with pro-inflammatory 
genes in the MHC region (TNF-a, MICA) and established them as genuine 
associations via meta-analysis of previously published works. The work 
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presented here is among the first to examine genes involved in angiogenesis, 
observing associations with both PPAR-y and VEGF. The association with VEGF 
is particularly noteworthy, as this gene also plays a role in inflammation. The 
results regarding T-cell activating PTPN22 gene have proven controversial with 
respect to PsA; however, we have observed an association which has been 
replicated (228-230), adding to the evidence that this gene may play a role in 
several immunologically mediated diseases. 
While not as exciting as positive associations, negative associations are 
important results as they exclude targets. This research is also among the first to 
examine genes involved in bone morphogenesis, observing no association 
between the OPG, RANK, and RANKL genes. We have also been able to narrow 
the possible factors for the overlap between PsA and conditions such as RA and 
Crohn disease by eliminating NFKB1, NFKBIA, RELA, SLC22A4, SLC22A5, 
SLC9A3R1 and RUNX1 as candidate genes for PsA. Likewise, the failure to 
replicate SNPs in the /L-1 gene cluster- while confounding results observed in 
the Newfoundland cohort - serve to add to the information scope of the impact of 
high-priority candidate genes, and remind us that all results from a small , 
relatively homogenous population must be interpreted with caution due to the 
possibilities of population stratification and founder effects. Finally, we are the 
first research team to analyze epistatic interactions in PsA, finding an association 
between variants of 1123-R, PTPN22, and PPARy, and the first to propose an 
algorithm capable of examining more than 6 epistatic interactions (421 ). The 
results obtained from the epistasis analysis are particularly interesting as they 
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illustrate once again that a complex disease is likely due to the interplay of 
several polymorphisms in different genes, each individually carrying only a small 
risk. 
To summarize, the proper design and execution of association study has 
been demonstrated here, by the use of several study motifs: univariate and 
multivariate analysis, meta-analysis, small and large-scale haplotyping, and the 
use of computational power to address epistatic interactions. Through careful 
design and analysis, the data collected here represent a large contribution to the 
body of knowledge regarding the genetics of PsA. 
7.7 Context of Results 
A model has been proposed which ties together genetic and immunologic 
elements for the development of psoriasis and PsA (465). While the precise role 
of HLA-Cw6 in psoriasis remains unknown, it has been postulated that it may be 
involved in antigen presentation to CD8+ T cells, whose migration into the 
epidermis appears to be required for the development of psoriatic lesions (466). 
During a flare of streptococcal infection, CD8+ T cells encounter strep antigens 
presented via HLA-Cw6 in the tonsils, where they proliferate and then migrate 
into epidermal tissue. This migration causes activation of macrophages and 
dendritic cells, which release TNF-a, which further facilitates the entry into 
epidermis, and thus begins activation of several TNF-a receptor mediated 
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pathways (via macrophages) which then signal to NF-KB in the nucleus. Genetic 
alterations in the tumour necrosis factor a interacting protein 3 ( TNFAIP3) and 
TNFAIP3-interacting protein 1 (TNIP1) genes may play very important roles in 
antigen presenting cells and macrophages because of the central role of these 
genes in regulating NF-kB signalling (note that TNFAIP3 and TNIP1 have been 
noted to be associated with psoriasis via GWAS (241 )). A subset of these CD8+ 
T cells will express 11-17 (known as Th-17 cells). As production of 11-17 is partially 
stimulated by 11-23 and 11-1 , variations in the 11-128, 1123A, II-23R and/or 11-1 gene 
cluster and associated subunits and receptors, genetic alterations in any of these 
genes could cause an upregulation in the number of Th17 cells present. These 
cytokines stimulate keratinocyte proliferation and up regulate keratinocyte innate 
immune defence mechanisms, including defensin, psoriasin, and other proteins 
that are highly expressed in psoriasis lesions, provoking epidermal hyperplasia. 
While this does explain some of the genetic involvement in the 
immunology of psoriasis, clearly something more must occur in order for 
uncomplicated psoriasis to proceed into PsA. As virtually all of the cytokines 
described in the preceding paragraph also play a role in synovial inflammation , 
bone remodelling, enthesitis, and the initiation of angiogenesis (as described in 
section 1.6), further genetic variation in any of the described genes in these 
pathways could lead to the development of arthritis accompanying psoriasis. The 
fact that PsA typically develops 7-1 0 years after the onset of psoriasis gives 
adequate time following a triggering event for the dysregulation of skin 
histopathology to migrate further into bone and joint areas to cause PsA if 
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predisposing genetic variation is present. The results of our epistasis algorithm, 
showing the interaction of variants in //23-R, PTPN22, and PPARy serve to 
reinforce this hypothesis. 
7.8 - Possible Future Directions 
Despite the successes, it is important to keep these results in context as 
there are criticisms which can be fairly attributed to these studies. PsA is a 
heterogeneous disease with several endophenotypes. Stratifying arthritic disease 
according to endophenotype has previously been shown to be a successful 
method in order to identify genetic association when none was evident prior to 
stratifying patient groups (467). The problem with this is that in performing such 
stratification, we reduce sample size and therefore power to detect an 
association. Given that PsA has a population prevalence of 0.25%, and that the 
population of Newfoundland and Labrador is approximately 507 900, there is 
approximately a maximum of 1270 PsA patients in Newfoundland and Labrador. 
Given the extreme population spread on the island of Newfoundland, and the 
division of health care services into regional health boards, we are likely now 
approaching the maximum number of PsA patients available. Further reducing 
the sample size by stratifying patients would likely jeopardize the opportunity to 
observe a gene effect if one is present. Also, population stratification in the 
structure of the Newfoundland population is an important characteristic to 
consider. As most residents of Newfoundland are largely descended from 
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immigrants from small areas of southwest England and southeast Ireland, there 
are likely to be founder effects in the genetic structure of the population. This is 
quite evident as there is an over representation of monogenic diseases in our 
population - approximately 10 fold higher than the other Atlantic Provinces (305). 
This evident founder effect could also serve to bias our results in both positive 
and negative fashions: it is possible for instance that our observed positive 
associations could be the result of a gene variant that is simply present in our 
population at a higher frequency than other admixed Caucasian populations due 
to the founder effect. Likewise, it is possible that our inability to replicate 
candidate gene variants observed in other populations could be due to an under 
representation of that variant in the founding population. 
PsA does present unique challenges in the study of complex disease 
when compared to others, as it represents a "disease-within-a-disease". As 
described previously in approximately 70% of PsA cases psoriasis precedes the 
onset of arthritis by between 7 - 10 years (25), and only about 30% of patients 
with psoriasis develop PsA (8). Distinguishing between genetic variants 
responsible for PsA and those responsible for uncomplicated psoriasis is a large 
challenge for well designed studies of PsA; however the time of onset of PsA 
from psoriasis does provide investigators with a potential mechanism to 
investigate genetic differences between the two. By performing a case control 
study using psoriasis patients who have had established disease for longer than 
10 years as a control group, an investigator will have ensured that the control 
group is unlikely to develop PsA, as they have surpassed the typical time frame 
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for development of PsA. Thus, any differences in allele frequencies between the 
PsA cohort and psoriasis control cohort may represent genuine PsA markers. For 
those markers which appear to be associated with both conditions, a comparison 
of the relative risk for each group could potentially reveal a real PsA association: 
as PsA represents a "disease-within-a-disease", an associated marker has the 
potential to appear in both PsA and psoriasis groups. If the calculated relative risk 
is higher for the PsA cohort as opposed to the psoriasis cohort, then that marker 
is likely to represent a PsA risk allele. The stratification of PsA patients by 
endophenotype can serve to further strengthen this finding by examining the 
marker in an AS cohort as well . If the marker is found to be associated with the 
spondylitis sub-form of PsA, and it is found to be associated with AS, then it is 
more likely to be involved with arthritic disease as opposed to psoriatic skin 
disease. 
A further manner in which to identify true PsA genes is through the use of 
expression studies. There are medications which can have different effects on 
psoriasis and PsA. The drug efalizumab (also known as Raptiva, which has 
recently been removed from the market) effectively treats psoriasis patients and 
the psoriasis of PsA patients; however it does not affect the arthritis portion of the 
disease, and may in fact worsen the course of arthritis (468,469). Examining the 
gene expression levels of PsA patients before and after treatment with 
efalizumab would likely provide more evidence regarding genes involved in PsA 
rather than uncomplicated psoriasis, as you would expect the expression levels 
of psoriasis-related genes to drop following treatment. Genes that still remained 
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over or under expressed after treatment when compared to healthy controls 
would likely be involved in the arthritis portion of PsA. 
More recent work has identified another source of genetic influence on 
psoriasis, as micro RNAs (miRNAs) have been implicated in the pathogenesis of 
psoriasis (470). MicroRNAs (miRNAs) are an abundant class of short (-22 
nucleotides), non-protein-coding RNAs that regulate the expression of protein-
coding genes at the posttranscriptional level. Specifically, the authors of this 
study identified the first miRNA that is entirely restricted to skin epithelium and 
showed that it is over expressed in psoriasis. One of the targets of this miRNA for 
post-transcriptional suppression is a negative regulator of the STAT3 pathway, 
which is activated by inflammatory cytokines (e.g. lnterleukin-6, interferon-y) and 
functions in the regulation of both innate and adaptive immunity. Constitutive 
activation of this pathway has been reported to lead to a psoriasis-like phenotype 
in transgenic mice, stressing its relevance in psoriasis (471 ). Their results 
suggest that the increased expression of this miRNA leads sustained activation of 
the ST AT3 signalling pathway, and thus may contribute to increased or prolonged 
skin inflammation in response to T cell-derived cytokines, due to a seemingly 
aberrant negative feedback in cytokine signalling in keratinocytes. Interestingly 
for the pathogenesis of both psoriasis and PsA, two other miRNAs (one which 
was found to be significantly over-expressed, and one which was significantly 
under-expressed) were direct mediators of the TNF-a pathway. Clearly, future 
genetic studies of PsA should examine these emerging genetic regulators. 
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Copy-number variation (CNV) is also another emerging area of genetic 
study that is worthy of consideration in the investigation of PsA, as data has 
already established that a deletion comprising the genes LCE3B and LCE3C is 
significantly associated with risk of psoriasis (4 72). Likewise, a higher copy 
number of the ~-defensin gene cluster found on chromosome 8 has been 
demonstrated to be a susceptibility factor for psoriasis (473). While no specific 
CNVs have been found for PsA, others have been found to be associated with 
susceptibility to autoimmune and inflammatory disorders (474). As the extent of 
CNVs in the human genome has only recently begun to be fully appreciated 
(475,476), investigating this form of genetic variation could lead to new insights 
regarding the genetic contribution to PsA. 
Regardless of the method used to investigate the genetics of PsA, the 
difficulties in study design and analysis can be overcome. As described 
previously, the choice of adequate control groups is crucial. The ideal genetic 
study of PsA (whether through SNPs, CNVs, miRNAs, or direct sequencing) 
would consist of large (the ideal sample size being over 1 000), well characterized 
and stratified PsA patient groups (according to pattern of arthritis, and also 
according to whether the cases were sporadic or had a family history), but would 
also contain multiple control groups. In addition to normal, healthy controls, 
control groups should consist of uncomplicated psoriasis patients, AS patients, 
and in addition to this every effort should be made by researchers to collect and 
characterized as many PsA patients as possible who develop arthritis prior to 
psoriasis - what is known as "psoriatic arthritis sine psoriasis" (477,478). The 
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inclusion of sufficient numbers of these proposed control cohorts would allow 
investigators to definitively distinguish between variations associated specifically 
with PsA as opposed to psoriasis. Comparison of DNA from disease sites as well 
as that from white blood cells would also be beneficial. In addition to identifying 
rare variants involved in common disease, examining tissue from these multiple 
groups of patients with autoimmune diseases would help to characterize the 
exact disease processes involved across multiple autoimmune diseases, and 
further help to elucidate the common shared pathways in these types of diseases 
(300). 
Finally, the possibility also exists that the genetic nature of PsA is more 
complex than we currently understand and thus, better targets than the ones we 
have chosen to investigate exist. There has, at the time of this writing, been only 
a single genome wide association study performed specifically in PsA. As we 
approach the post-genomic era and more and different markers are available for 
analysis such as the locations of Copy Number Variants and non-coding RNA 
silencers, the genetic analysis of complex and uncommon diseases such as PsA 
will become easier, especially as computational problems towards solving 
epistatic interactions between all of these variants are overcome, and the 
networks of interactions of all of these genetic elements are more clearly 
established. 
As a final summary of the work in this thesis, Figure 7 -2a describes all 
candidate genes which to date have been analysed in PsA. Figure 7 -2b indicates 
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those which have reported positive associations, and figure 7 -2c shows which 
have been replicated by subsequent reports. 
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Figure 7-2a: Summary of all candidate genes for PsA assessed in the literature 
up to September 2009. 
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Figure 7 -2c: Genes shown here are the only candidate genes with replicated 
associations with PsA reported in the literature - current as of September 2009. 
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Introductory Note 
The algorithm which follows was originally written by Mr. Mohammed Uddin as 
part of his Master's dissertation (2008). The algorithm is reprinted here with his 
kind permission. Mr. Uddin remains the sole copyright holder of this algorithm, 
and it is entirely his intellectual property. 
Co-operative Coevolutionary Algorithm (CCA) 
There is no recognized single best method to detect gene-gene 
interactions comprehensively. Moreover, it is not feasible to perform exhaustive 
search on non-trivial amounts of single nucleotide polymorphism (SNP) data to 
detect gene-gene interaction. A case-control cohort consists of m case and m' 
control individuals for a panel of n SNPs; hence, the case and control matrices M 
and M' consist of 2m and 2m' haplotype-rows, respectively, and n SNP-columns. 
In each column, let 1 and 0 denote the major and minor alleles, respectively, of 
the SNP associated with that column and "- " denote a missing value. The size 
of the search space of all haplotypes with contiguous and non-contiguous SNPs 
in M and M' is at least 2" (each row in M and M' is identical) and at most 
(2m x 2m'J2." (each row in M and M' is different). Given the size of this search 
space, any usable algorithm for large datasets must sample this search space in 
a quick yet approximately comprehensive manner. A genetic algorithm (which 
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approximates optimal solutions by iteratively evolving a population of initially 
random solutions) is one such type of algorithm. We use a variant of standard 
genetic algorithms called cooperative co-evolutionary genetic algorithms (CCA), 
which were defined by Potter et al. (479). The main distinction between a 
standard genetic algorithm and a CCA is that the latter simultaneously evolves 
multiple subpopulations, where each subpopulation evolves a portion of a 
solution for the given problem n and members of these subpopulations are 
combined to create complete solutions for n. Since each subpopulation's search 
space is smaller than the complete solution search space, CCA may find better 
solutions faster than standard genetic algorithms (480), and seems in practice to 
give better performance for various complex problems (481 ). Pseudocode for our 
CCA for detecting allelic interactions of genes from case-control haplotype data is 
shown in Figure 1. In this algorithm, each member x of subpopulation Sk 
corresponds to a haplotype-fragment over a certain set of contiguous SNPs. This 
haplotype-fragment is encoded as a vector of subpopulation-specific length lcs.J 
such that there is a 1, 0, or* at each position, where 1 and 0 represent the major 
and minor alleles of the SNP associated with that position and * means that this 
SNP is not included in the haplotype-fragment. A complete solution is a 
concatenation of subpopulation members forming a vector of length n such that 
here is a 1, 0, or * at each position. Details of the central aspects of and 
operations in this algorithm are given in the following subsections. 
1. gen = 0 
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2. for each subpopulation sk, 
3. randomly generate initial subpopulation members, i.e., S tk.o} 
4. while ( gen < gen"= ) 
5. for each subpopulation s(k .gen) 
6. select parent member(s) from S(k .gen} and apply genetic operators 
7. perform best member collaboration to form a complete solution C,,; 
8. for each member x of Stk.gen) 
9. evaluate fitness of x 
10. if (fitness of x > t) 
11. compute Haplotype Risk Ratio (HRR) for C,.; and perform Permutation Test 
12. apply Niching 
13. perform Selection 
14. gen = gen + 1 
end. 
Genetic Operators 
We use two genetic operators in our CCA. The first operator (one-point 
crossover) is applied to a pair of parents in a subpopulation to produce an 
offspring . A random point r is drawn from the range 1 to I, where I is length of the 
members in that subpopulation. The offspring is produced by copying positions 0 
to r-1 from the first parent and positions r to I from the second parent. The second 
operator (mutation) is applied to a single parent to produce an offspring, and is an 
adaptation of the one-point bit-flip mutation operator. A position in the parent's 
vector is chosen randomly and that position is flipped by the following rules: 
• if there is a 1, the bit is flipped to 0 
• if there is a 0, the bit is flipped to * 
• if there is a *, the bit is flipped to 1. 
We have used random selection to select parents for genetic operator application 
in line 6 of the algorithm. The proposed CCA is steady-state, such that parents 
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and offspring compete with each other to remain in Sk after the offspring are 
created. In particular, the fittest pair of the two parents and the offspring (in the 
case of crossover) and the fittest of the parent and the offspring (in the case of 
mutation) is selected and kept for subsequent processing. 
Collaboration 
Collaboration is a mechanism where a member from each subpopulation 
is picked to form a complete solution. We use the best member collaboration 
method proposed by De Jong et al. (480). In best member collaboration, the 
fittest member of each subpopulation is chosen as that subpopulation's 
representative. Each member x of a subpopulation is then combined with the 
provided representatives of other subpopulations to form a complete solution. 
The fitness of this solution becomes the fitness of x and is not shared with 
representatives of other subpopulations that participated in the collaboration. In 
our CCA, this process is first done relative to S1 , followed by S2 , and continuing 
to the other subpopulations. 
Complete-Solution Fitness Evaluation 
Our fitness function for complete solutions is based on the MDR approach 
proposed by Ritchie et al. for assessing the significance of haplotypes in case-
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control SNP data (482). This approach computes case-control frequency 
differences for each multilocus genotype and if a difference exceeds a specified 
threshold, that haplotype is considered significant. Similarly, we define the fitness 
of a complete solution haplotype Cf,; in terms of case-control frequency 
differences as fol lows: 
(2) 
This in turn relies on estimates of haplotype frequencies specific to a case or 
control matrix M, which are computed as 
2m n LIT F(Cx,i> J,y) 
fr (M ,C ) =..:...i=_l ..:...y=_l ___ _ 
-'·' 2m 
where, 
{ 
I, 
F(Cx,,, J, y) = Pva/(M, j ,C<,;(y], 
0, 
if M [j ,y ] = Cf,;(y ] and CxJ Y] :.e * 
if M [j , y ] = - and Cx.JY] :.e * 
if M [j,y ] ;e C.<Jy] and Cx.JY] ;e * 
(3) 
(4) 
Equation 3 computes the frequencies by scanning the Cx,i and ignores the 
computation for the positions c ... [Y] = *, where y ~ n . Hence, this computation 
allows the algorithm to compute frequency for haplotypes with non-adjacent 
SNPs from matrix M. Frequency is computed by scanning each row in matrix M, 
one row at a time, and matching the content of each position with the content of 
Cx.i at the corresponding position as specified in Equation 4 . Function 
Pval(M,J ,Cx,[y ]) is invoked when there is missing data in the matrix M. The 
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easiest and most commonly-used approach is to simply ignore such positions, 
i.e., Pval(M,J,Cx.JYD = 0; however, our algorithm uses a novel and much more 
intelligent approach that is described in a later section. 
Niching 
Maintaining the diversity of members in a subpopulation helps prevent the 
members of that subpopulation from prematurely converging to a local optimum 
as that subpopulation evolves. Niching is a method that maintains diversity and 
prohibits different members of a subpopulation from crowding into the same area 
of the solution search space (483). Our algorithm implements niching using the 
popular fitness sharing technique. This technique computes, for each 
subpopulation member x, the Hamming distance between x and all other 
members of a subpopulation and applies a fitness-reduction penalty to all other 
members that are close to x. As this penalty reduces the probability of a member 
being selected for the next generation, a high penalty rate can prematurely 
remove a useful member from the subpopulation and hence misdirect the 
evolutionary search. Therefore, we use a relatively moderate penalty rate of 15%. 
Measures of Haplotype Significance 
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Several measures of haplotype frequency difference significance are 
computed for the purpose of assessing the quality of derived haplotypes but do 
not affect the haplotypes derived by the CCA, i.e., these measures are not part of 
fitness evaluation or subpopulation evolution. After haplotype frequency 
estimation, the Haplotype Risk Ratio (HRR) is computed for each C . , and 
.t',l 
Pearson's X2 test (1 d.f.) issued to quantify the significance level of each HRR 
value. No test for multiple corrections exists relative to the large number of tests 
performed by the CCA in each generation. Hence, we have applied the standard 
permutation test to reduce type 1 error (484 ). AS the permutation test is 
computationally expensive, it is only applied when the HRR ~ 1.5 and the x2 
significance level is 1 0"3 . 
Estimating Haplotype Frequencies for Missing Data 
Missing data in haplotypes arises primarily in two ways - when errors 
occur in genotyping and when the phasing algorithm is unable to resolve certain 
genotypes into haplotypes. To handle such data when computing haplotype 
frequencies, we use the non-missing alleles and their relative LD information to 
impute the frequencies of the missing alleles. 
Algorithm 
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Let L denote the LD matrix, an n x n matrix that stores all pairwise r2 
values of the n SNPs from matrix M, where r2 measure defines the correlation of 
alleles in the SNP pair, such that r2 = 1 is known as complete LD and if the r2 
value between a pair of SNPs is greater than 1/3, the two SNPs are considered 
to be linked (414 ). Moreover, though LD decays as the distance between SNPs 
increases, extensive research has shown that an SNP can be linked with another 
SNP that is up to 1 OOkb distant (414,485). Thus, the algorithm will consider a pair 
of SNPs as linked if their physical distance on the chromosome is within 1 OOkb 
and their ,-2 value is greater than 1/3. When Mlj, y} contains a missing value "-", 
the function Pval(M, j , Cx.JY]) finds a set of SN Ps Z such that each z E Z is 
strongly linked with the yth SNP of matrix M, and uses this information to 
estimate the frequency of the alleles that can occur in C T,i in the position 
corresponding to the missing value Mlj, y} as follows: 
L fr(M,Cx,;[y],z) 
Pval(M, j , C.,;[Y]) = zeZ !Z! (5) 
Following the guidelines described above, Z is constructed such that each z in Z 
is within 1 OOkb with the yth SNP of matrix M and the r2 value between z and y is 
> 1/3. It is possible to have an empty set Z for a set of loosely linked SNPs where 
all pairwise LD values in L are < 1 /3; in this case, the set Z consists of all SNPs 
within 1 OOkb of the yth SNP of matrix M. The function fr(M, Cx.Jy], z) in Equation 
5 gives the average frequency of the allele CxAY] from matrix M. Essentially, this 
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function computes the average frequency of allele C [y] from the SNPs that are X,l 
in set Z, which gives the approximate frequency with which allele Cx}Y] can 
occur in a missing position of the matrix M. 
Comparison of New Algorithm with Existing Approaches 
To compare haplotype estimation in the presence of missing data, we 
compared haplotype frequencies within haplotype blocks computed by our CCA 
with those computed by the popular analysis package Haploview (387) on 5 
simulated datasets. To ensure realistic allele frequencies and SNP 
dependencies, we created our simulated datasets by mutating a real dataset cf. 
creation of simulated datasets ab initio from random allele sequences. Our 
source dataset consisted of 40 SNPs which span a 205 kb region on 
chromosome 2 genotyped from 401 ethnically matched individuals in Alberta 
population (data not shown). The haplotypes for this dataset were inferred for 
each individual using PHASE (348) and then used to create 5 progressively 
worse simulated missing-data haplotype datasets by randomly implanting 3%, 
5%, 10%, 15%, and 20% missing data, respectively, in the PHASE-produced 
haplotype dataset. Haplotype blocks in strong LD and their associated haplotypes 
frequencies were then obtained for each simulated dataset using Haploview. 
Recall that Haploview uses an EM-algorithm to impute missing values during the 
computation of frequencies for haplotypes 
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with missing data. For each haplotype block, we compared the frequencies 
obtained by our CCA and the EM-algorithm using the mean square error (MSE) 
measure given below, 
MSE = ~ X I (h/M - h,CCA)2 
I 
where H is the number of haplotypes in a block that are in strong LD, h ;EM is the 
frequency of i1h haplotype in that block obtained by the EM-algorithm, and h;cCA is 
the frequency of the i1h haplotype obtained by the proposed method. Note that 
MSE captures the overall differences between the haplotype differences 
computed by the two methods. 
Experiment Setup 
The optimal values for parameters to run a genetic algorithm are still 
unknown but parameters of the CCA were set to maintain a balance so that the 
algorithm's evolution is not disruptive and does not demonstrate random search 
behavior. The crossover rate was set to 1 00% as one-point crossover is not as 
disruptive as uniform crossover (486). To exploit the fitness landscape with 
adequate chromosomal swapping, this rate of crossover is favourable . The 
mutation rate was set to 5%. 100 CCA runs were carried out for each four 
datasets. The AS and Schizophrenia datasets were separated into two 
subpopulations to evolve independently. Each subpopulation of the AS and 
Schizophrenia data sets consists of 1 0 and 5 SNPs, respectively. The PsA 
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dataset was separated into three subpopulations; each containing 10 SNPs. The 
member of each subpopulation in the AS dataset was set to 250 and each run 
evolves for 1000 generations. The sub populations in the Schizophrenia dataset 
consists with 25 members due to it small number of SNPs. The strategy for the 
PsA cohort was to evolve large number of generations with small size 
subpopulation. Hence, each subpopulation with 100 members evolved for 1500 
generations in each CCA run. 
Results 
Performance of Missing-Data Handling Algorithm 
As expected, the MSE showed a positive correlation with error rate, such that 
error increased as the amount of missing data increased. However, below 15% 
missing data, there was no apparent difference observed between the haplotype 
frequencies obtained by our new method and the EM-algorithm in Haploview 
(Figure 2). In particular, for 3-15% missing data, the MSE varied between 4.12 x 
10-6 and 8.79 x 1 o·3 for haplotype frequencies in a block, and at 20% missing 
data, the MSE varied between 2.36 x 1 o·3 to 1.61 x 1 o·2. This validates our 
haplotype frequency estimation method, in that its results did not deviate 
significantly from those produced by EM-algorithm estimation up to 15% missing 
data. Our proposed CCA is scalable to large data sets and can handle up to 15% 
missing/ambiguous data. 
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Validation 
The cohorts for Ankylosing Spondylitis were taken from Maksymowych et al. 
(487). We have retained only the Newfoundland (NF) (112 AS cases, and 150 
controls.) and Alberta (AL) (200 cases and 200 controls) cohorts for our analysis 
and excluded the Toronto cohort due to the possibility of population stratification. 
The ethnic background of the Newfoundland and Alberta population cohorts have 
been stable with little in-migration for several generations which is likely to make 
them much more homogenous than that of the Toronto cohort (305). The 
genotype data for both populations includes a set of 20 SNPs located on 
chromosome 2q14 which includes interleukin 1 alpha (IL 1A; GeneiD 3552), 
interleukin 1 beta (IL 1 8; GeneiD 3553), interleukin 1 family member 7 (IL 1 F7; 
GeneiD 27178), interleukin 1 family member 6 (IL 1 F6; GeneiD 27179), 
interleukin 1 family member 8 (IL 1 FB; GeneiD 27177), interleukin 1 family 
member 10 (IL 1 F10; GeneiD 84639) and interleukin 1 receptor antagonist 
(IL 1 RN; GeneiD 3557) in a 360 kb region . The Schizophrenia cohort was taken 
from Fukasawa et al. (488) in which 10 SNPs were genotyped from Netrin G1 
(NTNG1 ; GeneiD 22854) gene located on chromosome 1 p13.3. The genotyping 
was done on 180 cases with confirmed Schizophrenia and an equal number of 
ethnically matched controls from the Japanese population. 
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Ankylosing Spondylitis 
After 1 00 runs of the CCA in our Alberta AS cohort, 53 haplotypes showed 
significance after 10000 permutations with p < 5.0 x 1 0-4 and HRR ~ 1.5. The 
significant haplotypes consisted of major alleles from SNPs rs3783550, 
rs3783543, rs3783526, rs1143630, rs3917354, rs1143627, rs2723187, and 
rs3811058 located in genes /L 1A, /L 18, /L 1F7 and IL 1F10. The interaction 
captured by the CCA can be defined entirely by rs3811 058 in the IL 1 F1 0 gene 
because the major allele of this SNP is included in all haplotypes containing 
markers from IL 1 A, IL 18, and IL 1 Fl. The most significant interaction observed 
was with the haplotype TT obtained from IL 18 and IL 1 F1 0 genes with a 
haplotype risk ratio (HRR) of 2.19. (95% Cl 1.63 - 2.91 ). In our Newfoundland 
cohort, only two haplotypes were detected with smaller frequency differences 
between case and controls; AGCCTG (p < 2.0 x 10-4, HRR = 2.125(95% Cl 1.445-
3.142)) and AGCCG (p < 1.0x 10-4, HRR = 2.144(95% Cl1.474-3.201)) and both 
haplotypes includes SNPs from genes IL 1A, IL 18 and IL 1RN (Fig. 5). These 
results are particularly interesting as we have previously reported a univariate 
analysis of this data set and observed no significance (347), however, using our 
model in the absence of single locus association or haplotype analysis of 
sequential SNPs we observed three genes interacting with in two significant 
haplotypes. 
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Schizophrenia 
Two analyses have been done in the Netrin G1 gene region that is located 
on chromosome 1. Fukasawa et a/. (488) conducted a case-control cohort 
analysis from the Japanese population that included genotypes for 10 SNPs in 
this Netrin G1 region. The authors performed single window, 2-window and 3-
window analyses to evaluate SNPs and their underlying haplotypes for possible 
susceptibility to schizophrenia. In their single window analysis, they have found 
significant association (p < 0.05) in SNP rs1373336. The 2-window and 3-window 
analyses showed significant association with haplotypes from SNPs rs894904, 
rs2218404, rs1373336, and rs1444042. The authors concluded that rs1373336 
was the most significant SNP which has been detected by the three different 
analyses. In another independent study (489), the authors performed a family 
based analysis on a broader chromosomal region that also includes the 10 SNPs 
in the Netrin G1 gene region. The authors reported strong association of SNPs 
rs4307594, rs3924253, rs1373336, and rs96501 in their single window results. In 
their 3-window analysis, the SNPs rs4307594, rs3924253, rs4132604, 
rs2218404, rs1373336, and rs1444042 showed susceptibility to Schizophrenia. 
The results in both studies detected the susceptibility of rs1373336 to 
Schizophrenia. In our results, we have found 8 haplotype patterns consisting of 
SNPs rs4481881, rs4307594, rs3924253, rs4132604, rs1373336, rs1444042, 
and rs96501 (see Figure). Our results also show that rs1373336 is the most 
significant SNP because all the haplotype patterns detected by the CCGA from 
the Schizophrenia cohort contain the major allele from SNP rs1373336. The 
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haplotype patterns that were captured by the CCGA contain major alleles in all 
SNPs except rs4132604, where the rare allele was included in the haplotype 
patterns. The most significant haplotype captured by our algorithm is ACT from 
SNP rs3924253, rs1373336, and rs96501, such that the HRR is 2.34 with p < 
0.0001. 
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Figure A-1: The mean squared error (MSE) measure for haplotype 
frequencies in 5 datasets in the presence of missing data. 
The plot illustrates the influence of missing genotypes on haplotype frequency 
estimation. Each line defines the error rate for a dataset, where the x-axis 
contains the number of haplotype block for that dataset and the y-axis is the 
corresponding MSE. 
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Figure A-2: Evolution of each subpopulation in a typical CCA run. 
The subpopulation in each dataset shows similar behaviour of fitness progression 
in the initial generations and convergence after certain generations of evolution. 
The average fitness for each subpopulation was plotted in the y-axis relative to a 
single CCA run. 
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FigureA-3: Fitness for 100 CCA run plotted for the IL 1-AL, IL 1-NF, Netrin G1, 
and PsA-NF dataset. 
The solid line represents the average maximum fitness in a CCA run and the 
dotted line is the average fitness for each CCA run. 
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Table A-1. Distribution characteristics and statistical significance tests for 
the performance of CCA on each dataset. 
The pairwise t-test was performed to quantify the level of significant difference 
among average fitness and average maximum fitness to ensure the evolvability 
of the CCA. 
Avera~ e Fitness Average Maximum Fitness 
Averag Std Mean (95% Cl) Ave rag Std Mean (95% Cl) t-test 
e e 
IL 1-AL 0.121 0.03 0.122(0.116- 0.143 0.02 0.144(0.137- 1.0 X 10· 
0 0.127) 7 0.149) 4 
IL 1-NF 0.103 0.01 0.1 04(0.099- 0.133 0.02 0.134(0.129- 1.0 X 10· 
6 0.107) 2 0.137) 4 
Netrin 0.085 0.01 0.085(0.081- 0.104 0.02 0.105(0.100- 1.0 X 10· 
G1 9 0.917) 4 0.1 09) 4 
PsA 0.191 0.03 0.192(0.184- 0.210 0.04 0.211 (0.202- 7.0 X 10· 
6 0.199) 0 0.218) 4 
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Figure A-4: Results of the Competitive Co-Evolutionary Algorithm for the 11-
1 gene cluster in AS 
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Figure A-5: Results of the Competitive Co-Evolutionary Algorithm in 
Schizophrenia 
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